



The
**National
Association
for Proton
Therapy**

Model Policy

Coverage of Proton Therapy

Endorsed by:

National Association for Proton Therapy
Particle Therapy Cooperative Group – North America
The Alliance Dedicated Cancer Centers

Last revised February 2023

INTRODUCTION

Proton therapy is a technologically advanced method to deliver curative radiation doses to cancerous tumors. The unique characteristics of how protons interact within the human body allow the delivery of radiation doses to a tumor while reducing radiation doses to surrounding healthy tissues and organs, resulting in fewer complications and side effects than standard radiation therapy. Understanding how proton therapy works provides patients, providers, payers, policymakers, and other stakeholders with insight into the clinical advantages of this treatment modality.

Fundamentally, all tissue cells are made up of molecules with atoms as their basic building blocks. In the center of every atom is the nucleus. Orbiting the nucleus of the atom are negatively charged electrons. When energized protons pass near orbiting electrons, the positive charge of the protons attracts the negatively charged electrons, pulling them out of their orbits. This is called ionization. Because of ionization, the radiation damages molecules within the cells, especially the DNA. Damaging the DNA destroys specific cell functions, particularly the ability to divide or proliferate. While both normal and cancerous cells go through this repair process, a cancer cell's ability to repair molecular injury is frequently inferior. As a result, cancer cells sustain more permanent damage and subsequent cell death than occurs in the normal cell population.

Both standard radiation therapy and proton therapy work on the same principle of damaging cellular DNA. The major advantage of proton therapy over standard radiation therapy, however, is that protons slowly deposit their energy as they travel towards the cancerous tumor and then, due to a unique physical characteristic called the Bragg Peak, deposit the majority of the radiation dose directly in the tumor and travel no further through the body. This significantly minimizes the amount of unnecessary radiation delivered to healthy tissues and organs, thereby reducing unwanted complications and side effects. Standard radiation therapy utilizes x-rays which deposit the majority of the radiation dose immediately upon entering the body while traveling to the tumor. Unlike protons, after depositing radiation dose in the tumor, the x-rays continue traveling through the body until exiting out the other side, resulting in the delivery of unnecessary radiation to healthy tissues and organs.

Proton therapy may be delivered in two methods: passive scattering (also known as single and double scattering) and active scanning (also known as uniform and “pencil beam scanning”). With passive scattering and uniform scanning, apertures and compensators are used to shape and fine tune the depth of the proton beam. With pencil beam scanning, there is generally no need for apertures and compensators, as the dose is “painted” in layers, producing more proximal conformity of the dose distribution as well as modulation of the dose within a field, referred to as “intensity modulated proton therapy” or IMPT.

POLICY DESCRIPTION

This document is intended as a model coverage policy for proton therapy. This model policy identifies under which clinical indications such therapy is clinically appropriate to administer to patients. The use of proton therapy in patients with the indications delineated in the policy is

supported by references to peer-reviewed, scientific literature. The applicable ICD-10-CM codes that correlate to each of the clinical indications are listed in **Appendix 1**.

INDICATIONS FOR COVERAGE

Based on the peer-reviewed scientific literature references listed in **Appendix 2**, proton therapy is considered medically necessary for the following conditions:

- **Ocular tumors^{*,+}**, including *intraocular melanomas and ocular adnexal tumors* such as *tumors of the lacrimal gland*;
- **Malignant or benign conditions of the base of the skull or axial skeleton^{*,+}** including but not limited to *chordomas, chondrosarcomas, and osteosarcomas*;
- **Malignant or benign central nervous system tumors^{*,+}**;
- **Malignant or benign tumors of the spine or around the spinal cord^{*}** where the radiation tolerance of the spinal cord may be comprised or previous radiation has occurred;
- **Hepatocellular carcinoma^{*,+} and cholangiocarcinoma**;
- **Malignant or benign pediatric solid tumors^{*}** in children up to age 18;
- **Malignant lesions of the head and neck^{*,**,+}**, including but not limited to *nasopharyngeal, oropharyngeal, paranasal sinus and nasal cavity cancers* as well as *benign head and neck tumors* with long anticipated survivorship, such as *glomus tumors*;
- **Gastrointestinal cancers^{**}** including *pancreatic, rectal and anal tumors*;
- **Retroperitoneal sarcomas^{*,+}**;
- **Prostate Cancer^{**,+}** (non-metastatic);
- **Breast Cancer^{**}**;
- **Thoracic tumors^{**,+}** including *lung cancers, esophageal cancers⁺⁺, mediastinal lymphomas, thymomas, sarcomas, and mesothelioma*;
- **Hodgkin's Lymphoma^{**,+}**;
- **B-Cell Lymphomas⁺**; and,
- **Re-irradiation^{*}** of previously treated areas where the radiation dose tolerance of critical organs and structures would be exceeded.

In addition, Proton Therapy is indicated when:

- The Dose Volume Histogram (DVH) illustrates at least one (1) or more critical structures or organs that must be considered at risk in or adjacent to the treatment volume to be protected by the use of proton therapy;
- There is documented clinical rationale that doses generally thought to be above the level otherwise attainable with other radiation methods might improve control rates, and/or;

- Other radiation therapy treatment plans (e.g., photon based treatment plans) would have a greater probability of causing clinically meaningful acute and late normal tissue toxicity;
- The proposed treatment volume or an immediately adjacent volume has been previously irradiated, and the dose must therefore be tightly conformed to avoid exceeding the tolerance dose of nearby normal organs and tissues and proton therapy would result in less risk; or
- There is documented clinical rationale that the higher levels of precision associated with proton therapy compared to other radiation treatments are clinically necessary.

Other factors considered favorable for coverage for additional indications than those listed above include enrollment of the patient in a clinical trial or an appropriate prospective clinical registry for planned assessment and publication. Any denials for indications not listed in this policy can have medical documentation and adequate literature submitted in the appeals process for potential coverage.

LIMITATIONS FOR COVERAGE

- Proton therapy is generally not indicated for cancers that are *widely disseminated*.
- For the treatment of primary lesions, the intent of treatment should be curative; in the retreatment scenario, *long-term durable local control is an acceptable intent*.
- For the treatment of recurrent or metastatic lesions, there should be the expectation at the time of treatment of a *long term benefit* (greater than 12 months of life expectancy).

PROTON THERAPY TREATMENT DELIVERY CPT® CODES

- **77520 Proton treatment delivery; simple, without compensation** – Treatment to a single treatment area utilizing a single non-tangential/oblique port, custom block, without compensation.
- **77522 Proton treatment delivery; simple, with compensation** – Treatment to a single treatment area utilizing a single non-tangential/oblique port, custom block, with compensation.
- **77523 Proton treatment delivery; intermediate** – Treatment delivery to one or more treatment areas utilizing two or more ports or one or more tangential/oblique ports, with custom blocks and compensations.
- **77525 Proton treatment delivery; complex** – Treatment delivery to one or more treatment areas utilizing two or more ports per treatment area with matching or patching fields and/or multiple isocenters, with custom blocks and compensators.

* American Society of Radiation Oncology (ASTRO) 2017 Model Policy supports the use of proton therapy.

** American Society of Radiation Oncology (ASTRO) 2017 Model Policy supports the use of proton therapy under a Coverage with Evidence Development model.

+ National Comprehensive Cancer Network (NCCN) Guidelines supports the use of proton therapy when appropriate.

++ National Comprehensive Cancer Network (NCCN) Guidelines supports the use of proton therapy within a clinical trial.

- **77373 Stereotactic body radiation therapy** – Treatment delivery, per fraction to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions.

POLICY DISCLAIMERS

While this model coverage policy for proton therapy is an excellent guide for clinicians and payers alike, it should not be used as a comprehensive tool. As technologies and best practices in our medical field change and evolve, so too will this model coverage policy. In addition, clinical decision-making regarding the appropriate application of proton therapy for a given patient should remain solely with the patient with guidance from the patient's treating physician. We acknowledge that the information provided in this document is focused on the typical patient's clinical indications and there will always be patients who present with indications or symptoms not captured within this model coverage policy. In those cases, it is our expectation that providers will adhere to literature based guidelines and provide the payer with as much clinical information as possible to support the use of performing a proton therapy procedure in an atypical patient.

This policy covers the proton therapy delivery service itself and is not intended to cover the entire scope of services associated with proton therapy (i.e., treatment planning, simulation and imaging, contouring, radiation dose prescribing, dosimetric planning and calculations, and patient specific dose verification). These services may have separate coding and reporting requirements that are not addressed in this policy.

AMA CPT®

CPT® codes, descriptions, and other data only are copyright 2021 American Medical Association (or such other date or publication of CPT®) / All Rights Reserved.

APPENDIX 1 – CODING AND DOCUMENTATION INFORMATION

CPT®/HCPCS Codes

Italicized and/or quoted material is excerpted from the American Medical Association (AMA), *Current Procedural Terminology* (CPT®) codes.

Note: SBRT can be delivered with photons or *protons*. Other CPT/HCPCS radiation therapy ancillary codes may be associated with the treatment delivery codes

Code	Descriptor
<i>PBT Treatment Delivery</i>	
77520	Proton treatment delivery; simple, without compensation
77522	Proton treatment delivery; simple, with compensation
77523	Proton treatment delivery; intermediate
77525	Proton treatment delivery; complex
<i>SBRT Treatment Delivery</i>	
77373	Stereotactic body radiation therapy, treatment delivery

ICD-10-CM Codes

It is the provider's responsibility to select codes carried out to the highest level of specificity and selected from the ICD-10-CM codebook appropriate to the year in which the service is rendered for the claim(s) submitted. If the indications of this policy have been satisfied, then the following ICD-10-CM codes may be relevant

Code	Descriptor
<i>Ocular tumors</i>	
C43.10	Malignant melanoma of unspecified eyelid, including canthus
C43.11	Malignant melanoma of right eyelid, including canthus
C43.12	Malignant melanoma of left eyelid, including canthus
C44.101	Unspecified malignant neoplasm skin/ Unspecified eyelid, including canthus
C44.102	Unspecified malignant neoplasm skin/ right eyelid, including canthus
C44.109	Unspecified malignant neoplasm skin/ left eyelid, including canthus
C44.111	Basal cell carcinoma skin/ unspecified eyelid, including canthus
C44.112	Basal cell carcinoma skin/ right eyelid, including canthus
C44.119	Basal cell carcinoma skin/ left eyelid, including canthus
C44.121	Squamous cell carcinoma skin/ unspecified eyelid, including canthus
C44.122	Squamous cell carcinoma skin/ right eyelid, including canthus
C44.129	Squamous cell carcinoma skin/ left eyelid, including canthus
C44.191	Other malignant neoplasm skin/ unspecified eyelid, including canthus
C44.192	Other malignant neoplasm skin/ right eyelid, including canthus
C44.199	Other malignant neoplasm skin/ left eyelid, including canthus
C4A.10	Merkel cell carcinoma of unspecified eyelid, including canthus
C4A.11	Merkel cell carcinoma of right eyelid, including canthus

Code	Descriptor
C4A.12	Merkel cell carcinoma of left eyelid, including canthus
C69.00	Malignant neoplasm of unspecified conjunctiva
C69.01	Malignant neoplasm of right conjunctiva
C69.02	Malignant neoplasm of left conjunctiva
C69.10	Malignant neoplasm of unspecified cornea
C69.11	Malignant neoplasm of right cornea
C69.12	Malignant neoplasm of left cornea
C69.20	Malignant neoplasm of unspecified retina
C69.21	Malignant neoplasm of right retina
C69.22	Malignant neoplasm of left retina
C69.30	Malignant neoplasm of unspecified choroid
C69.31	Malignant neoplasm of right choroid
C69.32	Malignant neoplasm of left choroid
C69.40	Malignant neoplasm of unspecified ciliary body
C69.41	Malignant neoplasm of right ciliary body
C69.42	Malignant neoplasm of left ciliary body
C69.50	Malignant neoplasm of unspecified lacrimal gland and duct
C69.51	Malignant neoplasm of right lacrimal gland and duct
C69.52	Malignant neoplasm of left lacrimal gland and duct
C69.60	Malignant neoplasm of unspecified orbit
C69.61	Malignant neoplasm of right orbit
C69.62	Malignant neoplasm of left orbit
C69.80	Malignant neoplasm of overlapping sites of unspecified eye and adnexa
C69.81	Malignant neoplasm of overlapping sites of right eye and adnexa
C69.82	Malignant neoplasm of overlapping sites of left eye and adnexa
C69.90	Malignant neoplasm of unspecified site of unspecified eye
C69.91	Malignant neoplasm of unspecified site of right eye
C69.92	Malignant neoplasm of unspecified site of left eye
D03.10	Melanoma in situ of unspecified eyelid, including canthus
D03.11	Melanoma in situ of right eyelid, including canthus
D03.12	Melanoma in situ of left eyelid, including canthus
D04.10	Carcinoma in situ of skin of unspecified eyelid, including canthus
D04.11	Carcinoma in situ of skin of right eyelid, including canthus
D04.12	Carcinoma in situ of skin of left eyelid, including canthus
D09.20	Carcinoma in situ of unspecified eye
D09.21	Carcinoma in situ of right eye
D09.22	Carcinoma in situ of left eye
D22.10	Melanocytic nevi of unspecified eyelid, including canthus
D22.11	Melanocytic nevi of right eyelid, including canthus
D22.12	Melanocytic nevi of left eyelid, including canthus

Code	Descriptor
D23.10	Other benign neoplasm skin/ unspecified eyelid, including canthus
D23.11	Other benign neoplasm skin/ right eyelid, including canthus
D23.12	Other benign neoplasm skin/ left eyelid, including canthus
D31.00	Benign neoplasm of unspecified conjunctiva
D31.01	Benign neoplasm of right conjunctiva
D31.02	Benign neoplasm of left conjunctiva
D31.10	Benign neoplasm of unspecified cornea
D31.11	Benign neoplasm of right cornea
D31.12	Benign neoplasm of left cornea
D31.20	Benign neoplasm of unspecified retina
D31.21	Benign neoplasm of right retina
D31.22	Benign neoplasm of left retina
D31.30	Benign neoplasm of unspecified choroid
D31.31	Benign neoplasm of right choroid
D31.32	Benign neoplasm of left choroid
D31.40	Benign neoplasm of unspecified ciliary body
D31.41	Benign neoplasm of right ciliary body
D31.42	Benign neoplasm of left ciliary body
D31.50	Benign neoplasm of unspecified lacrimal gland and duct
D31.51	Benign neoplasm of right lacrimal gland and duct
D31.52	Benign neoplasm of left lacrimal gland and duct
D31.60	Benign neoplasm of unspecified site of unspecified orbit
D31.61	Benign neoplasm of unspecified site of right orbit
D31.62	Benign neoplasm of unspecified site of left orbit
D31.90	Benign neoplasm of unspecified part of unspecified eye
D31.91	Benign neoplasm of unspecified part of right eye
D31.92	Benign neoplasm of unspecified part of left eye
D49.81	Neoplasm of unspecified behavior of retina and choroid
<i>Malignant or Benign Conditions of the Base of the Skull or Axial Skeleton</i>	
C41.0	Malignant neoplasm of bones of skull and face
C41.1	Malignant neoplasm of mandible
C41.2	Malignant neoplasm of vertebral column
C41.3	Malignant neoplasm of ribs, sternum and clavicle
C41.4	Malignant neoplasm of pelvic bones, sacrum and coccyx
C41.9	Malignant neoplasm of bone and articular cartilage, unspecified
D16.4	Benign neoplasm of bones of skull and face
D16.5	Benign neoplasm of lower jaw bone
D16.6	Benign neoplasm of vertebral column
D16.7	Benign neoplasm of ribs, sternum and clavicle
D16.8	Benign neoplasm of pelvic bones, sacrum and coccyx

Code	Descriptor
D16.9	Benign neoplasm of bone and articular cartilage, unspecified
<i>Central Nervous System Tumors (including spine and spinal cord)</i>	
C70.0	Malignant neoplasm of cerebral meninges
C70.1	Malignant neoplasm of spinal meninges
C70.9	Malignant neoplasm of meninges, unspecified
C71.0	Malignant neoplasm of cerebrum, except lobes and ventricles
C71.1	Malignant neoplasm of frontal lobe
C71.2	Malignant neoplasm of temporal lobe
C71.3	Malignant neoplasm of parietal lobe
C71.4	Malignant neoplasm of occipital lobe
C71.5	Malignant neoplasm of cerebral ventricle
C71.6	Malignant neoplasm of cerebellum
C71.7	Malignant neoplasm of brain stem
C71.8	Malignant neoplasm of overlapping sites of brain
C71.9	Malignant neoplasm of brain, unspecified
C72.0	Malignant neoplasm of spinal cord
C72.1	Malignant neoplasm of cauda equina
C72.20	Malignant neoplasm of unspecified olfactory nerve
C72.21	Malignant neoplasm of right olfactory nerve
C72.22	Malignant neoplasm of left olfactory nerve
C72.30	Malignant neoplasm of unspecified optic nerve
C72.31	Malignant neoplasm of right optic nerve
C72.32	Malignant neoplasm of left optic nerve
C72.40	Malignant neoplasm of unspecified acoustic nerve
C72.41	Malignant neoplasm of right acoustic nerve
C72.42	Malignant neoplasm of left acoustic nerve
C72.50	Malignant neoplasm of unspecified cranial nerve
C72.59	Malignant neoplasm of other cranial nerves
C72.9	Malignant neoplasm of central nervous system, unspecified
C79.31	Secondary malignant neoplasm of brain
C79.32	Secondary malignant neoplasm of cerebral meninges
C79.40	Secondary malignant neoplasm of unspecific part of nervous system
C79.49	Secondary malignant neoplasm of other parts of nervous system
D32.0	Benign neoplasm of cerebral meninges
D32.1	Benign neoplasm of spinal meninges
D32.9	Benign neoplasm of meninges, unspecified
D33.0	Benign neoplasm of brain, supratentorial
D33.1	Benign neoplasm of brain, infratentorial
D33.2	Benign neoplasm of brain, unspecified
D33.3	Benign neoplasm of cranial nerves

Code	Descriptor
D33.4	Benign neoplasm of spinal cord
D33.7	Benign neoplasm of oth parts of central nervous system
D33.9	Benign neoplasm of central nervous system, unspecified
D42.0	Neoplasm of uncertain behavior of cerebral meninges
D42.1	Neoplasm of uncertain behavior of spinal meninges
D42.9	Neoplasm of uncertain behavior of meninges, unspecified
D43.0	Neoplasm of uncertain behavior of brain, supratentorial
D43.1	Neoplasm of uncertain behavior of brain, infratentorial
D43.2	Neoplasm of uncertain behavior of brain, unspecified
D43.3	Neoplasm of uncertain behavior of cranial nerves
D43.4	Neoplasm of uncertain behavior of spinal cord
D43.8	Neoplasm of uncertain behavior of other specified parts of central nervous system
D43.9	Neoplasm of uncertain behavior of central nervous system, unspecified
D49.6	Neoplasm of unspecified behavior of brain
Hepatocellular Carcinoma	
C22.0	Liver cell carcinoma
C22.1	Intrahepatic bile duct carcinoma
C22.2	Hepatoblastoma
C22.3	Angiosarcoma of liver
C22.4	Other sarcomas of liver
C22.7	Other specified carcinomas of liver
C22.8	Malignant neoplasm of liver, primary, unspecified as to type
C22.9	Malignant neoplasm of liver, not specified as primary or sec
C78.7	Secondary malignant neoplasm of liver and intrahepatic bile duct
C7B.02	Secondary carcinoid tumors of liver
D01.5	Carcinoma in situ of liver, gallbladder and bile ducts
D13.4	Benign neoplasm of liver
D13.5	Benign neoplasm of extrahepatic bile ducts
D37.6	Neoplasm of uncertain behavior of liver, gallbladder & bile duct
Head and Neck Tumors	
C00.0	Malignant neoplasm of external upper lip
C00.1	Malignant neoplasm of external lower lip
C00.2	Malignant neoplasm of external lip, unspecified
C00.3	Malignant neoplasm of upper lip, inner aspect
C00.4	Malignant neoplasm of lower lip, inner aspect
C00.5	Malignant neoplasm of lip, unspecified, inner aspect
C00.6	Malignant neoplasm of commissure of lip, unspecified
C00.8	Malignant neoplasm of overlapping sites of lip
C00.9	Malignant neoplasm of lip, unspecified
C01	Malignant neoplasm of base of tongue

Code	Descriptor
C02.0	Malignant neoplasm of dorsal surface of tongue
C02.1	Malignant neoplasm of border of tongue
C02.2	Malignant neoplasm of ventral surface of tongue
C02.3	Malignant neoplasm of anterior two-thirds of tongue, part unspecified
C02.4	Malignant neoplasm of lingual tonsil
C02.8	Malignant neoplasm of overlapping sites of tongue
C02.9	Malignant neoplasm of tongue, unspecified
C03.0	Malignant neoplasm of upper gum
C03.1	Malignant neoplasm of lower gum
C03.9	Malignant neoplasm of gum, unspecified
C04.0	Malignant neoplasm of anterior floor of mouth
C04.1	Malignant neoplasm of lateral floor of mouth
C04.8	Malignant neoplasm of overlapping sites of floor of mouth
C04.9	Malignant neoplasm of floor of mouth, unspecified
C05.0	Malignant neoplasm of hard palate
C05.1	Malignant neoplasm of soft palate
C05.2	Malignant neoplasm of uvula
C05.8	Malignant neoplasm of overlapping sites of palate
C05.9	Malignant neoplasm of palate, unspecified
C06.0	Malignant neoplasm of cheek mucosa
C06.1	Malignant neoplasm of vestibule of mouth
C06.2	Malignant neoplasm of retromolar area
C06.80	Malignant neoplasm of overlapping sites of unspecified parts of mouth
C06.89	Malignant neoplasm of overlapping sites of other parts mouth
C06.9	Malignant neoplasm of mouth, unspecified
C07	Malignant neoplasm of parotid gland
C08.0	Malignant neoplasm of submandibular gland
C08.1	Malignant neoplasm of sublingual gland
C08.9	Malignant neoplasm of major salivary gland, unspecified
C09.0	Malignant neoplasm of tonsillar fossa
C09.1	Malignant neoplasm of tonsillar pillar (anterior) (posterior)
C09.8	Malignant neoplasm of overlapping sites of tonsil
C09.9	Malignant neoplasm of tonsil, unspecified
C10.0	Malignant neoplasm of vallecula
C10.1	Malignant neoplasm of anterior surface of epiglottis
C10.2	Malignant neoplasm of lateral wall of oropharynx
C10.3	Malignant neoplasm of posterior wall of oropharynx
C10.4	Malignant neoplasm of branchial cleft
C10.8	Malignant neoplasm of overlapping sites of oropharynx
C10.9	Malignant neoplasm of oropharynx, unspecified

Code	Descriptor
C11.0	Malignant neoplasm of superior wall of nasopharynx
C11.1	Malignant neoplasm of posterior wall of nasopharynx
C11.2	Malignant neoplasm of lateral wall of nasopharynx
C11.3	Malignant neoplasm of anterior wall of nasopharynx
C11.8	Malignant neoplasm of overlapping sites of nasopharynx
C11.9	Malignant neoplasm of nasopharynx, unspecified
C12	Malignant neoplasm of pyriform sinus
C13.0	Malignant neoplasm of postcricoid region
C13.1	Malignant neoplasm of aryepiglottic fold, hypopharyngeal aspect
C13.2	Malignant neoplasm of posterior wall of hypopharynx
C13.8	Malignant neoplasm of overlapping sites of hypopharynx
C13.9	Malignant neoplasm of hypopharynx, unspecified
C14.0	Malignant neoplasm of pharynx, unspecified
C14.2	Malignant neoplasm of Waldeyer's ring
C14.8	Malignant neoplasm of overlapping sites of lip, oral cavity and pharynx
C30.0	Malignant neoplasm of nasal cavity
C30.1	Malignant neoplasm of middle ear
C31.0	Malignant neoplasm of maxillary sinus
C31.1	Malignant neoplasm of ethmoidal sinus
C31.2	Malignant neoplasm of frontal sinus
C31.3	Malignant neoplasm of sphenoid sinus
C31.8	Malignant neoplasm of overlapping sites of accessory sinuses
C31.9	Malignant neoplasm of accessory sinus, unspecified
C32.0	Malignant neoplasm of glottis
C32.1	Malignant neoplasm of supraglottis
C32.2	Malignant neoplasm of subglottis
C32.3	Malignant neoplasm of laryngeal cartilage
C32.8	Malignant neoplasm of overlapping sites of larynx
C32.9	Malignant neoplasm of larynx, unspecified
C43.0	Malignant melanoma of lip
C43.20	Malignant melanoma of unspecified ear and external auricular canal
C43.21	Malignant melanoma of right ear and external auricular canal
C43.22	Malignant melanoma of left ear and external auricular canal
C43.30	Malignant melanoma of unspecified part of face
C43.31	Malignant melanoma of nose
C43.39	Malignant melanoma of other parts of face
C43.4	Malignant melanoma of scalp and neck
C44.00	Unspecified malignant neoplasm of skin of lip
C44.01	Basal cell carcinoma of skin of lip
C44.02	Squamous cell carcinoma of skin of lip

Code	Descriptor
C44.09	Other specified malignant neoplasm of skin of lip
C44.201	Unspecified malignant neoplasm skin/ Unspecified ear and external auricular canal
C44.202	Unspecified malignant neoplasm skin/ right ear and external auricular canal
C44.209	Unspecified malignant neoplasm skin/ left ear and external auricular canal
C44.211	Basal cell carcinoma skin/ unspecified ear and external auricular canal
C44.212	Basal cell carcinoma skin/ r ear and external auricular canal
C44.219	Basal cell carcinoma skin/ left ear and external auricular canal
C44.221	Squamous cell carcinoma skin/ unspecified ear and external auricular canal
C44.222	Squamous cell carcinoma skin/ r ear and external auricular canal
C44.229	Squamous cell carcinoma skin/ left ear and external auricular canal
C44.291	Other malignant neoplasm skin/ unspecified ear and external auricular canal
C44.292	Other malignant neoplasm skin/ right ear and external auricular canal
C44.299	Other malignant neoplasm skin/ left ear and external auricular canal
C44.300	Unspecified malignant neoplasm of skin of unspecified part of face
C44.301	Unspecified malignant neoplasm of skin of nose
C44.309	Unspecified malignant neoplasm of skin of other parts of face
C44.310	Basal cell carcinoma of skin of unspecified parts of face
C44.311	Basal cell carcinoma of skin of nose
C44.319	Basal cell carcinoma of skin of other parts of face
C44.320	Squamous cell carcinoma of skin of unspecified parts of face
C44.321	Squamous cell carcinoma of skin of nose
C44.329	Squamous cell carcinoma of skin of other parts of face
C44.390	Other malignant neoplasm of skin of unspecified parts of face
C44.391	Other specified malignant neoplasm of skin of nose
C44.399	Other malignant neoplasm of skin of other parts of face
C44.40	Unspecified malignant neoplasm of skin of scalp and neck
C44.41	Basal cell carcinoma of skin of scalp and neck
C44.42	Squamous cell carcinoma of skin of scalp and neck
C44.49	Other specified malignant neoplasm of skin of scalp and neck
C46.2	Kaposi's sarcoma of palate
C47.0	Malignant neoplasm of peripheral nerves of head, face and neck
C49.0	Malignant neoplasm of connective and soft tissue of head, face and neck
C4A.0	Merkel cell carcinoma of lip
C4A.20	Merkel cell carcinoma of unspecified ear and external auric canal
C4A.21	Merkel cell carcinoma of right ear and external auric canal
C4A.22	Merkel cell carcinoma of left ear and external auric canal
C4A.30	Merkel cell carcinoma of unspecified part of face
C4A.31	Merkel cell carcinoma of nose
C4A.39	Merkel cell carcinoma of other parts of face
C4A.4	Merkel cell carcinoma of scalp and neck

Code	Descriptor
C76.0	Malignant neoplasm of head, face and neck
C77.0	Sec and unspecified malignant neoplasm of nodes of head, face and neck
D00.00	Carcinoma in situ of oral cavity, unspecified site
D00.01	Carcinoma in situ of labial mucosa and vermilion border
D00.02	Carcinoma in situ of buccal mucosa
D00.03	Carcinoma in situ of gingiva and edentulous alveolar ridge
D00.04	Carcinoma in situ of soft palate
D00.05	Carcinoma in situ of hard palate
D00.06	Carcinoma in situ of floor of mouth
D00.07	Carcinoma in situ of tongue
D02.0	Carcinoma in situ of larynx
D03.0	Melanoma in situ of lip
D03.20	Melanoma in situ of unspecified ear and external auricular canal
D03.21	Melanoma in situ of right ear and external auricular canal
D03.22	Melanoma in situ of left ear and external auricular canal
D03.30	Melanoma in situ of unspecified part of face
D03.39	Melanoma in situ of other parts of face
D03.4	Melanoma in situ of scalp and neck
D04.0	Carcinoma in situ of skin of lip
D04.20	Carcinoma in situ skin of unspecified ear and external auricular canal
D04.21	Carcinoma in situ skin of right ear and external auricular canal
D04.22	Carcinoma in situ skin of left ear and external auricular canal
D04.30	Carcinoma in situ of skin of unspecified part of face
D04.39	Carcinoma in situ of skin of other parts of face
D04.4	Carcinoma in situ of skin of scalp and neck
D10.0	Benign neoplasm of lip
D10.1	Benign neoplasm of tongue
D10.2	Benign neoplasm of floor of mouth
D10.30	Benign neoplasm of unspecified part of mouth
D10.39	Benign neoplasm of other parts of mouth
D10.4	Benign neoplasm of tonsil
D10.5	Benign neoplasm of other parts of oropharynx
D10.6	Benign neoplasm of nasopharynx
D10.7	Benign neoplasm of hypopharynx
D10.9	Benign neoplasm of pharynx, unspecified
D11.0	Benign neoplasm of parotid gland
D11.7	Benign neoplasm of other major salivary glands
D11.9	Benign neoplasm of major salivary gland, unspecified
D14.0	Benign neoplasm of mid ear, nasal cavity and accessory sinuses
D21.0	Benign neoplasm of connective/soft tissue of head, face and neck

Code	Descriptor
D22.20	Melanocytic nevi of unspecified ear and external auricular canal
D22.21	Melanocytic nevi of right ear and external auricular canal
D22.22	Melanocytic nevi of left ear and external auricular canal
D22.30	Melanocytic nevi of unspecified part of face
D22.39	Melanocytic nevi of other parts of face
D22.4	Melanocytic nevi of scalp and neck
D23.0	Other benign neoplasm of skin of lip
D23.20	Other benign neoplasm skin/ unspecified ear and external auric canal
D23.21	Other benign neoplasm skin/ right ear and external auric canal
D23.22	Other benign neoplasm skin/ left ear and external auric canal
D23.30	Other benign neoplasm of skin of unspecified part of face
D23.39	Other benign neoplasm of skin of Other parts of face
D23.4	Other benign neoplasm of skin of scalp and neck
D37.01	Neoplasm of uncertain behavior of lip
D37.02	Neoplasm of uncertain behavior of tongue
D37.030	Neoplasm of uncertain behavior of the parotid salivary gland
D37.031	Neoplasm of uncertain behavior of the sublingual salivary gland
D37.032	Neoplasm of uncertain behavior of the submandibular salivary gland
D37.039	Neoplasm of uncertain behavior of the major salivary gland, unspecified
D37.04	Neoplasm of uncertain behavior of the minor salivary glands
D37.05	Neoplasm of uncertain behavior of pharynx
D37.09	Neoplasm of uncertain behavior of sites of the oral cavity
Gastrointestinal Cancers	
C16.1	Malignant neoplasm of fundus of stomach
C16.2	Malignant neoplasm of body of stomach
C16.3	Malignant neoplasm of pyloric antrum
C16.4	Malignant neoplasm of pylorus
C16.5	Malignant neoplasm of lesser curvature of stomach, unspecified
C16.6	Malignant neoplasm of greater curvature of stomach, unspecified
C16.8	Malignant neoplasm of overlapping sites of stomach
C16.9	Malignant neoplasm of stomach, unspecified
C17.0	Malignant neoplasm of duodenum
C17.1	Malignant neoplasm of jejunum
C17.2	Malignant neoplasm of ileum
C17.3	Meckel's diverticulum, malignant
C17.8	Malignant neoplasm of overlapping sites of small intestine
C17.9	Malignant neoplasm of small intestine, unspecified
C18.0	Malignant neoplasm of cecum
C18.1	Malignant neoplasm of appendix
C18.2	Malignant neoplasm of ascending colon

Code	Descriptor
C18.3	Malignant neoplasm of hepatic flexure
C18.4	Malignant neoplasm of transverse colon
C18.5	Malignant neoplasm of splenic flexure
C18.6	Malignant neoplasm of descending colon
C18.7	Malignant neoplasm of sigmoid colon
C18.8	Malignant neoplasm of overlapping sites of colon
C18.9	Malignant neoplasm of colon, unspecified
C19	Malignant neoplasm of rectosigmoid junction
C20	Malignant neoplasm of rectum
C21.0	Malignant neoplasm of anus, unspecified
C21.1	Malignant neoplasm of anal canal
C21.2	Malignant neoplasm of cloacogenic zone
C21.8	Malignant neoplasm of overlapping sites of rectum, anus and anal canal
C23.	Malignant neoplasm of gallbladder
C24.0	Malignant neoplasm of extrahepatic bile duct
C24.1	Malignant neoplasm of ampulla of Vater
C24.8	Malignant neoplasm of overlapping sites of biliary tract
C24.9	Malignant neoplasm of biliary tract, unspecified
C25.0	Malignant neoplasm of head of pancreas
C25.1	Malignant neoplasm of body of pancreas
C25.2	Malignant neoplasm of tail of pancreas
C25.3	Malignant neoplasm of pancreatic duct
C25.4	Malignant neoplasm of endocrine pancreas
C25.7	Malignant neoplasm of other parts of pancreas
C25.8	Malignant neoplasm of overlapping sites of pancreas
C25.9	Malignant neoplasm of pancreas, unspecified
C26.0	Malignant neoplasm of intestinal tract, part unspecified
C26.1	Malignant neoplasm of spleen
C26.9	Malignant neoplasm of ill-defined sites within the digestive system
C43.51	Malignant melanoma of anal skin
C44.500	Unspecified malignant neoplasm of anal skin
C44.510	Basal cell carcinoma of anal skin
C44.520	Squamous cell carcinoma of anal skin
C44.590	Other specified malignant neoplasm of anal skin
C45.1	Mesothelioma of peritoneum
C46.4	Kaposi's sarcoma of gastrointestinal sites
C47.4	Malignant neoplasm of peripheral nerves of abdomen
C49.4	Malignant neoplasm of connective and soft tissue of abdomen
C4A.51	Merkel cell carcinoma of anal skin
C76.2	Malignant neoplasm of abdomen

Code	Descriptor
C77.2	Secondary and unspecified malignant neoplasm of intra-abdominal nodes
C78.4	Secondary malignant neoplasm of small intestine
C78.5	Secondary malignant neoplasm of large intestine and rectum
C78.80	Secondary malignant neoplasm of unspecified digestive organ
C78.89	Secondary malignant neoplasm of other digestive organs
C7A.00	Malignant carcinoid tumor of unspecified site
C7A.010	Malignant carcinoid tumor of the duodenum
C7A.011	Malignant carcinoid tumor of the jejunum
C7A.012	Malignant carcinoid tumor of the ileum
C7A.019	Malignant carcinoid tumor of the small intestine, unspecified portion
C7A.020	Malignant carcinoid tumor of the appendix
C7A.021	Malignant carcinoid tumor of the cecum
C7A.022	Malignant carcinoid tumor of the ascending colon
C7A.023	Malignant carcinoid tumor of the transverse colon
C7A.024	Malignant carcinoid tumor of the descending colon
C7A.025	Malignant carcinoid tumor of the sigmoid colon
C7A.026	Malignant carcinoid tumor of the rectum
C7A.029	Malignant carcinoid tumor of the large intestine, unspecified portion
C7A.092	Malignant carcinoid tumor of the stomach
C7A.093	Malignant carcinoid tumor of the kidney
C7A.094	Malignant carcinoid tumor of the foregut, unspecified
C7A.095	Malignant carcinoid tumor of the midgut, unspecified
C7A.096	Malignant carcinoid tumor of the hindgut, unspecified
D00.2	Carcinoma in situ of stomach
D01.0	Carcinoma in situ of colon
D01.1	Carcinoma in situ of rectosigmoid junction
D01.2	Carcinoma in situ of rectum
D01.3	Carcinoma in situ of anus and anal canal
D01.40	Carcinoma in situ of unspecified part of intestine
D01.49	Carcinoma in situ of other parts of intestine
D01.7	Carcinoma in situ of other specified digestive organs
D01.9	Carcinoma in situ of digestive organ, unspecified
D03.51	Melanoma in situ of anal skin
D12.0	Benign neoplasm of cecum
D12.1	Benign neoplasm of appendix
D12.2	Benign neoplasm of ascending colon
D12.3	Benign neoplasm of transverse colon
D12.4	Benign neoplasm of descending colon
D12.5	Benign neoplasm of sigmoid colon
D12.6	Benign neoplasm of colon, unspecified

Code	Descriptor
D12.7	Benign neoplasm of rectosigmoid junction
D12.8	Benign neoplasm of rectum
D12.9	Benign neoplasm of anus and anal canal
D13.1	Benign neoplasm of stomach
D13.2	Benign neoplasm of duodenum
D13.30	Benign neoplasm of unspecified part of small intestine
D13.39	Benign neoplasm of other parts of small intestine
D13.6	Benign neoplasm of pancreas
D13.7	Benign neoplasm of endocrine pancreas
D13.9	Benign neoplasm of ill-defined sites within the digestive system
D17.5	Benign lipomatous neoplasm of intra-abdominal organs
D18.03	Hemangioma of intra-abdominal structures
D21.4	Benign neoplasm of connective and other soft tissue of abdomen
D37.1	Neoplasm of uncertain behavior of stomach
D37.2	Neoplasm of uncertain behavior of small intestine
D37.3	Neoplasm of uncertain behavior of appendix
D37.4	Neoplasm of uncertain behavior of colon
D37.5	Neoplasm of uncertain behavior of rectum
D37.8	Neoplasm of uncertain behavior of other digestive organs
D37.9	Neoplasm of uncertain behavior of digestive organ, unspecified
D3A.00	Benign carcinoid tumor of unspecified site
D3A.010	Benign carcinoid tumor of the duodenum
D3A.011	Benign carcinoid tumor of the jejunum
D3A.012	Benign carcinoid tumor of the ileum
D3A.019	Benign carcinoid tumor of the small intestine, unspecified portion
D3A.020	Benign carcinoid tumor of the appendix
D3A.021	Benign carcinoid tumor of the cecum
D3A.022	Benign carcinoid tumor of the ascending colon
D3A.023	Benign carcinoid tumor of the transverse colon
D3A.024	Benign carcinoid tumor of the descending colon
D3A.025	Benign carcinoid tumor of the sigmoid colon
D3A.026	Benign carcinoid tumor of the rectum
D3A.029	Benign carcinoid tumor of the large intestine, unspecified portion
D3A.092	Benign carcinoid tumor of the stomach
D3A.093	Benign carcinoid tumor of the kidney
D3A.094	Benign carcinoid tumor of the foregut, unspecified
D3A.095	Benign carcinoid tumor of the midgut, unspecified
D3A.096	Benign carcinoid tumor of the hindgut, unspecified
<i>Retroperitoneal Sarcoma</i>	
C48.0	Malignant neoplasm of retroperitoneum

Code	Descriptor
D20.0	Benign neoplasm of soft tissue of retroperitoneum
D48.3	Neoplasm of uncertain behavior of retroperitoneum
Prostate Cancer	
C61	Malignant neoplasm of prostate
D07.5	Carcinoma in situ of prostate
D29.1	Benign neoplasm of prostate
D40.0	Neoplasm of uncertain behavior of prostate
Breast Cancer	
C43.52	Malignant melanoma of skin of breast
C44.501	Unspecified malignant neoplasm of skin of breast
C44.511	Basal cell carcinoma of skin of breast
C44.521	Squamous cell carcinoma of skin of breast
C44.591	Other specified malignant neoplasm of skin of breast
C4A.52	Merkel cell carcinoma of skin of breast
C50.011	Malignant neoplasm of nipple and areola, right female breast
C50.012	Malignant neoplasm of nipple and areola, left female breast
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast
C50.021	Malignant neoplasm of nipple and areola, right male breast
C50.022	Malignant neoplasm of nipple and areola, left male breast
C50.029	Malignant neoplasm of nipple and areola, unspecified male breast
C50.111	Malignant neoplasm of central portion of right female breast
C50.112	Malignant neoplasm of central portion of left female breast
C50.119	Malignant neoplasm of central portion of unspecified female breast
C50.121	Malignant neoplasm of central portion of right male breast
C50.122	Malignant neoplasm of central portion of left male breast
C50.129	Malignant neoplasm of central portion of unspecified male breast
C50.211	Malignant neoplasm of upper-inner quadrant of right female breast
C50.212	Malignant neoplasm of upper-inner quadrant of left female breast
C50.219	Malignant neoplasm of upper-inner quadrant of unspecified female breast
C50.221	Malignant neoplasm of upper-inner quadrant of right male breast
C50.222	Malignant neoplasm of upper-inner quadrant of left male breast
C50.229	Malignant neoplasm of upper-inner quadrant of unspecified male breast
C50.311	Malignant neoplasm of lower-inner quadrant of right female breast
C50.312	Malignant neoplasm of lower-inner quadrant of left female breast
C50.319	Malignant neoplasm of lower-inner quadrant of unspecified female breast
C50.321	Malignant neoplasm of lower-inner quadrant of right male breast
C50.322	Malignant neoplasm of lower-inner quadrant of left male breast
C50.329	Malignant neoplasm of lower-inner quadrant of unspecified male breast
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast

Code	Descriptor
C50.419	Malignant neoplasm of upper-outer quadrant of unspecified female breast
C50.421	Malignant neoplasm of upper-outer quadrant of right male breast
C50.422	Malignant neoplasm of upper-outer quadrant of left male breast
C50.429	Malignant neoplasm of upper-outer quadrant of unspecified male breast
C50.511	Malignant neoplasm of lower-outer quadrant of right female breast
C50.512	Malignant neoplasm of lower-outer quadrant of left female breast
C50.519	Malignant neoplasm of lower-outer quadrant of unspecified female breast
C50.521	Malignant neoplasm of lower-outer quadrant of right male breast
C50.522	Malignant neoplasm of lower-outer quadrant of left male breast
C50.529	Malignant neoplasm of lower-outer quadrant of unspecified male breast
C50.611	Malignant neoplasm of axillary tail of right female breast
C50.612	Malignant neoplasm of axillary tail of left female breast
C50.619	Malignant neoplasm of axillary tail of unspecified female breast
C50.621	Malignant neoplasm of axillary tail of right male breast
C50.622	Malignant neoplasm of axillary tail of left male breast
C50.629	Malignant neoplasm of axillary tail of unspecified male breast
C50.811	Malignant neoplasm of overlapping sites of right female breast
C50.812	Malignant neoplasm of overlapping sites of left female breast
C50.819	Malignant neoplasm of overlapping sites of unspecified female breast
C50.821	Malignant neoplasm of overlapping sites of right male breast
C50.822	Malignant neoplasm of overlapping sites of left male breast
C50.829	Malignant neoplasm of overlapping sites of unspecified male breast
C50.911	Malignant neoplasm of unspecified site of right female breast
C50.912	Malignant neoplasm of unspecified site of left female breast
C50.919	Malignant neoplasm of unspecified site of unspecified female breast
C50.921	Malignant neoplasm of unspecified site of right male breast
C50.922	Malignant neoplasm of unspecified site of left male breast
C50.929	Malignant neoplasm of unspecified site of unspecified male breast
C79.81	Secondary malignant neoplasm of breast
D03.52	Melanoma in situ of breast (skin) (soft tissue)
D05.00	Lobular carcinoma in situ of unspecified breast
D05.01	Lobular carcinoma in situ of right breast
D05.02	Lobular carcinoma in situ of left breast
D05.10	Intraductal carcinoma in situ of unspecified breast
D05.11	Intraductal carcinoma in situ of right breast
D05.12	Intraductal carcinoma in situ of left breast
D05.80	Other type of carcinoma in situ of unspecified breast
D05.81	Other specified type of carcinoma in situ of right breast
D05.82	Other specified type of carcinoma in situ of left breast
D05.90	Unspecified type of carcinoma in situ of Unspecified breast

Code	Descriptor
D05.91	Unspecified type of carcinoma in situ of right breast
D05.92	Unspecified type of carcinoma in situ of left breast
D24.1	Benign neoplasm of right breast
D24.2	Benign neoplasm of left breast
D24.9	Benign neoplasm of unspecified breast
D48.60	Neoplasm of uncertain behavior of unspecified breast
D48.61	Neoplasm of uncertain behavior of right breast
D48.62	Neoplasm of uncertain behavior of left breast
D49.3	Neoplasm of unspecified behavior of breast
Thoracic Tumors	
C15.3	Malignant neoplasm of upper third of esophagus
C15.4	Malignant neoplasm of middle third of esophagus
C15.5	Malignant neoplasm of lower third of esophagus
C15.8	Malignant neoplasm of overlapping sites of esophagus
C15.9	Malignant neoplasm of esophagus, unspecified
C16.0	Malignant neoplasm of cardia
C33.	Malignant neoplasm of trachea
C34.00	Malignant neoplasm of unspecified main bronchus
C34.01	Malignant neoplasm of right main bronchus
C34.02	Malignant neoplasm of left main bronchus
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung
C34.2	Malignant neoplasm of middle lobe, bronchus or lung
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung
C37.	Malignant neoplasm of thymus
C38.0	Malignant neoplasm of heart
C38.1	Malignant neoplasm of anterior mediastinum
C38.2	Malignant neoplasm of posterior mediastinum
C38.3	Malignant neoplasm of mediastinum, part unspecified
C38.4	Malignant neoplasm of pleura
C38.8	Malignant neoplasm of overlapping sites of heart, mediastinum and pleura

Code	Descriptor
C39.0	Malignant neoplasm of upper respiratory tract, part unspecified
C39.9	Malignant neoplasm of lower respiratory tract, part unspecified
C45.0	Mesothelioma of pleura
C45.2	Mesothelioma of pericardium
C46.50	Kaposi's sarcoma of unspecified lung
C46.51	Kaposi's sarcoma of right lung
C46.52	Kaposi's sarcoma of left lung
C47.3	Malignant neoplasm of peripheral nerves of thorax
C49.3	Malignant neoplasm of connective and soft tissue of thorax
C76.1	Malignant neoplasm of thorax
C77.1	Secondary and unspecified malignant neoplasm of intrathoracic nodes
C78.00	Secondary malignant neoplasm of unspecified lung
C78.01	Secondary malignant neoplasm of right lung
C78.02	Secondary malignant neoplasm of left lung
C78.1	Secondary malignant neoplasm of mediastinum
C78.2	Secondary malignant neoplasm of pleura
C78.30	Secondary malignant neoplasm of unspecified respiratory organ
C78.39	Secondary malignant neoplasm of other respiratory organs
C7A.090	Malignant carcinoid tumor of the bronchus and lung
C7A.091	Malignant carcinoid tumor of the thymus
C7B.04	Secondary carcinoid tumors of peritoneum
D00.08	Carcinoma in situ of pharynx
D00.1	Carcinoma in situ of esophagus
D02.1	Carcinoma in situ of trachea
D02.20	Carcinoma in situ of unspecified bronchus and lung
D02.21	Carcinoma in situ of right bronchus and lung
D02.22	Carcinoma in situ of left bronchus and lung
D02.3	Carcinoma in situ of other parts of respiratory system
D02.4	Carcinoma in situ of respiratory system, unspecified
D13.0	Benign neoplasm of esophagus
D14.1	Benign neoplasm of larynx
D14.2	Benign neoplasm of trachea
D14.30	Benign neoplasm of unspecified bronchus and lung
D14.31	Benign neoplasm of right bronchus and lung
D14.32	Benign neoplasm of left bronchus and lung
D14.4	Benign neoplasm of respiratory system, unspecified
D15.0	Benign neoplasm of thymus
D15.1	Benign neoplasm of heart
D15.2	Benign neoplasm of mediastinum
D15.7	Benign neoplasm of other specified intrathoracic organs

Code	Descriptor
D15.9	Benign neoplasm of intrathoracic organ, unspecified
D17.4	Benign lipomatous neoplasm of intrathoracic organs
D19.0	Benign neoplasm of mesothelial tissue of pleura
D21.3	Benign neoplasm of connective and other soft tissue of thorax
D38.0	Neoplasm of uncertain behavior of larynx
D38.1	Neoplasm of uncertain behavior of trachea, bronchus and lung
D38.2	Neoplasm of uncertain behavior of pleura
D38.3	Neoplasm of uncertain behavior of mediastinum
D38.4	Neoplasm of uncertain behavior of thymus
D38.5	Neoplasm of uncertain behavior of other respiratory organs
D38.6	Neoplasm of uncertain behavior of respiratory organ, unspecified
D3A.090	Benign carcinoid tumor of the bronchus and lung
D3A.091	Benign carcinoid tumor of the thymus
D49.1	Neoplasm of unspecified behavior of respiratory system
<i>Hodgkin's Lymphoma</i>	
C81.00	Nodular lymphocyte predominant Hodgkin lymphoma, unspecified site
C81.01	Nodular lymphocyte predominant Hodgkin lymph, nodes of head, face, & neck
C81.02	Nodular lymphocyte predominant Hodgkin lymphoma, intrathoracic nodes
C81.03	Nodular lymphocyte predominant Hodgkin lymphoma, intra-abdominal nodes
C81.04	Nodular lymphocyte predominant Hodgkin lymph, nodes of axilla and upper limb
C81.05	Nodular lymphocyte predominant Hodgkin lymph, nodes of inguinal region & low limb
C81.06	Nodular lymphocyte predominant Hodgkin lymphoma, intrapelvic nodes
C81.07	Nodular lymphocyte predominant Hodgkin lymphoma, spleen
C81.08	Nodular lymphocyte predominant Hodgkin lymphoma, nodes multiple site
C81.09	Nodular lymphocyte predominant Hodgkin lymph, extranodal & solid org site
C81.10	Nodular sclerosis classical Hodgkin lymphoma, unspecified site
C81.11	Nodular sclerosis classical Hodgkin lymphoma, nodes of head, face, and neck
C81.12	Nodular sclerosis class Hodgkin lymphoma, intrathoracic nodes
C81.13	Nodular sclerosis class Hodgkin lymphoma, intra-abdominal nodes
C81.14	Nodular sclerosis class Hodgkin lymph, nodes of axilla and upper limb
C81.15	Nodular sclerosis class Hodgkin lymph, nodes of inguinal region and low limb
C81.16	Nodular sclerosis class Hodgkin lymphoma, intrapelvic nodes
C81.17	Nodular sclerosis classical Hodgkin lymphoma, spleen
C81.18	Nodular sclerosis class Hodgkin lymphoma, nodes of multiple sites
C81.19	Nodular sclerosis class Hodgkin lymph, extranodal and solid organ sites
C81.20	Mixed cellularity classical Hodgkin lymphoma, unspecified site
C81.21	Mix cellular class Hodgkin lymph, nodes of head, face, and neck
C81.22	Mixed cellular classical Hodgkin lymphoma, intrathoracic nodes
C81.23	Mixed cellular classical Hodgkin lymphoma, intra-abdominal nodes

Code	Descriptor
C81.24	Mix cellular class Hodgkin lymph, nodes of axilla and upper limb
C81.25	Mix cellular class Hodgkin lymph, nodes of inguinal region and low limb
C81.26	Mixed cellular classical Hodgkin lymphoma, intrapelvic nodes
C81.27	Mixed cellularity classical Hodgkin lymphoma, spleen
C81.28	Mixed cellular classical Hodgkin lymphoma, nodes of multiple sites
C81.29	Mix cellular class Hodgkin lymph, extranodal and solid org sites
C81.30	Lymphocyte depleted classical Hodgkin lymphoma, unspecified site
C81.31	Lymphocyte depleted class Hodgkin lymph, nodes of head, face, & neck
C81.32	Lymphocyte depleted class Hodgkin lymphoma, intrathoracic nodes
C81.33	Lymphocyte depleted class Hodgkin lymphoma, intra-abdominal nodes
C81.34	Lymphocyte depleted class Hodgkin lymph, nodes of axilla and upper limb
C81.35	Lymphocyte depleted class Hodgkin lymph, nodes of inguinal region & low limb
C81.36	Lymphocyte depleted class Hodgkin lymphoma, intrapelvic nodes
C81.37	Lymphocyte depleted classical Hodgkin lymphoma, spleen
C81.38	Lymphocyte depleted class Hodgkin lymphoma, nodes of multiple sites
C81.39	Lymphocyte depleted class Hodgkin lymph, extranodal & solid org site
C81.40	Lymphocyte-rich classical Hodgkin lymphoma, unspecified site
C81.41	Lymphocyte-rich class Hodgkin lymph, nodes of head, face, and neck
C81.42	Lymphocyte-rich classical Hodgkin lymphoma, intrathoracic nodes
C81.43	Lymphocyte-rich classical Hodgkin lymphoma, intra-abdominal lymph nodes
C81.44	Lymphocyte-rich class Hodgkin lymph, nodes of axilla and upper limb
C81.45	Lymphocyte-rich class Hodgkin lymph, nodes of inguinal region and lower limb
C81.46	Lymphocyte-rich classical Hodgkin lymphoma, intrapelvic lymph nodes
C81.47	Lymphocyte-rich classical Hodgkin lymphoma, spleen
C81.48	Lymphocyte-rich classical Hodgkin lymphoma, lymph nodes of multiple sites
C81.49	Lymphocyte-rich class Hodgkin lymph, extranodal and solid organ sites
C81.70	Other classical Hodgkin lymphoma, unspecified site
C81.71	Other class Hodgkin lymphoma, nodes of head, face, and neck
C81.72	Other classical Hodgkin lymphoma, intrathoracic lymph nodes
C81.73	Other classical Hodgkin lymphoma, intra-abdominal lymph nodes
C81.74	Other class Hodgkin lymphoma, nodes of axilla and upper limb
C81.75	Other class Hodgkin lymph, nodes of inguinal region and lower limb
C81.76	Other classical Hodgkin lymphoma, intrapelvic lymph nodes
C81.77	Other classical Hodgkin lymphoma, spleen
C81.78	Other classical Hodgkin lymphoma, lymph nodes of multiple sites
C81.79	Other class Hodgkin lymphoma, extranodal and solid organ sites
C81.90	Hodgkin lymphoma, unspecified, unspecified site
C81.91	Hodgkin lymphoma, unspecified, lymph nodes of head, face, and neck
C81.92	Hodgkin lymphoma, unspecified, intrathoracic lymph nodes
C81.93	Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes

Code	Descriptor
C81.94	Hodgkin lymphoma, unspecified, lymph nodes of axilla and upper limb
C81.95	Hodgkin lymphoma, unspecified, nodes of inguinal region and lower limb
C81.96	Hodgkin lymphoma, unspecified, intrapelvic lymph nodes
C81.97	Hodgkin lymphoma, unspecified, spleen
C81.98	Hodgkin lymphoma, unspecified, lymph nodes of multiple sites
C81.99	Hodgkin lymphoma, unspecified, extranodal and solid organ sites
B-Cell Lymphomas	
C83.00	Small cell b-cell lymphoma, unspecified site
C83.01	Small cell b-cell lymphoma, nodes of head, face, and neck
C83.02	Small cell b-cell lymphoma, intrathoracic lymph nodes
C83.03	Small cell b-cell lymphoma, intra-abdominal lymph nodes
C83.04	Small cell b-cell lymphoma, nodes of axilla and upper limb
C83.05	Small cell b-cell lymph, nodes of inguinal region and lower limb
C83.06	Small cell b-cell lymphoma, intrapelvic lymph nodes
C83.07	Small cell b-cell lymphoma, spleen
C83.08	Small cell b-cell lymphoma, lymph nodes of multiple sites
C83.09	Small cell b-cell lymphoma, extranodal and solid organ sites
C83.30	Diffuse large b-cell lymphoma, unspecified site
C83.31	Diffuse large b-cell lymphoma, nodes of head, face, and neck
C83.32	Diffuse large b-cell lymphoma, intrathoracic lymph nodes
C83.33	Diffuse large b-cell lymphoma, intra-abdominal lymph nodes
C83.34	Diffuse large b-cell lymph, nodes of axilla and upper limb
C83.35	Diffuse large b-cell lymph, nodes of inguinal region and lower limb
C83.36	Diffuse large b-cell lymphoma, intrapelvic lymph nodes
C83.37	Diffuse large b-cell lymphoma, spleen
C83.38	Diffuse large b-cell lymphoma, lymph nodes of multiple sites
C83.39	Diffuse large b-cell lymphoma, extranodal and solid organ sites
C85.10	Unspecified b-cell lymphoma, Unspecified site
C85.11	Unspecified b-cell lymphoma, lymph nodes of head, face, and neck
C85.12	Unspecified b-cell lymphoma, intrathoracic lymph nodes
C85.13	Unspecified b-cell lymphoma, intra-abdominal lymph nodes
C85.14	Unspecified b-cell lymphoma, lymph nodes of axilla and upper limb
C85.15	Unspecified b-cell lymphoma, nodes of ing region and lower limb
C85.16	Unspecified b-cell lymphoma, intrapelvic lymph nodes
C85.17	Unspecified b-cell lymphoma, spleen
C85.18	Unspecified b-cell lymphoma, lymph nodes of multiple sites
C85.19	Unspecified b-cell lymphoma, extranodal and solid organ sites
C85.20	Mediastinal (thymic) large b-cell lymphoma, unspecified site
C85.21	Mediastinal large b-cell lymph, nodes of head, face, and neck
C85.22	Mediastinal (thymic) large b-cell lymphoma, intrathoracic nodes

Code	Descriptor
C85.23	Mediastinal (thymic) large b-cell lymphoma, intra-abdominal nodes
C85.24	Mediastinal large b-cell lymph, nodes of axilla and upper limb
C85.25	Mediastinal large b-cell lymph, nodes of inguinal region and lower limb
C85.26	Mediastinal (thymic) large b-cell lymphoma, intrapelvic nodes
C85.27	Mediastinal (thymic) large b-cell lymphoma, spleen
C85.28	Mediastinal (thymic) large b-cell lymphoma, nodes of multiple sites
C85.29	Mediastinal large b-cell lymph, extranodal and solid organ sites
Other Carcinomas	
C40.00	Malignant neoplasm of scapula and long bones of unspecified upper limb
C40.01	Malignant neoplasm of scapula and long bones of right upper limb
C40.02	Malignant neoplasm of scapula and long bones of left upper limb
C40.10	Malignant neoplasm of short bones of unspecified upper limb
C40.11	Malignant neoplasm of short bones of right upper limb
C40.12	Malignant neoplasm of short bones of left upper limb
C40.20	Malignant neoplasm of long bones of unspecified lower limb
C40.21	Malignant neoplasm of long bones of right lower limb
C40.22	Malignant neoplasm of long bones of left lower limb
C40.30	Malignant neoplasm of short bones of unspecified lower limb
C40.31	Malignant neoplasm of short bones of right lower limb
C40.32	Malignant neoplasm of short bones of left lower limb
C40.80	Malignant neoplasm of overlapping sites of bone/articular cartilage of unspecified limb
C40.81	Malignant neoplasm of overlapping sites of bone/articular cartilage of right limb
C40.82	Malignant neoplasm of overlapping sites of bone/articular cartilage of left limb
C40.90	Malignant neoplasm of unspecified bones and articular cartilage of unspecified limb
C40.91	Malignant neoplasm of unspecified bones and articular cartilage of right limb
C40.92	Malignant neoplasm of unspecified bones and articular cartilage of left limb
C43.59	Malignant melanoma of other part of trunk
C43.60	Malignant melanoma of unspecified upper limb, including shoulder
C43.61	Malignant melanoma of right upper limb, including shoulder
C43.62	Malignant melanoma of left upper limb, including shoulder
C43.70	Malignant melanoma of unspecified lower limb, including hip
C43.71	Malignant melanoma of right lower limb, including hip
C43.72	Malignant melanoma of left lower limb, including hip
C43.8	Malignant melanoma of overlapping sites of skin
C43.9	Malignant melanoma of skin, unspecified
C44.509	Unspecified malignant neoplasm of skin of other part of trunk
C44.519	Basal cell carcinoma of skin of other part of trunk
C44.529	Squamous cell carcinoma of skin of other part of trunk
C44.599	Other malignant neoplasm of skin of other part of trunk

Code	Descriptor
C44.601	Unspecified malignant neoplasm skin/ Unspecified upper limb, including shoulder
C44.602	Unspecified malignant neoplasm skin/ right upper limb, including shoulder
C44.609	Unspecified malignant neoplasm skin/ left upper limb, including shoulder
C44.611	Basal cell carcinoma skin/ unspecified upper limb, including shoulder
C44.612	Basal cell carcinoma skin/ right upper limb, including shoulder
C44.619	Basal cell carcinoma skin/ left upper limb, including shoulder
C44.621	Squamous cell carcinoma skin/ unspecified upper limb, including shoulder
C44.622	Squamous cell carcinoma skin/ right upper limb, including shoulder
C44.629	Squamous cell carcinoma skin/ left upper limb, including shoulder
C44.691	Other malignant neoplasm skin/ unspecified upper limb, including shoulder
C44.692	Other malignant neoplasm skin/ right upper limb, including shoulder
C44.699	Other malignant neoplasm skin/ left upper limb, including shoulder
C44.701	Unspecified malignant neoplasm skin/ Unspecified lower limb, including hip
C44.702	Unspecified malignant neoplasm skin/ right lower limb, including hip
C44.709	Unspecified malignant neoplasm skin/ left lower limb, including hip
C44.711	Basal cell carcinoma skin/ unspecified lower limb, including hip
C44.712	Basal cell carcinoma skin/ right lower limb, including hip
C44.719	Basal cell carcinoma skin/ left lower limb, including hip
C44.721	Squamous cell carcinoma skin/ unspecified lower limb, including hip
C44.722	Squamous cell carcinoma skin/ right lower limb, including hip
C44.729	Squamous cell carcinoma skin/ left lower limb, including hip
C44.791	Other malignant neoplasm skin/ unspecified lower limb, including hip
C44.792	Other malignant neoplasm skin/ right lower limb, including hip
C44.799	Other malignant neoplasm skin/ left lower limb, including hip
C44.80	Unspecified malignant neoplasm of overlapping sites of skin
C44.81	Basal cell carcinoma of overlapping sites of skin
C44.82	Squamous cell carcinoma of overlapping sites of skin
C44.89	Other malignant neoplasm of overlapping sites of skin
C44.90	Unspecified malignant neoplasm of skin, Unspecified
C44.91	Basal cell carcinoma of skin, unspecified
C44.92	Squamous cell carcinoma of skin, unspecified
C44.99	Other specified malignant neoplasm of skin, unspecified
C45.7	Mesothelioma of other sites
C45.9	Mesothelioma, unspecified
C46.0	Kaposi's sarcoma of skin
C46.1	Kaposi's sarcoma of soft tissue
C46.3	Kaposi's sarcoma of lymph nodes
C46.7	Kaposi's sarcoma of other sites
C46.9	Kaposi's sarcoma, unspecified

Code	Descriptor
C47.10	Malignant neoplasm of peripheral nerves of unspecified upper limb, including shoulder
C47.11	Malignant neoplasm of peripheral nerves of right upper limb, including shoulder
C47.12	Malignant neoplasm of peripheral nerves of left upper limb, including shoulder
C47.20	Malignant neoplasm of peripheral nerves of unspecified lower limb, including hip
C47.21	Malignant neoplasm of peripheral nerves of right lower limb, including hip
C47.22	Malignant neoplasm of peripheral nerves of left lower limb, including hip
C47.5	Malignant neoplasm of peripheral nerves of pelvis
C47.6	Malignant neoplasm of peripheral nerves of trunk, unspecified
C47.8	Malignant neoplasm of overlapping sites of peripheral nerves and autonomic nervous system
C47.9	Malignant neoplasm of peripheral nerves and autonomic nervous system, unspecified
C48.1	Malignant neoplasm of specified parts of peritoneum
C48.2	Malignant neoplasm of peritoneum, unspecified
C48.8	Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum
C49.10	Malignant neoplasm of connective and soft tissue of unspecified upper limb, including shoulder
C49.11	Malignant neoplasm of connective and soft tissue of right upper limb, including shoulder
C49.12	Malignant neoplasm of connective and soft tissue of left upper limb, including shoulder
C49.20	Malignant neoplasm of connective and soft tissue of unspecified low limb, including hip
C49.21	Malignant neoplasm of connective and soft tissue of right low limb, including hip
C49.22	Malignant neoplasm of connective and soft tissue of left low limb, including hip
C49.5	Malignant neoplasm of connective and soft tissue of pelvis
C49.6	Malignant neoplasm of conn and soft tissue of trunk, unspecified
C49.8	Malignant neoplasm of overlapping sites of connective and soft tissue
C49.9	Malignant neoplasm of connective and soft tissue, unspecified
C4A.59	Merkel cell carcinoma of other part of trunk
C4A.60	Merkel cell carcinoma of unspecified upper limb, including shoulder
C4A.61	Merkel cell carcinoma of right upper limb, including shoulder
C4A.62	Merkel cell carcinoma of left upper limb, including shoulder
C4A.70	Merkel cell carcinoma of unspecified lower limb, including hip
C4A.71	Merkel cell carcinoma of right lower limb, including hip
C4A.72	Merkel cell carcinoma of left lower limb, including hip
C4A.8	Merkel cell carcinoma of overlapping sites
C4A.9	Merkel cell carcinoma, unspecified
C51.0	Malignant neoplasm of labium majus
C51.1	Malignant neoplasm of labium minus

Code	Descriptor
C51.2	Malignant neoplasm of clitoris
C51.8	Malignant neoplasm of overlapping sites of vulva
C51.9	Malignant neoplasm of vulva, unspecified
C52.	Malignant neoplasm of vagina
C53.0	Malignant neoplasm of endocervix
C53.1	Malignant neoplasm of exocervix
C53.8	Malignant neoplasm of overlapping sites of cervix uteri
C53.9	Malignant neoplasm of cervix uteri, unspecified
C54.0	Malignant neoplasm of isthmus uteri
C54.1	Malignant neoplasm of endometrium
C54.2	Malignant neoplasm of myometrium
C54.3	Malignant neoplasm of fundus uteri
C54.8	Malignant neoplasm of overlapping sites of corpus uteri
C54.9	Malignant neoplasm of corpus uteri, unspecified
C55.	Malignant neoplasm of uterus, part unspecified
C56.1	Malignant neoplasm of right ovary
C56.2	Malignant neoplasm of left ovary
C56.9	Malignant neoplasm of unspecified ovary
C57.00	Malignant neoplasm of unspecified fallopian tube
C57.01	Malignant neoplasm of right fallopian tube
C57.02	Malignant neoplasm of left fallopian tube
C57.10	Malignant neoplasm of unspecified broad ligament
C57.11	Malignant neoplasm of right broad ligament
C57.12	Malignant neoplasm of left broad ligament
C57.20	Malignant neoplasm of unspecified round ligament
C57.21	Malignant neoplasm of right round ligament
C57.22	Malignant neoplasm of left round ligament
C57.3	Malignant neoplasm of parametrium
C57.4	Malignant neoplasm of uterine adnexa, unspecified
C57.7	Malignant neoplasm of other specified female genital organs
C57.8	Malignant neoplasm of overlapping sites of female genital organs
C57.9	Malignant neoplasm of female genital organ, unspecified
C58.	Malignant neoplasm of placenta
C60.0	Malignant neoplasm of prepuce
C60.1	Malignant neoplasm of glans penis
C60.2	Malignant neoplasm of body of penis
C60.8	Malignant neoplasm of overlapping sites of penis
C60.9	Malignant neoplasm of penis, unspecified
C62.00	Malignant neoplasm of unspecified undescended testis
C62.01	Malignant neoplasm of undescended right testis

Code	Descriptor
C62.02	Malignant neoplasm of undescended left testis
C62.10	Malignant neoplasm of unspecified descended testis
C62.11	Malignant neoplasm of descended right testis
C62.12	Malignant neoplasm of descended left testis
C62.90	Malignant neoplasm of unspecified testis, unspecified descended or undescended
C62.91	Malignant neoplasm of right testis, unspecified descended or undescended
C62.92	Malignant neoplasm of left testis, unspecified descended or undescended
C63.00	Malignant neoplasm of unspecified epididymis
C63.01	Malignant neoplasm of right epididymis
C63.02	Malignant neoplasm of left epididymis
C63.10	Malignant neoplasm of unspecified spermatic cord
C63.11	Malignant neoplasm of right spermatic cord
C63.12	Malignant neoplasm of left spermatic cord
C63.2	Malignant neoplasm of scrotum
C63.7	Malignant neoplasm of other specified male genital organs
C63.8	Malignant neoplasm of overlapping sites of male genital organs
C63.9	Malignant neoplasm of male genital organ, unspecified
C64.1	Malignant neoplasm of right kidney, except renal pelvis
C64.2	Malignant neoplasm of left kidney, except renal pelvis
C64.9	Malignant neoplasm of unspecified kidney, except renal pelvis
C65.1	Malignant neoplasm of right renal pelvis
C65.2	Malignant neoplasm of left renal pelvis
C65.9	Malignant neoplasm of unspecified renal pelvis
C66.1	Malignant neoplasm of right ureter
C66.2	Malignant neoplasm of left ureter
C66.9	Malignant neoplasm of unspecified ureter
C67.0	Malignant neoplasm of trigone of bladder
C67.1	Malignant neoplasm of dome of bladder
C67.2	Malignant neoplasm of lateral wall of bladder
C67.3	Malignant neoplasm of anterior wall of bladder
C67.4	Malignant neoplasm of posterior wall of bladder
C67.5	Malignant neoplasm of bladder neck
C67.6	Malignant neoplasm of ureteric orifice
C67.7	Malignant neoplasm of urachus
C67.8	Malignant neoplasm of overlapping sites of bladder
C67.9	Malignant neoplasm of bladder, unspecified
C68.0	Malignant neoplasm of urethra
C68.1	Malignant neoplasm of paraurethral glands
C68.8	Malignant neoplasm of overlapping sites of urinary organs
C68.9	Malignant neoplasm of urinary organ, unspecified

Code	Descriptor
C73.	Malignant neoplasm of thyroid gland
C74.00	Malignant neoplasm of cortex of unspecified adrenal gland
C74.01	Malignant neoplasm of cortex of right adrenal gland
C74.02	Malignant neoplasm of cortex of left adrenal gland
C74.10	Malignant neoplasm of medulla of unspecified adrenal gland
C74.11	Malignant neoplasm of medulla of right adrenal gland
C74.12	Malignant neoplasm of medulla of left adrenal gland
C74.90	Malignant neoplasm of unspecified part of unspecified adrenal gland
C74.91	Malignant neoplasm of unspecified part of right adrenal gland
C74.92	Malignant neoplasm of unspecified part of left adrenal gland
C75.0	Malignant neoplasm of parathyroid gland
C75.1	Malignant neoplasm of pituitary gland
C75.2	Malignant neoplasm of craniopharyngeal duct
C75.3	Malignant neoplasm of pineal gland
C75.4	Malignant neoplasm of carotid body
C75.5	Malignant neoplasm of aortic body and other paraganglia
C75.8	Malignant neoplasm with pluriglandular involvement, unspecified
C75.9	Malignant neoplasm of endocrine gland, unspecified
C76.3	Malignant neoplasm of pelvis
C76.40	Malignant neoplasm of unspecified upper limb
C76.41	Malignant neoplasm of right upper limb
C76.42	Malignant neoplasm of left upper limb
C76.50	Malignant neoplasm of unspecified lower limb
C76.51	Malignant neoplasm of right lower limb
C76.52	Malignant neoplasm of left lower limb
C76.8	Malignant neoplasm of other specified ill defined sites
C77.3	Sec and unspecified malignant neoplasm of axilla and upper limb nodes
C77.4	Sec and unspecified malignant neoplasm of inguinal and lower limb nodes
C77.5	Secondary and unspecified malignant neoplasm of intrapelvic nodes
C77.8	Sec and unspecified malignant neoplasm of nodes of multiple regions
C77.9	Secondary and unspecified malignant neoplasm of lymph node, unspecified
C78.6	Secondary malignant neoplasm of retroperitoneum and peritoneum
C79.00	Secondary malignant neoplasm of unspecified kidney and renal pelvis
C79.01	Secondary malignant neoplasm of right kidney and renal pelvis
C79.02	Secondary malignant neoplasm of left kidney and renal pelvis
C79.10	Secondary malignant neoplasm of unspecified urinary organs
C79.11	Secondary malignant neoplasm of bladder
C79.19	Secondary malignant neoplasm of other urinary organs
C79.2	Secondary malignant neoplasm of skin
C79.51	Secondary malignant neoplasm of bone

Code	Descriptor
C79.52	Secondary malignant neoplasm of bone marrow
C79.60	Secondary malignant neoplasm of unspecified ovary
C79.61	Secondary malignant neoplasm of right ovary
C79.62	Secondary malignant neoplasm of left ovary
C79.70	Secondary malignant neoplasm of unspecified adrenal gland
C79.71	Secondary malignant neoplasm of right adrenal gland
C79.72	Secondary malignant neoplasm of left adrenal gland
C79.82	Secondary malignant neoplasm of genital organs
C79.89	Secondary malignant neoplasm of other specified sites
C79.9	Secondary malignant neoplasm of unspecified site
C7A.098	Malignant carcinoid tumors of other sites
C7A.1	Malignant poorly differentiated neuroendocrine tumors
C7A.8	Other malignant neuroendocrine tumors
C7B.00	Secondary carcinoid tumors, unspecified site
C7B.01	Secondary carcinoid tumors of distant lymph nodes
C7B.03	Secondary carcinoid tumors of bone
C7B.09	Secondary carcinoid tumors of other sites
C7B.1	Secondary Merkel cell carcinoma
C7B.8	Other secondary neuroendocrine tumors
C80.0	Disseminated malignant neoplasm, unspecified
C80.1	Malignant (primary) neoplasm, unspecified
C80.2	Malignant neoplasm associated with transplanted organ
C82.00	Follicular lymphoma grade I, unspecified site
C82.01	Follicular lymphoma grade I, nodes of head, face, and neck
C82.02	Follicular lymphoma grade I, intrathoracic lymph nodes
C82.03	Follicular lymphoma grade I, intra-abdominal lymph nodes
C82.04	Follicular lymphoma grade I, nodes of axilla and upper limb
C82.05	Follicular lymphoma grade I, nodes of inguinal region and lower limb
C82.06	Follicular lymphoma grade I, intrapelvic lymph nodes
C82.07	Follicular lymphoma grade I, spleen
C82.08	Follicular lymphoma grade I, lymph nodes of multiple sites
C82.09	Follicular lymphoma grade I, extranodal and solid organ sites
C82.10	Follicular lymphoma grade II, unspecified site
C82.11	Follicular lymphoma grade II, nodes of head, face, and neck
C82.12	Follicular lymphoma grade II, intrathoracic lymph nodes
C82.13	Follicular lymphoma grade II, intra-abdominal lymph nodes
C82.14	Follicular lymphoma grade II, nodes of axilla and upper limb
C82.15	Follicular lymphoma grade II, nodes of inguinal region and lower limb
C82.16	Follicular lymphoma grade II, intrapelvic lymph nodes
C82.17	Follicular lymphoma grade II, spleen

Code	Descriptor
C82.18	Follicular lymphoma grade II, lymph nodes of multiple sites
C82.19	Follicular lymphoma grade II, extranodal and solid organ sites
C82.20	Follicular lymphoma grade III, unspecified, unspecified site
C82.21	Follicular lymph grade III, unspecified, nodes of head, face, and neck
C82.22	Follicular lymphoma grade III, unspecified, intrathoracic lymph nodes
C82.23	Follicular lymphoma grade III, unspecified, intra-abdominal lymph nodes
C82.24	Follicular lymph grade III, unspecified, nodes of axilla and upper limb
C82.25	Follicular lymph grade III, unspecified, nodes of inguinal region and low limb
C82.26	Follicular lymphoma grade III, unspecified, intrapelvic lymph nodes
C82.27	Follicular lymphoma grade III, unspecified, spleen
C82.28	Follicular lymphoma grade III, unspecified, lymph nodes of multiple sites
C82.29	Follicular lymphoma grade III, unspecified, extranodal and solid org sites
C82.30	Follicular lymphoma grade IIIa, unspecified site
C82.31	Follicular lymphoma grade IIIa, nodes of head, face, and neck
C82.32	Follicular lymphoma grade IIIa, intrathoracic lymph nodes
C82.33	Follicular lymphoma grade IIIa, intra-abdominal lymph nodes
C82.34	Follicular lymphoma grade IIIa, nodes of axilla and upper limb
C82.35	Follicular lymphoma grade IIIa, nodes of inguinal region and lower limb
C82.36	Follicular lymphoma grade IIIa, intrapelvic lymph nodes
C82.37	Follicular lymphoma grade IIIa, spleen
C82.38	Follicular lymphoma grade IIIa, lymph nodes of multiple sites
C82.39	Follicular lymphoma grade IIIa, extranodal and solid organ sites
C82.40	Follicular lymphoma grade IIIb, unspecified site
C82.41	Follicular lymphoma grade IIIb, nodes of head, face, and neck
C82.42	Follicular lymphoma grade IIIb, intrathoracic lymph nodes
C82.43	Follicular lymphoma grade IIIb, intra-abdominal lymph nodes
C82.44	Follicular lymphoma grade IIIb, nodes of axilla and upper limb
C82.45	Follicular lymphoma grade IIIb, nodes of inguinal region and lower limb
C82.46	Follicular lymphoma grade IIIb, intrapelvic lymph nodes
C82.47	Follicular lymphoma grade IIIb, spleen
C82.48	Follicular lymphoma grade IIIb, lymph nodes of multiple sites
C82.49	Follicular lymphoma grade IIIb, extranodal and solid organ sites
C82.50	Diffuse follicle center lymphoma, unspecified site
C82.51	Diffuse follicle center lymphoma, nodes of head, face, and neck
C82.52	Diffuse follicle center lymphoma, intrathoracic lymph nodes
C82.53	Diffuse follicle center lymphoma, intra-abdominal lymph nodes
C82.54	Diffuse follicle center lymphoma, nodes of axilla and upper limb
C82.55	Diffuse follicle center lymphoma, nodes of inguinal region and lower limb
C82.56	Diffuse follicle center lymphoma, intrapelvic lymph nodes
C82.57	Diffuse follicle center lymphoma, spleen

Code	Descriptor
C82.58	Diffuse follicle center lymphoma, lymph nodes of multiple sites
C82.59	Diffuse follicle center lymphoma, extranodal and solid organ sites
C82.60	Cutaneous follicle center lymphoma, unspecified site
C82.61	Cutaneous follicle center lymphoma, nodes of head, face, and neck
C82.62	Cutaneous follicle center lymphoma, intrathoracic lymph nodes
C82.63	Cutaneous follicle center lymphoma, intra-abdominal lymph nodes
C82.64	Cutaneous follicle center lymphoma, nodes of axilla and upper limb
C82.65	Cutaneous follicle center lymphoma, nodes of inguinal region and lower limb
C82.66	Cutaneous follicle center lymphoma, intrapelvic lymph nodes
C82.67	Cutaneous follicle center lymphoma, spleen
C82.68	Cutaneous follicle center lymphoma, lymph nodes of multiple sites
C82.69	Cutaneous follicle center lymphoma, extranodal and solid organ sites
C82.80	Other types of follicular lymphoma, unspecified site
C82.81	Other types of follicular lymphoma, nodes of head, face, and neck
C82.82	Other types of follicular lymphoma, intrathoracic lymph nodes
C82.83	Other types of follicular lymphoma, intra-abdominal lymph nodes
C82.84	Other types of follicular lymphoma, nodes of axilla and upper limb
C82.85	Other types of follicular lymphoma, nodes of inguinal region and lower limb
C82.86	Other types of follicular lymphoma, intrapelvic lymph nodes
C82.87	Other types of follicular lymphoma, spleen
C82.88	Other types of follicular lymphoma, lymph nodes of multiple sites
C82.89	Other types of follicular lymphoma, extranodal and solid organ sites
C82.90	Follicular lymphoma, unspecified, unspecified site
C82.91	Follicular lymphoma, unspecified, nodes of head, face, and neck
C82.92	Follicular lymphoma, unspecified, intrathoracic lymph nodes
C82.93	Follicular lymphoma, unspecified, intra-abdominal lymph nodes
C82.94	Follicular lymphoma, unspecified, nodes of axilla and upper limb
C82.95	Follicular lymphoma, unspecified, nodes of inguinal region and lower limb
C82.96	Follicular lymphoma, unspecified, intrapelvic lymph nodes
C82.97	Follicular lymphoma, unspecified, spleen
C82.98	Follicular lymphoma, unspecified, lymph nodes of multiple sites
C82.99	Follicular lymphoma, unspecified, extranodal and solid organ sites
C83.10	Mantle cell lymphoma, unspecified site
C83.11	Mantle cell lymphoma, lymph nodes of head, face, and neck
C83.12	Mantle cell lymphoma, intrathoracic lymph nodes
C83.13	Mantle cell lymphoma, intra-abdominal lymph nodes
C83.14	Mantle cell lymphoma, lymph nodes of axilla and upper limb
C83.15	Mantle cell lymphoma, nodes of inguinal region and lower limb
C83.16	Mantle cell lymphoma, intrapelvic lymph nodes
C83.17	Mantle cell lymphoma, spleen

Code	Descriptor
C83.18	Mantle cell lymphoma, lymph nodes of multiple sites
C83.19	Mantle cell lymphoma, extranodal and solid organ sites
C83.50	Lymphoblastic (diffuse) lymphoma, unspecified site
C83.51	Lymphoblastic lymphoma, nodes of head, face, and neck
C83.52	Lymphoblastic (diffuse) lymphoma, intrathoracic lymph nodes
C83.53	Lymphoblastic (diffuse) lymphoma, intra-abdominal lymph nodes
C83.54	Lymphoblastic lymphoma, nodes of axilla and upper limb
C83.55	Lymphoblastic lymphoma, nodes of inguinal region and lower limb
C83.56	Lymphoblastic (diffuse) lymphoma, intrapelvic lymph nodes
C83.57	Lymphoblastic (diffuse) lymphoma, spleen
C83.58	Lymphoblastic (diffuse) lymphoma, lymph nodes of multiple sites
C83.59	Lymphoblastic lymphoma, extranodal and solid organ sites
C83.70	Burkitt lymphoma, unspecified site
C83.71	Burkitt lymphoma, lymph nodes of head, face, and neck
C83.72	Burkitt lymphoma, intrathoracic lymph nodes
C83.73	Burkitt lymphoma, intra-abdominal lymph nodes
C83.74	Burkitt lymphoma, lymph nodes of axilla and upper limb
C83.75	Burkitt lymphoma, nodes of inguinal region and lower limb
C83.76	Burkitt lymphoma, intrapelvic lymph nodes
C83.77	Burkitt lymphoma, spleen
C83.78	Burkitt lymphoma, lymph nodes of multiple sites
C83.79	Burkitt lymphoma, extranodal and solid organ sites
C83.80	Other non-follicular lymphoma, unspecified site
C83.81	Other non-follicular lymphoma, lymph nodes of head, face, and neck
C83.82	Other non-follicular lymphoma, intrathoracic lymph nodes
C83.83	Other non-follicular lymphoma, intra-abdominal lymph nodes
C83.84	Other non-follicular lymphoma, nodes of axilla and upper limb
C83.85	Other non-follicular lymphoma, nodes of inguinal region and lower limb
C83.86	Other non-follicular lymphoma, intrapelvic lymph nodes
C83.87	Other non-follicular lymphoma, spleen
C83.88	Other non-follicular lymphoma, lymph nodes of multiple sites
C83.89	Other non-follicular lymphoma, extranodal and solid organ sites
C83.90	Non-follicular (diffuse) lymphoma, unspecified, unspecified site
C83.91	Non-follicular lymphoma, unspecified, nodes of head, face, and neck
C83.92	Non-follicular (diffuse) lymphoma, unspecified, intrathoracic lymph nodes
C83.93	Non-follicular (diffuse) lymphoma, unspecified, intra-abdominal lymph nodes
C83.94	Non-follicular lymphoma, unspecified, nodes of axilla and upper limb
C83.95	Non-follicular lymph, unspecified, nodes of inguinal region and lower limb
C83.96	Non-follicular (diffuse) lymphoma, unspecified, intrapelvic lymph nodes
C83.97	Non-follicular (diffuse) lymphoma, unspecified, spleen

Code	Descriptor
C83.98	Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of multiple sites
C83.99	Non-follicular lymphoma, unspecified, extranodal and solid organ sites
C84.00	Mycosis fungoides, unspecified site
C84.01	Mycosis fungoides, lymph nodes of head, face, and neck
C84.02	Mycosis fungoides, intrathoracic lymph nodes
C84.03	Mycosis fungoides, intra-abdominal lymph nodes
C84.04	Mycosis fungoides, lymph nodes of axilla and upper limb
C84.05	Mycosis fungoides, nodes of inguinal region and lower limb
C84.06	Mycosis fungoides, intrapelvic lymph nodes
C84.07	Mycosis fungoides, spleen
C84.08	Mycosis fungoides, lymph nodes of multiple sites
C84.09	Mycosis fungoides, extranodal and solid organ sites
C84.10	Sezary disease, unspecified site
C84.11	Sezary disease, lymph nodes of head, face, and neck
C84.12	Sezary disease, intrathoracic lymph nodes
C84.13	Sezary disease, intra-abdominal lymph nodes
C84.14	Sezary disease, lymph nodes of axilla and upper limb
C84.15	Sezary disease, nodes of inguinal region and lower limb
C84.16	Sezary disease, intrapelvic lymph nodes
C84.17	Sezary disease, spleen
C84.18	Sezary disease, lymph nodes of multiple sites
C84.19	Sezary disease, extranodal and solid organ sites
C84.40	Peripheral t-cell lymphoma, not classified, unspecified site
C84.41	Peripheral t-cell lymph, not class, nodes of head, face, and neck
C84.42	Peripheral t-cell lymphoma, not class, intrathoracic nodes
C84.43	Peripheral t-cell lymphoma, not classified, intra-abdominal nodes
C84.44	Peripheral t-cell lymph, not class, nodes of axilla and upper limb
C84.45	Peripheral t-cell lymph, not class, nodes of inguinal region and low limb
C84.46	Peripheral t-cell lymphoma, not classified, intrapelvic nodes
C84.47	Peripheral t-cell lymphoma, not classified, spleen
C84.48	Peripheral t-cell lymphoma, not classified, nodes of multiple sites
C84.49	Peripheral t-cell lymph, not class, extranodal and solid organ sites
C84.60	Anaplastic large cell lymphoma, ALK-positive, unspecified site
C84.61	Anaplastic large cell lymph, ALK-positive, nodes of head, face, and neck
C84.62	Anaplastic large cell lymphoma, ALK-positive, intrathoracic nodes
C84.63	Anaplastic large cell lymphoma, ALK-positive, intra-abdominal nodes
C84.64	Anaplastic large cell lymph, ALK-positive, nodes of axilla and upper limb
C84.65	Anaplastic large cell lymph, ALK-positive, nodes of inguinal region & low limb
C84.66	Anaplastic large cell lymphoma, ALK-positive, intrapelvic nodes
C84.67	Anaplastic large cell lymphoma, ALK-positive, spleen

Code	Descriptor
C84.68	Anaplastic large cell lymphoma, ALK-positive, nodes of multiple sites
C84.69	Anaplastic large cell lymph, ALK-positive, extranodal and solid org sites
C84.70	Anaplastic large cell lymphoma, ALK-negative, unspecified site
C84.71	Anaplastic large cell lymph, ALK-negative, nodes of head, face, and neck
C84.72	Anaplastic large cell lymphoma, ALK-negative, intrathoracic nodes
C84.73	Anaplastic large cell lymphoma, ALK-negative, intra-abdominal nodes
C84.74	Anaplastic large cell lymph, ALK-negative, nodes of axilla and upper limb
C84.75	Anaplastic large cell lymph, ALK-negative, nodes of inguinal region & low limb
C84.76	Anaplastic large cell lymphoma, ALK-negative, intrapelvic nodes
C84.77	Anaplastic large cell lymphoma, ALK-negative, spleen
C84.78	Anaplastic large cell lymphoma, ALK-negative, nodes of multiple sites
C84.79	Anaplastic large cell lymph, ALK-negative, extranodal and solid org sites
C84.90	Mature T/NK -cell lymphomas, unspecified, unspecified site
C84.91	Mature T/NK -cell lymph, unspecified, nodes of head, face, and neck
C84.92	Mature T/NK -cell lymphomas, unspecified, intrathoracic lymph nodes
C84.93	Mature T/NK -cell lymphomas, unspecified, intra-abdominal lymph nodes
C84.94	Mature T/NK -cell lymph, unspecified, nodes of axilla and upper limb
C84.95	Mature T/NK -cell lymph, unspecified, nodes of inguinal region and low limb
C84.96	Mature T/NK -cell lymphomas, unspecified, intrapelvic lymph nodes
C84.97	Mature T/NK -cell lymphomas, unspecified, spleen
C84.98	Mature T/NK -cell lymphomas, unspecified, lymph nodes of multiple sites
C84.99	Mature T/NK -cell lymph, unspecified, extranodal and solid organ sites
C84.A0	Cutaneous t-cell lymphoma, unspecified, unspecified site
C84.A1	Cutaneous t-cell lymphoma, unspecified nodes of head, face, and neck
C84.A2	Cutaneous t-cell lymphoma, unspecified, intrathoracic lymph nodes
C84.A3	Cutaneous t-cell lymphoma, unspecified, intra-abdominal lymph nodes
C84.A4	Cutaneous t-cell lymphoma, unspecified, nodes of axilla and upper limb
C84.A5	Cutaneous t-cell lymph, unspecified, nodes of inguinal region and lower limb
C84.A6	Cutaneous t-cell lymphoma, unspecified, intrapelvic lymph nodes
C84.A7	Cutaneous t-cell lymphoma, unspecified, spleen
C84.A8	Cutaneous t-cell lymphoma, unspecified, lymph nodes of multiple sites
C84.A9	Cutaneous t-cell lymphoma, unspecified, extranodal and solid organ sites
C84.Z0	Other mature T/NK-cell lymphomas, unspecified site
C84.Z1	Other mature T/NK -cell lymph, nodes of head, face, and neck
C84.Z2	Other mature T/NK -cell lymphomas, intrathoracic lymph nodes
C84.Z3	Other mature T/NK -cell lymphomas, intra-abdominal lymph nodes
C84.Z4	Other mature T/NK -cell lymph, nodes of axilla and upper limb
C84.Z5	Other mature T/NK -cell lymph, nodes of inguinal region and lower limb
C84.Z6	Other mature T/NK -cell lymphomas, intrapelvic lymph nodes
C84.Z7	Other mature T/NK -cell lymphomas, spleen

Code	Descriptor
C84.Z8	Other mature T/NK -cell lymphomas, lymph nodes of multiple sites
C84.Z9	Other mature T/NK -cell lymph, extranodal and solid organ sites
C85.80	Other types of non-Hodgkin lymphoma, unspecified site
C85.81	Other types of non-Hodgkin lymph, nodes of head, face, and neck
C85.82	Other types of non-Hodgkin lymphoma, intrathoracic lymph nodes
C85.83	Other types of non-Hodgkin lymphoma, intra-abdominal lymph nodes
C85.84	Other types of non-Hodgkin lymph, nodes of axilla and upper limb
C85.85	Other types of non-Hodgkin lymph, nodes of inguinal region and lower limb
C85.86	Other types of non-Hodgkin lymphoma, intrapelvic lymph nodes
C85.87	Other specified types of non-Hodgkin lymphoma, spleen
C85.88	Other types of non-Hodgkin lymphoma, lymph nodes of multiple sites
C85.89	Other types of non-Hodgkin lymph, extranodal and solid organ sites
C85.90	Non-Hodgkin lymphoma, unspecified, unspecified site
C85.91	Non-Hodgkin lymphoma, unspecified, nodes of head, face, and neck
C85.92	Non-Hodgkin lymphoma, unspecified, intrathoracic lymph nodes
C85.93	Non-Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes
C85.94	Non-Hodgkin lymphoma, unspecified, nodes of axilla and upper limb
C85.95	Non-Hodg lymphoma, unspecified, nodes of ing region and lower limb
C85.96	Non-Hodgkin lymphoma, unspecified, intrapelvic lymph nodes
C85.97	Non-Hodgkin lymphoma, unspecified, spleen
C85.98	Non-Hodgkin lymphoma, unspecified, lymph nodes of multiple sites
C85.99	Non-Hodgkin lymphoma, unspecified, extranodal and solid organ sites
C86.0	Extranodal NK/T-cell lymphoma, nasal type
C86.1	Hepatosplenic T-cell lymphoma
C86.2	Enteropathy-type (intestinal) T-cell lymphoma
C86.3	Subcutaneous panniculitis-like T-cell lymphoma
C86.4	Blastic NK-cell lymphoma
C86.5	Angioimmunoblastic T-cell lymphoma
C86.6	Primary cutaneous cd30-positive T-cell proliferations
C88.0	Waldenstrom macroglobulinemia
C88.2	Heavy chain disease
C88.3	Immunoproliferative small intestinal disease
C88.4	Extranodal marginal zone b-cell lymphoma mucosa-associated lymphoid tissue (MALT-lymphoma)
C88.8	Other malignant immunoproliferative diseases
C88.9	Malignant immunoproliferative disease, unspecified
C90.00	Multiple myeloma not having achieved remission
C90.01	Multiple myeloma in remission
C90.02	Multiple myeloma in relapse
C90.10	Plasma cell leukemia not having achieved remission

Code	Descriptor
C90.11	Plasma cell leukemia in remission
C90.12	Plasma cell leukemia in relapse
C90.20	Extramedullary plasmacytoma not having achieved remission
C90.21	Extramedullary plasmacytoma in remission
C90.22	Extramedullary plasmacytoma in relapse
C90.30	Solitary plasmacytoma not having achieved remission
C90.31	Solitary plasmacytoma in remission
C90.32	Solitary plasmacytoma in relapse
C91.00	Acute lymphoblastic leukemia not having achieved remission
C91.01	Acute lymphoblastic leukemia, in remission
C91.02	Acute lymphoblastic leukemia, in relapse
C91.10	Chronic lymphocytic leukemia of b-cell type not achieve remission
C91.11	Chronic lymphocytic leukemia of b-cell type in remission
C91.12	Chronic lymphocytic leukemia of b-cell type in relapse
C91.30	Prolymphocytic leukemia of b-cell type not achieve remission
C91.31	Prolymphocytic leukemia of b-cell type, in remission
C91.32	Prolymphocytic leukemia of b-cell type, in relapse
C91.40	Hairy cell leukemia not having achieved remission
C91.41	Hairy cell leukemia, in remission
C91.42	Hairy cell leukemia, in relapse
C91.50	Adult t-cell lymphoma/leukemia (htlv-1-assoc) not achieve remission
C91.51	Adult t-cell lymphoma/leukemia (htlv-1-assoc), in remission
C91.52	Adult t-cell lymphoma/leukemia (htlv-1-assoc), in relapse
C91.60	Prolymphocytic leukemia of t-cell type not achieve remission
C91.61	Prolymphocytic leukemia of t-cell type, in remission
C91.62	Prolymphocytic leukemia of t-cell type, in relapse
C91.90	Lymphoid leukemia, unspecified not having achieved remission
C91.91	Lymphoid leukemia, unspecified, in remission
C91.92	Lymphoid leukemia, unspecified, in relapse
C91.A0	Mature b-cell leukemia Burkitt-type not achieve remission
C91.A1	Mature b-cell leukemia Burkitt-type, in remission
C91.A2	Mature b-cell leukemia Burkitt-type, in relapse
C91.Z0	Other lymphoid leukemia not having achieved remission
C91.Z1	Other lymphoid leukemia, in remission
C91.Z2	Other lymphoid leukemia, in relapse
C92.00	Acute myeloblastic leukemia, not having achieved remission
C92.01	Acute myeloblastic leukemia, in remission
C92.02	Acute myeloblastic leukemia, in relapse
C92.10	Chronic myeloid leukemia, bcr/abl-positive, not having achieved remission
C92.11	Chronic myeloid leukemia, bcr/abl-positive, in remission

Code	Descriptor
C92.12	Chronic myeloid leukemia, bcr/abl-positive, in relapse
C92.20	Atypical chronic myeloid leukemia, bcr/abl-negative, not having achieved remission
C92.21	Atypical chronic myeloid leukemia, bcr/abl-negative, in remission
C92.22	Atypical chronic myeloid leukemia, bcr/abl-negative, in relapse
C92.30	Myeloid sarcoma, not having achieved remission
C92.31	Myeloid sarcoma, in remission
C92.32	Myeloid sarcoma, in relapse
C92.40	Acute promyelocytic leukemia, not having achieved remission
C92.41	Acute promyelocytic leukemia, in remission
C92.42	Acute promyelocytic leukemia, in relapse
C92.50	Acute myelomonocytic leukemia, not having achieved remission
C92.51	Acute myelomonocytic leukemia, in remission
C92.52	Acute myelomonocytic leukemia, in relapse
C92.60	Acute myeloid leukemia w 11q23-abnormality not having achieved remission
C92.61	Acute myeloid leukemia with 11q23-abnormality in remission
C92.62	Acute myeloid leukemia with 11q23-abnormality in relapse
C92.90	Myeloid leukemia, unspecified, not having achieved remission
C92.91	Myeloid leukemia, unspecified in remission
C92.92	Myeloid leukemia, unspecified in relapse
C92.A0	Acute myeloid leukemia with multilineage dysplasia, not having achieved remission
C92.A1	Acute myeloid leukemia with multilineage dysplasia, in remission
C92.A2	Acute myeloid leukemia with multilineage dysplasia, in relapse
C92.Z0	Other myeloid leukemia not having achieved remission
C92.Z1	Other myeloid leukemia, in remission
C92.Z2	Other myeloid leukemia, in relapse
C93.00	Acute monoblastic/monocytic leukemia, not having achieved remission
C93.01	Acute monoblastic/monocytic leukemia, in remission
C93.02	Acute monoblastic/monocytic leukemia, in relapse
C93.10	Chronic myelomonocytic leukemia not having achieved remission
C93.11	Chronic myelomonocytic leukemia, in remission
C93.12	Chronic myelomonocytic leukemia, in relapse
C93.30	Juvenile myelomonocytic leukemia, not having achieved remission
C93.31	Juvenile myelomonocytic leukemia, in remission
C93.32	Juvenile myelomonocytic leukemia, in relapse
C93.90	Monocytic leukemia, unsp, not having achieved remission
C93.91	Monocytic leukemia, unspecified in remission
C93.92	Monocytic leukemia, unspecified in relapse
C93.Z0	Other monocytic leukemia, not having achieved remission
C93.Z1	Other monocytic leukemia, in remission
C93.Z2	Other monocytic leukemia, in relapse

Code	Descriptor
C94.00	Acute erythroid leukemia, not having achieved remission
C94.01	Acute erythroid leukemia, in remission
C94.02	Acute erythroid leukemia, in relapse
C94.20	Acute megakaryoblastic leukemia not having achieved remission
C94.21	Acute megakaryoblastic leukemia, in remission
C94.22	Acute megakaryoblastic leukemia, in relapse
C94.30	Mast cell leukemia not having achieved remission
C94.31	Mast cell leukemia, in remission
C94.32	Mast cell leukemia, in relapse
C94.40	Acute panmyelosis with myelofibrosis not having achieved remission
C94.41	Acute panmyelosis with myelofibrosis, in remission
C94.42	Acute panmyelosis with myelofibrosis, in relapse
C94.6	Myelodysplastic disease, not classified
C94.80	Other specified leukemias not having achieved remission
C94.81	Other specified leukemias, in remission
C94.82	Other specified leukemias, in relapse
C95.00	Acute leukemia of unspecified cell type not having achieved remission
C95.01	Acute leukemia of unspecified cell type, in remission
C95.02	Acute leukemia of unspecified cell type, in relapse
C95.10	Chronic leukemia of unspecified cell type not having achieved remission
C95.11	Chronic leukemia of unspecified cell type, in remission
C95.12	Chronic leukemia of unspecified cell type, in relapse
C95.90	Leukemia, unspecified not having achieved remission
C95.91	Leukemia, unspecified, in remission
C95.92	Leukemia, unspecified, in relapse
C96.0	Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis
C96.2	Malignant mast cell tumor
C96.4	Sarcoma of dendritic cells (accessory cells)
C96.5	Multifocal and unisystemic Langerhans-cell histiocytosis
C96.6	Unifocal Langerhans-cell histiocytosis
C96.9	Malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified
C96.A	Histiocytic sarcoma
C96.Z	Other specified malignant neoplasms of lymphoid, hematopoietic and related tissue
D03.59	Melanoma in situ of other part of trunk
D03.60	Melanoma in situ of unspecified upper limb, including shoulder
D03.61	Melanoma in situ of right upper limb, including shoulder
D03.62	Melanoma in situ of left upper limb, including shoulder
D03.70	Melanoma in situ of unspecified lower limb, including hip
D03.71	Melanoma in situ of right lower limb, including hip
D03.72	Melanoma in situ of left lower limb, including hip

Code	Descriptor
D03.8	Melanoma in situ of other sites
D03.9	Melanoma in situ, unspecified
D04.5	Carcinoma in situ of skin of trunk
D04.60	Carcinoma in situ skin of unspecified upper limb, including shoulder
D04.61	Carcinoma in situ skin of right upper limb, including shoulder
D04.62	Carcinoma in situ skin of left upper limb, including shoulder
D04.70	Carcinoma in situ of skin of unsp lower limb, including hip
D04.71	Carcinoma in situ of skin of right lower limb, including hip
D04.72	Carcinoma in situ of skin of left lower limb, including hip
D04.8	Carcinoma in situ of skin of other sites
D04.9	Carcinoma in situ of skin, unspecified
D06.0	Carcinoma in situ of endocervix
D06.1	Carcinoma in situ of exocervix
D06.7	Carcinoma in situ of other parts of cervix
D06.9	Carcinoma in situ of cervix, unspecified
D07.0	Carcinoma in situ of endometrium
D07.1	Carcinoma in situ of vulva
D07.2	Carcinoma in situ of vagina
D07.30	Carcinoma in situ of unspecified female genital organs
D07.39	Carcinoma in situ of other female genital organs
D07.4	Carcinoma in situ of penis
D07.60	Carcinoma in situ of unspecified male genital organs
D07.61	Carcinoma in situ of scrotum
D07.69	Carcinoma in situ of other male genital organs
D09.0	Carcinoma in situ of bladder
D09.10	Carcinoma in situ of unspecified urinary organ
D09.19	Carcinoma in situ of other urinary organs
D09.3	Carcinoma in situ of thyroid and other endocrine glands
D09.8	Carcinoma in situ of other specified sites
D09.9	Carcinoma in situ, unspecified
D16.00	Benign neoplasm of scapula and long bones of unspecified upper limb
D16.01	Benign neoplasm of scapula and long bones of right upper limb
D16.02	Benign neoplasm of scapula and long bones of left upper limb
D16.10	Benign neoplasm of short bones of unspecified upper limb
D16.11	Benign neoplasm of short bones of right upper limb
D16.12	Benign neoplasm of short bones of left upper limb
D16.20	Benign neoplasm of long bones of unspecified lower limb
D16.21	Benign neoplasm of long bones of right lower limb
D16.22	Benign neoplasm of long bones of left lower limb
D16.30	Benign neoplasm of short bones of unspecified lower limb

Code	Descriptor
D16.31	Benign neoplasm of short bones of right lower limb
D16.32	Benign neoplasm of short bones of left lower limb
D17.0	Benign lipomatous neoplasm of skin, subcutaneous tissue of head, face and neck
D17.1	Benign lipomatous neoplasm of skin, subcutaneous tissue of trunk
D17.20	Benign lipomatous neoplasm of skin, subcutaneous tissue of unspecified limb
D17.21	Benign lipomatous neoplasm of skin, subcutaneous tissue of right arm
D17.22	Benign lipomatous neoplasm of skin, subcutaneous tissue of left arm
D17.23	Benign lipomatous neoplasm of skin, subcutaneous tissue of right leg
D17.24	Benign lipomatous neoplasm of skin, subcutaneous tissue of left leg
D17.30	Benign lipomatous neoplasm of skin, subcutaneous tissue of unspecified sites
D17.39	Benign lipomatous neoplasm of skin, subcutaneous tissue of sites
D17.6	Benign lipomatous neoplasm of spermatic cord
D17.71	Benign lipomatous neoplasm of kidney
D17.72	Benign lipomatous neoplasm of other genitourinary organ
D17.79	Benign lipomatous neoplasm of other sites
D17.9	Benign lipomatous neoplasm, unspecified
D18.00	Hemangioma unspecified site
D18.01	Hemangioma of skin and subcutaneous tissue
D18.02	Hemangioma of intracranial structures
D18.09	Hemangioma of other sites
D18.1	Lymphangioma, any site
D19.1	Benign neoplasm of mesothelial tissue of peritoneum
D19.7	Benign neoplasm of mesothelial tissue of other sites
D19.9	Benign neoplasm of mesothelial tissue, unspecified
D20.1	Benign neoplasm of soft tissue of peritoneum
D21.10	Benign neoplasm of connective/soft tissue of unspecified upper limb, including shoulder
D21.11	Benign neoplasm of connective/soft tissue of right upper limb, including shoulder
D21.12	Benign neoplasm of connective/soft tissue of left upper limb, including shoulder
D21.20	Benign neoplasm of connective/soft tissue of unspecified lower limb, including hip
D21.21	Benign neoplasm of connective/soft tissue of right lower limb, including hip
D21.22	Benign neoplasm of connective/soft tissue of left lower limb, including hip
D21.5	Benign neoplasm of connective and other soft tissue of pelvis
D21.6	Benign neoplasm of connective/soft tissue of trunk, unspecified
D21.9	Benign neoplasm of connective and other soft tissue, unspecified
D22.0	Melanocytic nevi of lip
D22.5	Melanocytic nevi of trunk
D22.60	Melanocytic nevi of unspecified upper limb, including shoulder
D22.61	Melanocytic nevi of right upper limb, including shoulder
D22.62	Melanocytic nevi of left upper limb, including shoulder

Code	Descriptor
D22.70	Melanocytic nevi of unspecified lower limb, including hip
D22.71	Melanocytic nevi of right lower limb, including hip
D22.72	Melanocytic nevi of left lower limb, including hip
D22.9	Melanocytic nevi, unspecified
D23.5	Other benign neoplasm of skin of trunk
D23.60	Other benign neoplasm skin/ unspecified upper limb, including shoulder
D23.61	Other benign neoplasm skin/ right upper limb, including shoulder
D23.62	Other benign neoplasm skin/ left upper limb, including shoulder
D23.70	Other benign neoplasm skin/ unspecified lower limb, including hip
D23.71	Other benign neoplasm skin/ right lower limb, including hip
D23.72	Other benign neoplasm skin/ left lower limb, including hip
D23.9	Other benign neoplasm of skin, unspecified
D25.0	Submucous leiomyoma of uterus
D25.1	Intramural leiomyoma of uterus
D25.2	Subserosal leiomyoma of uterus
D25.9	Leiomyoma of uterus, unspecified
D26.0	Other benign neoplasm of cervix uteri
D26.1	Other benign neoplasm of corpus uteri
D26.7	Other benign neoplasm of Other parts of uterus
D26.9	Other benign neoplasm of uterus, unspecified
D27.0	Benign neoplasm of right ovary
D27.1	Benign neoplasm of left ovary
D27.9	Benign neoplasm of unspecified ovary
D28.0	Benign neoplasm of vulva
D28.1	Benign neoplasm of vagina
D28.2	Benign neoplasm of uterine tubes and ligaments
D28.7	Benign neoplasm of other specified female genital organs
D28.9	Benign neoplasm of female genital organ, unspecified
D29.0	Benign neoplasm of penis
D29.20	Benign neoplasm of unspecified testis
D29.21	Benign neoplasm of right testis
D29.22	Benign neoplasm of left testis
D29.30	Benign neoplasm of unspecified epididymis
D29.31	Benign neoplasm of right epididymis
D29.32	Benign neoplasm of left epididymis
D29.4	Benign neoplasm of scrotum
D29.8	Benign neoplasm of other specified male genital organs
D29.9	Benign neoplasm of male genital organ, unspecified
D30.00	Benign neoplasm of unspecified kidney
D30.01	Benign neoplasm of right kidney

Code	Descriptor
D30.02	Benign neoplasm of left kidney
D30.10	Benign neoplasm of unspecified renal pelvis
D30.11	Benign neoplasm of right renal pelvis
D30.12	Benign neoplasm of left renal pelvis
D30.20	Benign neoplasm of unspecified ureter
D30.21	Benign neoplasm of right ureter
D30.22	Benign neoplasm of left ureter
D30.3	Benign neoplasm of bladder
D30.4	Benign neoplasm of urethra
D30.8	Benign neoplasm of other specified urinary organs
D30.9	Benign neoplasm of urinary organ, unspecified
D34	Benign neoplasm of thyroid gland
D35.00	Benign neoplasm of unspecified adrenal gland
D35.01	Benign neoplasm of right adrenal gland
D35.02	Benign neoplasm of left adrenal gland
D35.1	Benign neoplasm of parathyroid gland
D35.2	Benign neoplasm of pituitary gland
D35.3	Benign neoplasm of craniopharyngeal duct
D35.4	Benign neoplasm of pineal gland
D35.5	Benign neoplasm of carotid body
D35.6	Benign neoplasm of aortic body and other paraganglia
D35.7	Benign neoplasm of other specified endocrine glands
D35.9	Benign neoplasm of endocrine gland, unspecified
D36.0	Benign neoplasm of lymph nodes
D36.10	Benign neoplasm of peripheral nerves and autonomic nervous sys, unspecified
D36.11	Ben neoplasm of peripheral nerves and autonomic nervous system of face/head/neck
D36.12	Ben neoplasm of peripheral nerves & autonomic nervous system, upper limb, including shoulder
D36.13	Ben neoplasm of peripheral nerves & autonomic nervous system of low limb, including hip
D36.14	Benign neoplasm of peripheral nerves and autonomic nervous system of thorax
D36.15	Benign neoplasm of peripheral nerves and autonomic nervous system of abdominal
D36.16	Benign neoplasm of peripheral nerves and autonomic nervous system of pelvis
D36.17	Benign neoplasm of peripheral nerves and autonomic nervous system of trunk, unspecified
D36.7	Benign neoplasm of other specified sites
D36.9	Benign neoplasm, unspecified site
D39.0	Neoplasm of uncertain behavior of uterus
D39.10	Neoplasm of uncertain behavior of unspecified ovary
D39.11	Neoplasm of uncertain behavior of right ovary

Code	Descriptor
D39.12	Neoplasm of uncertain behavior of left ovary
D39.2	Neoplasm of uncertain behavior of placenta
D39.8	Neoplasm of uncertain behavior of other female genital organs
D39.9	Neoplasm of uncertain behavior of female genital organ, unspecified
D3A.098	Benign carcinoid tumors of other sites
D3A.8	Other benign neuroendocrine tumors
D40.10	Neoplasm of uncertain behavior of unspecified testis
D40.11	Neoplasm of uncertain behavior of right testis
D40.12	Neoplasm of uncertain behavior of left testis
D40.8	Neoplasm of uncertain behavior of other male genital organs
D40.9	Neoplasm of uncertain behavior of male genital organ, unspecified
D41.00	Neoplasm of uncertain behavior of unspecified kidney
D41.01	Neoplasm of uncertain behavior of right kidney
D41.02	Neoplasm of uncertain behavior of left kidney
D41.10	Neoplasm of uncertain behavior of unspecified renal pelvis
D41.11	Neoplasm of uncertain behavior of right renal pelvis
D41.12	Neoplasm of uncertain behavior of left renal pelvis
D41.20	Neoplasm of uncertain behavior of unspecified ureter
D41.21	Neoplasm of uncertain behavior of right ureter
D41.22	Neoplasm of uncertain behavior of left ureter
D41.3	Neoplasm of uncertain behavior of urethra
D41.4	Neoplasm of uncertain behavior of bladder
D41.8	Neoplasm of uncertain behavior of other urinary organs
D41.9	Neoplasm of uncertain behavior of unspecified urinary organ
D44.0	Neoplasm of uncertain behavior of thyroid gland
D44.10	Neoplasm of uncertain behavior of unspecified adrenal gland
D44.11	Neoplasm of uncertain behavior of right adrenal gland
D44.12	Neoplasm of uncertain behavior of left adrenal gland
D44.2	Neoplasm of uncertain behavior of parathyroid gland
D44.3	Neoplasm of uncertain behavior of pituitary gland
D44.4	Neoplasm of uncertain behavior of craniopharyngeal duct
D44.5	Neoplasm of uncertain behavior of pineal gland
D44.6	Neoplasm of uncertain behavior of carotid body
D44.7	Neoplasm of uncertain behavior of aortic body and other paraganglia
D44.9	Neoplasm of uncertain behavior of unspecified endocrine gland
D45.	Polycythemia vera
D46.0	Refractory anemia without ring sideroblasts, so stated
D46.1	Refractory anemia with ring sideroblasts
D46.20	Refractory anemia with excess of blasts, unspecified
D46.21	Refractory anemia with excess of blasts 1

Code	Descriptor
D46.22	Refractory anemia with excess of blasts 2
D46.4	Refractory anemia, unspecified
D46.9	Myelodysplastic syndrome, unspecified
D46.A	Refractory cytopenia with multilineage dysplasia
D46.B	Refractory cytopenia with multilineage dysplasia and ring sideroblasts
D46.C	Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality
D46.Z	Other myelodysplastic syndromes
D47.0	Histiocytic and mast cell tumors of uncertain behavior
D47.1	Chronic myeloproliferative disease
D47.2	Monoclonal gammopathy
D47.3	Essential (hemorrhagic) thrombocythemia
D47.4	Osteomyelofibrosis
D47.9	Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified
D47.Z1	Post-transplant lymphoproliferative disorder (PTLD)
D47.Z9	Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue
D48.0	Neoplasm of uncertain behavior of bone/articular cartilage
D48.1	Neoplasm of uncertain behavior of connective/soft tissue
D48.2	Neoplasm of uncertain behavior of peripheral nerves and autonomic nervous system
D48.4	Neoplasm of uncertain behavior of peritoneum
D48.5	Neoplasm of uncertain behavior of skin
D48.7	Neoplasm of uncertain behavior of other specified sites
D48.9	Neoplasm of uncertain behavior, unspecified
D49.0	Neoplasm of unspecified behavior of digestive system
D49.2	Neoplasm of unspecified behavior of bone, soft tissue, and skin
D49.4	Neoplasm of unspecified behavior of bladder
D49.5	Neoplasm of unspecified behavior of other genitourinary organs
D49.7	Neoplasm of unspecified behavior of endo glands and other parts of nervous system
D49.89	Neoplasm of unspecified behavior of other specified sites
D49.9	Neoplasm of unspecified behavior of unspecified site

It is the provider's responsibility to select codes carried out to the highest level of specificity and selected from the ICD-10-CM codebook appropriate to the year in which the service is rendered for the claim(s) submitted. If the indications of this policy have been satisfied, then the following ICD-10-CM codes may be relevant.

OTHER INFORMATION

Documentation Requirements

1. All documentation must be maintained in the patient's medical record and available to the contractor / payer upon request.
2. Every page of the record must be legible and include appropriate patient identification information (e.g., complete name, dates of service(s)). The record must include the physician or non-physician practitioner responsible for and providing the care of the patient.
3. The submitted medical record should support the use of the selected ICD-10-CM code(s). The submitted CPT®/HCPCS code should describe the service performed.
4. Each claim must be submitted with the ICD-10-CM code(s) that reflect the condition of the patient, and indicate the reason(s) for which the service was performed. Claims submitted without ICD-10-CM codes will be returned.
5. Documentation in the patient medical record must support:
 - a. The reasonable and necessary requirements as outlined under the coverage and limitations sections of this policy and must be available to the contractor / payer for review upon request.
 - b. Documentation must include the planned course of therapy, type and delivery of treatment, level of clinical management involved and ongoing documentation of any changes in the course of treatment, and DHV as noted in the covered indications section.

APPENDIX 2 – SCIENTIFIC LITERATURE REFERENCES

BREAST

1. Ares C, Khan S, Macartain AM, et al. Postoperative proton radiotherapy for localized and locoregional breast cancer: potential for clinically relevant improvements? *Int J Radiat Oncol Biol Phys*. 2010 Mar 1;76(3):685-97.
2. Bekelman JE, Lu H, Pugh Stephanie, et al. Pragmatic randomized clinical trial of proton versus photon therapy for patients with non-metastatic breast cancer: the Radiotherapy Comparative Effectiveness (RadComp) Consortium trial protocol. *BMJ*. 2019;9(10).
3. Bradley JA, Dagan R, Ho MW, et al. Initial report of a prospective dosimetric and clinical feasibility trial demonstrates the potential of protons to increase the therapeutic ratio in breast cancer compared with photons. *Int J Radiat Oncol Biol Phys*. 2016 May 1;95(1):411-21.
4. Bush DA, Do S, Lum S, et al. Partial breast radiation therapy with proton beam: 5-year results with cosmetic outcomes. *Int J Radiat Oncol Biol Phys*. 2014;90(3):501-505.
5. Bush DA, Slater JD, Garberoglio C, et al. A technique of partial breast irradiation utilizing proton beam radiotherapy: comparison with conformal x-ray therapy. *Cancer J*. 2007;13(2):114-118.
6. Bush DA, Slater JD, Garberoglio C, et al. Partial breast irradiation delivered with proton beam: results of a phase II trial. *Clin Breast Cancer*. 2011;11(4):241-245.
7. Bush DA, Teichman SL, Do SY, et al. Long-term quality of life outcomes of proton beam PBI compared with photon whole breast radiation therapy. *Int J Radiat Oncol Biol Phys*. 2017 October 1; 99(2): E5.

8. Cartechini G, Fracchiolla F, Menegotti L, et al. Proton pencil beam scanning reduces secondary cancer risk in breast cancer patients with internal mammary chain involvement compared to photon radiotherapy. *Radiation Oncology*. 2020;15.
9. Chang JH, Lee NK, Kim JY, et al. Phase II trial of proton beam accelerated partial breast irradiation in breast cancer. *Radiother Oncol*. 2013;108(2):209-214.
10. Choi JI, Chang AL. Excellent acute toxicity outcomes with proton therapy for partial breast irradiation in early stage breast cancer: Initial results of a multi-institutional phase II trial [abstract]. *Cancer Res*. 2018;78(4).
11. Chowdhary M, Lee A, Gao S, et al. Is proton therapy a “pro” for breast cancer? A comparison of proton vs. non-proton radiotherapy using the National Cancer Database. *Front Oncol*. 2019.
12. Cuaron JJ, Chon B, Tsai H, et al. Early toxicity in patients treated with postoperative proton therapy for locally advanced breast cancer. *Int J Radiat Oncol Biol Phys*. 2015 Jun 1;92(2):284-291.
13. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. *N Eng J Med*. 2013;368(11):987-998.
14. Farace P, Deidda M, Amichetti M. Axillary irradiation omitting axillary dissection in breast cancer: is there a role for shoulder-sparing proton therapy. *Br J Radiol*. 2015 October;88(1054):20150274
15. Fattahi S, Mullikin TC, Aziz KA, et al. Proton therapy for the treatment of inflammatory breast cancer. *Radiother Oncol*. 2022 Jun;171:77-83. doi.org/10.1016/j.radonc.2022.04.008
16. Fega R, Vargas CE, Hartsell WF, et al. Clinical outcomes of breast proton radiation therapy: a multi-institutional analysis of the Proton Collaborative Group Registry. *Int J Radiat Oncol Biol Phys*. 2017;99(2S):S214.
17. Hansen TM, Bartless GK, Mannina EM, et al. Dosimetric comparison of treatment techniques: brachytherapy, intensity-modulated radiation therapy, and proton beam in partial breast irradiation. *Int J Part Ther*. 2015;2(2):376-384.
18. Jimenez RB, Goma C, Nyamwanda J, et al. Intensity modulated proton therapy for postmastectomy radiation of bilateral implant reconstructed breasts: a treatment planning study. *Radiother Oncol*. 2013 May;107(2):213-217.
19. Jimenez RB, Hickey S, DePauw N, et al. Phase II study of proton beam radiation therapy for patients with breast cancer requiring regional nodal irradiation. *J Clin Oncol*. 2019.
20. Kanemoto A, Ishikawa H, Mizumoto M, et al. Proton beam therapy for liver metastasis from breast cancer: five case reports and a review of the literature. *Int Canc Conf J*. 2012;1(4):210-214.
21. Kozak KR, Katz A, Adams J, et al. Dosimetric comparison of proton and photon three-dimensional, conformal, external beam accelerated partial breast irradiation techniques. *Int J Radiat Oncol Biol Phys*. 2006, 65(5):1572-1578.
22. Kozak KR, Smith BL, Adams J, et al. Accelerated partial-breast irradiation using proton beams: initial clinical experience. *Int J Radiat Oncol Biol Phys*. 2006;66(3):691-698.
23. Lin LL, Vennarini S, Dimofte A, et al. Proton beam versus photon beam dose to the heart and left anterior descending artery for left-sided breast cancer. *Acta Oncol*. 2015 Jul;54(7):1032-1039.

24. Lischalk JW, Chen H, Repka MC, et al. Definitive hypofractionated radiation therapy for early stage breast cancer: dosimetric feasibility of stereotactic ablative radiotherapy and proton beam therapy for intact breast tumors. *Adv Radiat Oncol*. 2018;3(3):447-457.
25. Lomax AJ, Cella L, Weber D, et al. Potential role of intensity modulated photons and protons in the treatment of the breast and regional nodes. *Int J Radiat Oncol Biol Phys*. 2003;55(3):785-792.
26. Lundkvist J, Ekman M, Ericsson SR, et al. Economic evaluation of proton radiation therapy in the treatment of breast cancer. *Radiother Oncol*. 2005a;75(2):179-185.
27. Luo L, Cuaron J, Braunstein L, et al. Early outcomes of breast cancer patients treated with post-mastectomy uniform scanning proton therapy. *Radiother Oncol*. 2018.
28. MacDonald SM, Patel SA, Hickey S, et al. Proton therapy for breast cancer after mastectomy: early outcomes of a prospective clinical trial. *Int J Radiat Oncol Biol Phys*. 2013;86(3):484-490.
29. Mailhot VR, Ishaq O, Raldow A, et al. Establishing cost-effective allocation of proton therapy for breast irradiation. *Int J Radiat Oncol Biol Phys*. 2016 May 1;95(1):11-18.
30. Mast ME, Vredevelde EJ, Credoe HM, et al. Whole breast proton irradiation for maximal reduction of heart dose in breast cancer patients. *Breast Cancer Res Treat*. 2014 November;148(1):33-39.
31. McGee LA, Iftekaruddin Z, Chang JHC, et al. Postmastectomy chest wall reirradiation with proton therapy for breast cancer. *Int J Radiat Oncol Biol Phys*. 2017;99(2S):E34.
32. Nichols EM, DeCesaris C, Paulosky K, et al. Cardiac risk factors in black women with breast cancer undergoing proton therapy (PBT): potential for increased therapeutic gain. *Int J Radiat Oncol Biol Phys*. 2021;111(3): e328.
33. Niska JR, Thorpe C, Brusio ME, et al. Proton beam therapy for isolated locoregional recurrence of breast cancer after mastectomy without prior radiation therapy: prospective PCG registry analysis. *Int J Radiat Oncol Biol Phys*. 2018.
34. Orecchia R, Fossati P, Zurrida S, Krengli M. New frontiers in proton therapy: applications in breast cancer. *Curr Opin Oncol*. 2015;26(6):427-432.
35. Santos AM, Kotsanis A, Cunningham L, et al. Estimated the second primary cancer risk due to proton therapy compared to hybrid IMRT for left sided breast cancer. *Acta Oncologica*. 2020.
36. Smith N, Jethwa KR, Gonuguntla K, et al. Early toxicity and patient reported outcomes of post-mastectomy pencil-beam scanning proton therapy in women with immediate tissue expander breast reconstruction. *Int J Radiat Oncol Biol Phys*. 2018;102(3):e573-574.
37. Smith N, Jethwa KR, Viehman JK, et al. Post-mastectomy intensity modulated proton therapy after immediate breast reconstruction: initial report of reconstruction outcomes and predictors of complications. *Radiotherapy and Oncology*. 2019;140:76-83.
38. Stick LB, Yu J, Maraldo MV, et al. Joint estimation of cardiac toxicity and recurrence risks after comprehensive nodal photon vs. proton therapy for breast cancer. *Int J Radiat Oncol Biol Phys*. 2016;97(4):754-761.
39. Taghian AG, Kozak KR, Katz A, et al. Accelerated partial breast irradiation using proton beams: initial dosimetric experience. *Int J Radiat Oncol Biol Phys*. 2006;65(5):1404-1410.
40. Tan T, Chin J, Lu HM, et al. Assessment of cardiac function following proton radiation in a cohort of post mastectomy patients with locally advanced breast cancer. *J Am Coll Cardiol*. 2015;65(10_S).

41. Taylor CW, Wang Z, Macaulay E, et al. Exposure of the heart in breast cancer radiation therapy: a systematic review of heart doses published during 2003-2013. *Int J Radiat Oncol Biol Phys*. 2015 Nov;93(4):845-853.
42. Teichman SL, Do S, Lum S, et al. Improved long-term patient-reported health and well-being outcomes of early-stage breast cancer treated with partial breast proton therapy. *Cancer Medicine*. 2018;7:6064-6076.
43. Thorpe C, Niska JR, Brusio ME, et al. Proton beam therapy reirradiation for recurrent breast cancer: multi-institutional prospective PCG registry analysis. *Int J Radiat Oncol Biol Phys*. 2018.
44. Vega RM, Ishaq O, Raldow A, et al. Establishing cost-effective allocation of proton therapy for breast irradiation. *Int J Radiat Oncol Biol Phys*. 2016 May 1;95(1):11-18.
45. Verma V, Iftekaruddin Z, Badar N, et al. Proton beam radiotherapy as part of comprehensive regional nodal irradiation for locally advanced breast cancer. *Radiother Oncol*. 2017 May;123(2):294-298.
46. Verma V, Shah C, Mehta MP. Clinical outcomes and toxicity of proton radiotherapy for breast cancer. *Clin Breast Cancer*. 2016 Jun;16(3):145-154.
47. Weber DC, Ares C, Lomax AJ, Kurtz JM. Radiation therapy planning with photons and protons for early and advanced breast cancer: an overview. *Radiat Oncol*. 2006;1:22.
48. Xu N, Ho MW, Li Z, et al. Can proton therapy improve the therapeutic ratio in breast cancer patients at risk for nodal disease? *Am J Clin Oncol*. 2014 Dec;37(6):568-574.
49. Yu J, Park SS, Herman MG, et al. Free breathing versus breath-hold scanning beam proton therapy and cardiac sparing in breast cancer. *Int J Part Ther*. 2016;3(3):407-413.

CENTRAL NERVOUS SYSTEM

50. Ajithkumar T, Mazhari A-L, Stickan-Verfürth M, et al. Proton therapy for craniopharyngioma — An early report from a single European centre. *Clin Oncol*. 2018; pii: S0936-6555(18)30043-8.
51. Amelio D, Scartoni D, Farace P, et al. P01.084 Re-irradiation in recurrent glioblastoma: proton therapy with or without chemotherapy. *Neuro-Oncology*. 2018;20(3).
52. Amsbaugh MJ, Grosshans DR, McAleer MF, et al. Proton therapy for spinal ependymomas: planning, acute toxicities, and preliminary outcomes. *Int J Radiat Oncol Biol Phys*. 2012;83(5):1419-1424.
53. Atkins KM, Pashtan IM, Bussiere MR, et al. Proton stereotactic radiosurgery for brain metastases: a single institution analysis of 370 patients. *Int J Radiat Oncol Biol Phys*. 2018; <https://doi.org/10.1016/j.ijrobp.2018.03.056>.
54. Barker FG II, Butler WE, Lyons S, et al. Dose-volume prediction of radiation-related complications after proton beam radiosurgery for cerebral arteriovenous malformations. *J Neurosurg*. 2003;99(2):254-263.
55. Barnes CJ, Bush DA, Grove RI, et al. Fractionated proton beam therapy for acoustic neuromas: tumor control and hearing preservation. *Int J Part Ther*. 2018.
56. Baumert BG, Lomax AJ. A comparison of dose distributions of proton and photon beams in stereotactic conformal radiotherapy of brain lesions. *Int J Radiat Oncol Biol Phys*. 2001;49 (5):1439-1449.
57. Baumert BG, Norton IA, Lomax AJ, et al. Dose conformation of intensity-modulated stereotactic photon beams, proton beams, and intensity-modulated proton beams for intracranial lesions. *Int J Radiat Oncol Biol Phys*. 2004;60:1314–1324

58. Beer J, Kountouri M, Kole AJ, et al. Outcomes, prognostic factors and salvage treatment for recurrent chordoma after pencil beam scanning proton therapy at the Paul Scherrer Institute. *Clin Oncol (R Coll Radiol)*. 2020 Aug;32(8):537-544.
59. Bhattacharyya N, Thornton AF, Joseph MP, et al. Successful treatment of esthesioneuroblastoma and neuroendocrine carcinoma with combined chemotherapy and proton radiation. Results in 9 cases. *Arch Otolaryngol Head Neck Surg*. 1997;123(1):34-40.
60. Bronk JK, Guha-Thakurta N, Allen PK, et al. Analysis of pseudoprogression after proton or photon therapy of 99 patients with low grade and anaplastic glioma. *Clin Translat Radiat Oncol*. 2018. doi: <https://doi.org/10.1016/j.ctro.2018.01.002>.
61. Brower JV, Gans S, Hartsell WF, et al. Proton therapy and helical tomotherapy result in reduced dose deposition to the pancreas in the setting of cranio-spinal irradiation for medulloblastoma: implications for reduced risk of diabetes mellitus in long-term survivors. *Acta Oncol*. 2015;54(4):522-526.
62. Brown AP, Barney CL, Grosshans DR, et al. Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastoma. *Int J Radiat Oncol Biol Phys*. 2013;86(2):277-284.
63. Brown PD, Chung C, Liu DD, et al. A prospective phase II randomized trial of proton radiotherapy vs. intensity modulated radiotherapy for patients with newly diagnosed glioblastoma. *Neuro Oncol*. 2021 Feb 27;noab040. doi: 10.1093/neuonc/noab040.
64. Brownstein J, Min HD, Bussiere M, et al. Particle therapy for the treatment of brain metastases. *Radiotherapy in Managing Brain Metastases*. 2020.
65. Buchwald ZS, Dang Q, Zhou J, et al. Proton radiation is associated with reduced lymphocyte-depleting blood volume in glioblastoma treatment. *Int J Radiat Oncol Biol Phys*. 2020;108(3S).
66. Bush DA, McAllister CJ, Loredó LN, et al. Fractionated proton beam radiotherapy for acoustic neuroma. *Neurosurgery*. 2002;50(2):270-273.
67. Chung C. Lessons learned from proton vs photon radiation therapy for glioblastoma signal-finding trial. *Neuro-Oncology*. 2022;24(5):851. doi.org/10.1093/neuonc/noac028
68. Combs SE, Welzel T, Habermehl D, et al. Prospective evaluation of early treatment outcome in patients with meningiomas treated with particle therapy based on target volume definition with MRI and 68Ga-DOTATOC-PET. *Acta Oncol*. 2013;52(3):514-520.
69. Combs SE. Does proton therapy have a future in CNS tumors? *Curr Treat Options Neurol*. 2017.
70. Combs SE. Proton and carbon ion therapy of intracranial gliomas. *Progress in Neurological Surgery*. 2018;32:57-65.
71. Cordova JS, Samson P, Huang J, et al. Patterns of lymphopenia in patients receiving proton craniospinal irradiation. *Int J Radiat Oncol Biol Phys*. 2020;108(3S).
72. De Amorim Bernstein K, Sethi R, Trofimov, et al. Early clinical outcomes using proton radiation for children with central nervous system atypical teratoid rhabdoid tumors. *Int J Radiat Oncol Biol Phys*. 2013;86(1):114-120.
73. DeLaney TF. Long term results of Phase II study of high dose photon/proton radiotherapy in the management of spine chordomas, chondrosarcomas, and other sarcomas. *J Surg Oncol*. 2014;110(2):115-122.

74. Dinh J, Stoker J, Georges RH, et al. Comparison of proton therapy techniques for treatment of the whole brain as a component of craniospinal radiation. *Radiat Oncol*. 2013;8:289.
75. Eaton BR, Esiashvili N, Kim S, et al. Endocrine outcomes with proton and photon radiotherapy for standard risk medulloblastoma. *Neuro Oncol*. 2016 Jun;18(6):881-887.
76. Eekers DBP, Roelofs E, Cubillos-Mesias M, et al. Intensity-modulated proton therapy decreases dose to organs at risk in low-grade glioma patients: results of a multicentric *in silico* ROCOCO trial. *Acta Oncologica*. 2018.
77. Fitzek MM, Linggood RM, Adams J, Munzenrider JE. Combined proton and photon irradiation for craniopharyngioma: long-term results of the early cohort of patients treated at Harvard Cyclotron Laboratory and Massachusetts General Hospital. *Int J Radiat Oncol Biol Phys*. 2006;64(5):1348-1354.
78. Fitzek MM, Thornton AF, Harsh G, et al. Dose-escalation with proton/photon irradiation for Daumas-Duport lower-grade glioma: results of an institutional phase I/II trial. *Int J Radiat Oncol Biol Phys*. 2001;51(1):131-137.
79. Fitzek MM, Thornton AF, Rabinov JD, et al. Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: results of a phase II prospective trial. *J Neurosurg*. 1999;91(2):251-260.
80. Giantsoudi D, Sethi RV, Yeap BY, et al. Incidence of CNS injury for a cohort of 111 patients treated with proton therapy for medulloblastoma: LET and RBE associations for areas of injury. *Int J Radiat Oncol Biol Phys*. 2016;95(1):287-296.
81. Gridley DS, Grover RS, Loredó LM, et al. Proton beam therapy for tumors of the CNS. *Expert Rev Neurother*. 2010 Feb;10(2):319-330.
82. Gunther JR, Rahman AR, Dong W, et al. Craniospinal irradiation prior to stem cell transplant for hematologic malignancies with CNS involvement: Effectiveness and toxicity after photon or proton treatment. *Prac Radiat Oncol*. 2017 Nov;7(6):e401-e408.
83. Harrabi SB, Bougati N, Mohr A, et al. Dosimetric advantages of proton therapy over conventional radiotherapy with photons in young patients and adults with low-grade glioma. *Strahlenther Onkol*. 2016 Nov;192(11):759-769.
84. Harsh GR, Thornton AF, Chapman PH, et al. Proton beam stereotactic radiosurgery of vestibular schwannomas. *Int J Radiat Oncol Biol Phys*. 2002;54(1):35-44.
85. Hattangadi JA, Chapman PH, Bussière MR, et al. Planned two-fraction proton beam stereotactic radiosurgery for high-risk inoperable cerebral arteriovenous malformations. *Int J Radiat Oncol Biol Phys*. 2012;83(2):533-541.
86. Hauswald H, Rieken S, Ecker S, et al. First experiences in treatment of low-grade glioma grade I and II with proton therapy. *Radiat Oncol*. 2012;7:189.
87. Hug EB, DeVries A, Thornton AF, et al. Management of atypical and malignant meningiomas: role of high-dose, 3D-conformal radiation therapy. *J Neurooncol*. 2000;48(2):151-160.
88. Ito Y, Okumura T, Suzuki K, et al. Long-term outcome of proton beam radiosurgery for arteriovenous malformations larger than 30 mm in diameter. *Neurol Med Chir (Tokyo)*. 2011;51(9):624-629.
89. Jhaveri J, Cheng E, Buchwald ZS, et al. Proton versus photon radiation therapy for primary gliomas: an analysis of the National Cancer Data Base. *Front Oncol*. 2018.

90. Johnson WD, Loredó LN, Chung A, et al. Surgery and radiotherapy: complementary tools in the management of benign intracranial tumors. *Neurosurg Focus*. 2008;24(5):E2.
91. Kahn J, Loeffler JS, Niemierko A, et al. Long-term outcomes of patients with spinal cord gliomas treated by modern conformal radiation techniques. *Int J Radiat Oncol Biol Phys*. 2011;81(1):232-238.
92. Kamran SC, Dworkin ML, Niemierko A, et al. Patterns of Failure and Risk Factors for Recurrence Among Low-Grade Glioma Patients Treated With Proton Radiation Therapy. *Int J Radiat Oncol Biol Phys*. 2017 Oct 1; 99(2): E83.
93. Kang KH, Schapira E, Niemierko A, et al. The role of proton beam therapy in central neurocytoma: a single-institution experience. *Pract Radiat Oncol*. 2018. <https://doi.org/10.1016/j.prro.2018.02.005>.
94. Kjellberg RN, Sweet WH, Preston WM, Koehler AM. The Bragg peak of a proton beam in intracranial therapy of tumors. *Trans Am Neurol Assoc*. 1962;87:216-218.
95. Kuchler M, El Shafie RA, Adeberg S, et al. Outcome after Radiotherapy for Vestibular Schwannomas (VS)—Differences in Tumor Control, Symptoms and Quality of Life after Radiotherapy with Photon versus Proton Therapy. *Cancers*. 2022;14(8):1916. <https://doi.org/10.3390/cancers14081916>
96. Langegard U, Ahlberg K, Fransson P, et al. Evaluation of quality of care in relation to health-related quality of life of patients diagnosed with brain tumor: a novel clinic for proton beam therapy. *Support Care Cancer*. 2019 Jul;27(7):2679-2691.
97. Lesueur P, Calugaru V, Nauraye C, et al. Proton therapy for treatment of intracranial benign tumors in adults: a systematic review. *Cancer Treatment Reviews*. 2019;72:56-64.
98. McDonald MW, Plankenhorn DA, McMullen KP, et al. Proton therapy for atypical meningiomas. *J Neurooncol*. 2015;123(1):123-128.
99. Mizumoto M, Okumura T, Ishikawa E, et al. Reirradiation for recurrent malignant brain tumor with radiotherapy or proton beam therapy. Technical considerations based on experience at a single institution. *Strahlenther Onkol*. 2013 August;189(8):656-663.
100. Mizumoto M, Tsuboi K, Igaki H, et al. Phase I/II trial of hyperfractionated concomitant boost proton radiotherapy for supratentorial glioblastoma multiforme. *Int J Radiat Oncol Biol Phys*. 2010;77(1):98-105.
101. Mizumoto M, Yamamoto T, Ishikawa E, et al, Tsuboi K. Proton beam therapy with concurrent chemotherapy for glioblastoma multiforme: comparison of nimustine hydrochloride and temozolomide. *J Neurooncol*. 2016 Oct;130(1):165-170.
102. Mohan R, Liu AY, Brown PD, et al. Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons. *Neuro-Oncology*. 2020.
103. Moignier A, Gelover E, Wang D, et al. Theoretical benefits of dynamic collimation in pencil beam scanning proton therapy for brain tumors: dosimetric and radiobiological metrics. *Int J Radiat Oncol Biol Phys*. 2016;95(1):171-180.
104. Murray FR, Snider JW, Schneider RA, et al. Prognostic factors for spinal chordomas and chondrosarcomas treated with postoperative pencil-beam scanning proton therapy: a large, single-institution experience. *Journal of Neurosurgery*. 2020.

105. Murray FR, Snider JW, Bolsi A, et al. Long-term clinical outcomes of Pencil Beam Scanning Proton Therapy for benign and non-benign intracranial meningiomas. *Int J Radiat Oncol Biol Phys*. 2017, doi: 10.1016/j.ijrobp.2017.08.005.
106. Nakai Y, Ito Y, Sato M, et al. Multimodality treatment for cerebral arteriovenous malformations. Complementary role of proton beam radiotherapy. *Neurol Med Chir (Tokyo)*. 2012;52(12):859-864.
107. Noël G, Bollet MA, Calugaru V, et al. Functional outcome of patients with benign meningioma treated by 3D conformal irradiation with a combination of photons and protons. *Int J Radiat Oncol Biol Phys*. 2005;62(5):1412-1422.
108. Noël G, Habrand JL, Mammar H, et al. Highly conformal therapy using proton component in the management of meningiomas. *Strahlenther Onkol*. 2002;178(9):480-485.
109. Oshiro Y, Mizumoto M, Okumura T, et al. Clinical results of proton beam therapy for advanced neuroblastoma. *Radiat Oncol*. 2013;8(1):142.
110. Palma G, Taffelli A, Fellin F, et al. Modelling the risk of radiation induced alopecia in brain tumor patients treated with scanned proton beams. *Radiotherapy and Oncology*. 2020;144:127-134.
111. Park J, Park Y, Lee SU, et al. Differential dosimetric benefit of proton beam therapy over intensity-modulated radiotherapy for a variety of targets in patients with intracranial germ cell tumors. *Radiat Oncol*. 2015 June;10:135.
112. Petit JH, Biller BMK, Yock TI, et al. Proton stereotactic radiotherapy for persistent adrenocorticotropin-producing adenomas. *J Clin Endocrinol Metab*. 2008;93(2):393-399.
113. Ronson BB, Schulte RW, Han KP, et al. Fractionated proton beam irradiation of pituitary adenomas. *Int J Radiat Oncol Biol Phys*. 2006;64(2):425-434.
114. Rutenberg MS, Rotondo RL, Rao D, et al. Clinical outcomes following proton therapy for adult craniopharyngioma: a single-institution cohort study. *Journal of Neuro-Oncology*. 2020;147:387-395.
115. Scartoni D, Amelio D, Lorentini S, et al. P05.58 Active beam scanning proton therapy for large skull base benign meningiomas: early outcomes. *Neuro-Oncology*. 2018;20(3).
116. Shih HA, Sherman JC, Nachtigall LB, et al. Proton therapy for low-grade gliomas: Results from a prospective trial. *Cancer*. 2015 May 15;121(10):1712-1719.
117. Silander H, Pellettieri L, Enblad P, et al. Fractionated, stereotactic proton beam treatment of cerebral arteriovenous malformations. *Acta Neurol Scand*. 2004;109(2):85-90.
118. Smith GL, Rahman AR, Dong W, et al. Proton versus photon craniospinal irradiation for hematologic malignancies involving the CNS: effectiveness and toxicity in the setting of stem cell transplant. *Int J Radiat Oncol Biol Phys*. 2016 Oct 1;96(2S):E496.
119. Snider JW, Schneider RA, Poelma-Tap D, et al. Long-term outcomes and prognostic factors following pencil-beam scanning proton radiotherapy for spinal chordomas: a large, single-institution cohort. *Int J Radiat Oncol Biol Phys*. 2018. <https://doi.org/10.1016/j.ijrobp.2018.01.060>.
120. Song J, Aljabab S, Abduljabbar L, et al. Radiation-induced brain injury in patients with meningioma treated with proton or photon therapy. *J Neurooncol*. 2021. <https://doi.org/10.1007/s11060-021-03758-y>.
121. Tabrizi S, Yeap BY, Sherman JC, et al. Long-term outcomes and late adverse effects of a prospective study on proton radiotherapy for patients with low-grade glioma. *Radiother Oncol*. 2019; 137:95-101.

122. Tabrizi S, Yeap BY, Sherman JC, et al. Long-term outcomes of a prospective trial on proton therapy for low-grade glioma. *Int J Radiat Oncol Biol Phys*. 2017 Oct 1;99(2):S189.
123. Vernimmen FJ, Mohamed Z, Slabbert JP, et al. Long-term results of stereotactic proton beam radiotherapy for acoustic neuromas. *Radiother Oncol*. 2009; 90(2): 208-212.
124. Vernimmen FJ, Slabbert JP, Wilson JA, et al. Stereotactic proton beam therapy for intracranial arteriovenous malformations. *Int J Radiat Oncol Biol Phys*. 2005;62(1):44-52.
125. Vlachogiannis P, Gudjonsson O, Montelius A, et al. Hypofractionated high-energy proton-beam irradiation is an alternative treatment for WHO grade I meningiomas. *Acta Neurochir*. 2017 Dec;159(12):2391-2400.
126. Wattson DA, Yanquturi SK, Spiegel DY, et al. Outcomes of proton therapy for patients with functional pituitary adenomas. *Int J Radiat Oncol Biol Phys*. 2014 Nov 1;90(3):532-539.
127. Weber DC, Chan AW, Bussiere MR, et al. Proton beam radiosurgery for vestibular schwannoma: tumor control and cranial nerve toxicity. *Neurosurgery*. 2003;53(3):577-586.
128. Weber DC, Lomax AJ, Rutz HP, et al. Spot-scanning proton radiation therapy for recurrent, residual or untreated intracranial meningiomas. *Radiother Oncol*. 2004;71(3):251-258.
129. Weber DC, Schneider R, Goitein G, et al. Spot scanning-based proton therapy for intracranial meningioma: long-term results from the Paul Scherrer Institute. *Int J Radiat Oncol Biol Phys*. 2012;83(3):865-871.
130. Wenkel E, Thornton AF, Finkelstein D, et al. Benign meningioma: partially resected, biopsied, and recurrent intracranial tumors treated with combined proton and photon radiotherapy. *Int J Radiat Oncol Biol Phys*. 2000;48(5):1363-1370.
131. Wilkinson B, Morgan H, Gondi V, et al. Low levels of acute toxicity associated with proton therapy for low-grade glioma: A Proton Collaborative Group study. *Int J Radiat Oncol Biol Phys*. 2016 Oct 1;96(2S):E135.
132. Williams V, Halasz L, Rockhill J, et al. RTHP-14. Pseudoprogression in high grade glioma patients after proton or photon therapy. *Neuro-Oncology*. 2019;21(6):vi213.
133. Yerramilli D, Bussiere MR, Loeffler JS, et al. Proton beam therapy (for CNS tumors). Adults In: Chang E., Brown P., Lo S., Sahgal A., Suh J. (eds) *Adult CNS Radiation Oncology*. Springer, Cham.
134. Yock TI, Weyman EA, Goldberg S, et al. HRQoL in medulloblastoma patients enrolled on a prospective phase II study of proton radiation. *J Clin Oncol*. 2015;33(15):e21029.
135. Zhu S, Rotondo R, Mendenhall WM, et al. Long-term outcomes of fractionated stereotactic proton therapy for vestibular schwannoma: a case series. *Int J Part Ther*. 2018.
136. Arnaud Beddok, MD, Nathaniel Scher, MD, et al. Protontherapy for adult craniopharyngioma: experience of a single institution in 91 consecutive patients, *Neuro-Oncology*, 2022;, noac210, <https://doi.org/10.1093/neuonc/noac210>

GASTROINTESTINAL

Anus

137. Anand A, Bues MWG, Keole SR, et al. Scanning proton beam therapy reduces normal tissue exposure in pelvic radiotherapy for anal cancer. *Radiother Oncol*. 2015 Dec;117(3):505-508.

138. Ojerholm E, Kirk ML, Thompson RF, et al. Pencil-beam scanning proton therapy for anal cancer: a dosimetric comparison with intensity-modulated radiotherapy. *Acta Oncol*. 2015;54(8):1209-1217.

Esophagus

139. Celik E, Baus W, Baues C, et al. Volumetric modulated arc therapy versus intensity-modulated proton therapy in neoadjuvant irradiation of locally advanced oesophageal cancer. *Radiat Oncol*. 2020;15(120).
140. Chuong MD, Hallemeier CL, Jabbour SK, Yu J, Badiyan S, Merrell KW, Mishra MV, Li H, Verma V, Lin SH. Improving outcomes for esophageal cancer using proton beam therapy. *Int J Radiat Oncol Biol Phys*. 2015; available online.
141. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial. *JAMA*. 1999 May 5;281(17):1623-7.
142. DeCesaris CM, Berger M, Choi JI, et al. Pathologic complete response (PCR) rates and outcomes after neoadjuvant chemoradiotherapy with proton or photon radiation for adenocarcinomas of the esophagus and gastroesophageal junction. *J Gastrointest Oncol*. 2020;11(4):663-73.
143. DeCesaris CM, McCarroll R, Mishra MV, et al. Assessing outcomes of patients treated with re-irradiation utilizing proton pencil-beam scanning for primary or recurrent malignancies of the esophagus and gastroesophageal junction. *J Thorac Oncol*. 2020;15(6):1054-1064.
144. Echeverria AE, McCurdy M, Castillo R, et al. Proton therapy radiation pneumonitis local doseresponse in esophagus cancer patients. *Radiother Oncol*. 2013;106(1):124-129.
145. Fang P, Shiraishi Y, Jiang W, et al. Lymphocyte-sparing effect of proton therapy in patients with esophageal cancer. *Int J Radiat Oncol Biol Phys*. 2017;98(2):e6.
146. Fernandes A, Berman AT, Mick R, et al. A prospective study of proton beam reirradiation for esophageal cancer. *Int J Radiat Oncol Biol Phys*. 2016 May 1;95(1):483-487.
147. Gajjar SR, Allen PK, He L, et al. Reduced incidence of severe acute toxicities in esophageal cancer treated with proton therapy. *Int J Part Ther*. 2015;2(2).
148. Gayed IW, Liu HH, Yusuf SW, et al. The prevalence of myocardial ischemia after concurrent chemoradiation therapy as detected by gated myocardial perfusion imaging in patients with esophageal cancer. *J Nucl Med*. 2006 Nov;47(11):1756-62.
149. Gergelis KR, Jethwa KR, Tryggestad EJ, et al. Proton beam radiotherapy for esophagus cancer: state of the art. *J Thorac Dis*. 2020;12(11):7002-7010.
150. Haque W, Verma V, Butler EB, The BS. Utilization of neoadjuvant intensity-modulated radiation therapy and proton beam therapy for esophageal cancer in the United States. *J Gastrointest Oncol*. 2018. <http://jgo.amegroups.com/article/view/18383>.
151. Hirano Y, Onozawa M, Hojo H, et al. Dosimetric comparison between proton beam therapy and photon radiation therapy for locally advanced esophageal squamous cell carcinoma. *Radiat Oncol*. 2018;13(23).
152. Ishikawa H, Hashimoto T, Moriwaki T, et al. Proton beam therapy combined with concurrent chemotherapy for esophageal cancer. *Anticancer Res*. 2015 Mar;35(3):1757-1762.

153. Jethwa KR, Haddock MG, Tryggestad EJ, et al. The emerging role of proton therapy for esophagus cancer. *J Gastrointest Oncol*. 2020 Feb;11(1):144-156.
154. Karube M, Nakayama H. Proton therapy for patients with esophageal cancer: history, characteristics, clinical outcome and future direction of proton beam therapy. *Global Health and Medicine*. 2020.
155. Koyama S, Tsujii H, Yokota H, et al. Proton beam therapy for patients with esophageal carcinoma. *Jpn J Clin Oncol*. 1994;24(3):144-153.
156. Koyama S, Tsujii H. Proton beam therapy with high-dose irradiation for superficial and advanced esophageal carcinomas. *Clin Cancer Res*. 2003;9(10 Pt 1):3571-3577.
157. Lester SC, Lin SH, Chuong M, et al. A multi-institutional analysis of trimodality therapy for esophageal cancer in elderly patients. *Int J Radiat Oncol Biol Phys*. 2017;98(4):820-828.
158. Lin SH, Hallemeier CL, Chuong M. Proton beam therapy for the treatment of esophageal cancer. *Chin Clin Oncol*. 2016 Aug;5(4):53. doi: 10.21037/cco.2016.07.04. PubMed PMID: 27558254.
159. Lin SH, Komaki R, Liao Z, et al. Proton beam therapy and concurrent chemotherapy for esophageal cancer. *Int J Radiat Oncol Biol Phys*. 2012;83(3):e345-e351.
160. Lin SH, Merrell KW, Shen J, et al. Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer. *Radiother Oncol*. 2017;123(3):376-381.
161. Ling TC, Slater JM, Nookala P, et al. Analysis of intensity-modulated radiation therapy (IMRT), proton and 3D conformal radiotherapy (3D-CRT) for reducing perioperative cardiopulmonary complications in esophageal cancer patients. *Cancers*. 2014;6(4):2356-2368.
162. Makishima H, Ishikawa H, Terunuma T, et al. Comparison of adverse effects of proton and X-ray chemoradiotherapy for esophageal cancer using an adaptive dose volume histogram analysis. *J Radiat Res*. 2015 May; 56(3):568-576.
163. Mizumoto M, Sugahara S, Nakayama H, et al. Clinical results of proton-beam therapy for locoregionally advanced esophageal cancer. *Strahlenther Onkol*. 2010;186(9):482-488.
164. Mizumoto M, Sugahara S, Okumura T, et al. Hyperfractionated concomitant boost proton beam therapy for esophageal carcinoma. *Int J Radiat Oncol Biol Phys*. 2011;81(4):e601-e606.
165. Ono T, Wada H, Ishikawa H, et al. Proton beam therapy is a safe and effective treatment in elderly patients with esophageal squamous cell carcinoma. *Thoracic Cancer*. 2020.
166. Patel SA, Edgington SK, Adams J, et al. Novel use of proton beam therapy for neoadjuvant treatment of radiation-associated squamous cell carcinoma of the esophagus. *J Gastrointest Oncol*. 2018.
167. Prayongrat A, Xu C, Li H, Lin SH. Clinical outcomes of intensity-modulated proton therapy and concurrent chemotherapy in esophageal carcinoma: a single institutional experience. *Adv Radiat Oncol*. 2017 Jun 13;2(3):301-307.
168. Sugahara S, Tokuyue K, Okumura T, et al. Clinical results of proton beam therapy for cancer of the esophagus. *Int J Radiat Oncol Biol Phys*. 2005;61(1):76-84.
169. Takada A, Nakamura T, Takayama K, et al. Preliminary treatment results of proton beam therapy with chemoradiotherapy for stage I-III esophageal cancer. *Cancer Med*. 2016 Mar;5(3):506-515.
170. Wang J, Wei C, Tucker SL, et al. Predictors of postoperative complications after trimodality therapy for esophageal cancer. *Int J Radiat Oncol Biol Phys*. 2013;86(5):885-891.

171. Warren S, Hurt CH, Crosby T, et al. The potential of proton therapy to reduce acute haematological toxicity in concurrent chemoradiotherapy for oesophageal cancer. *Int J Radiation Oncol Biol Phys*. 2017;99(3):729-737.
172. Xi M, Xu C, Liao Z, et al. Comparative outcomes after definitive chemoradiotherapy using proton beam therapy versus intensity-modulated radiation therapy for esophageal cancer: a retrospective single-institutional analysis. *Radiat Oncol*. 2017. DOI: 10.1016/j.ijrobp.2017.06.2450.
173. Zhang X, Zhao KL, Guerrero TM, et al. Four-dimensional computed tomography-based treatment planning for intensity-modulated radiation therapy and proton therapy for distal esophageal cancer. *Int J Radiat Oncol Biol Phys*. 2008 Sep 1;72(1):278-287.
174. Michael S. Rutenberg, Bradford S. Hoppe, et. Al. Proton Therapy With Concurrent Chemotherapy for Thoracic Esophageal Cancer: Toxicity, Disease Control, and Survival Outcomes. *Int J Part Ther* 1 January 2023; 9 (3): 18–29. doi: <https://doi.org/10.14338/IJPT-22-00021.1>

Liver

175. Abei M, Okumura T, Fukuda K, et al. A phase I study on combined therapy with proton-beam radiotherapy and in situ tumor vaccination for locally advanced recurrent hepatocellular carcinoma. *Radiat Oncol*. 2013;8:239.
176. Ahmadi T, Okumura T, Onaya H, et al. Preservation of hypervascularity in hepatocellular carcinoma after effective proton-beam radiotherapy – CT observation. *Clin Radiol*. 1999;54(4):253-256.
177. Apisarnthanarax S, Yeung R, Bowen S, Chapman TR. Proton beam therapy for hepatic malignancies. *Gastrointestinal Malignancies*. 2017: 171-195.
178. Bhangaroo RS, Mullikin TC, Ashman JB, et al. Intensity modulated proton therapy for hepatocellular carcinoma: initial clinical experience. *Adv Radiat Oncol*. 2021;6(4): 100675.
179. Bush DA, Hillebrand DJ, Slater JM, Slater JD. High-dose proton beam radiotherapy of hepatocellular carcinoma: preliminary results of a phase II trial. *Gastroenterology*. 2004;127(5 Suppl 1):S189-S193.
180. Bush DA, Kayali Z, Grove R, Slater JD. The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: a phase 2 prospective trial. *Cancer*. 2011;117(13):3053-3059.
181. Bush DA, Smith JC, Slater JD, et al. Randomized clinical trial comparing proton beam radiation therapy with transarterial chemoembolization for hepatocellular carcinoma: results of an interim analysis. *Int J Radiat Oncol Biol Phys*. 2016 May;95(1):477-82.
182. Chadha AS, Gunther JR, Minsky BD, et al. Proton therapy outcomes for localized, unresectable hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys*. 2016 Oct 1;96(2S):E181-E182.
183. Cheng JY, Liu CM, Wang YM, et al. Proton versus photon radiotherapy for primary hepatocellular carcinoma: a propensity-matched analysis. *Radiat Oncol*. 2020;15(1):159.
184. Chiba T, Tokuyue K, Matsuzaki Y, et al. Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients. *Clin Cancer Res*. 2005;11(10):3799-3805.
185. Chuong MD, et al. Proton beam therapy for liver cancer is well tolerated: outcomes from the Proton Collaborative Group REG001-09 trial. *J Clin Oncol*. 2017.
186. Colbert LE, Cloyd JM, Koay EJ, et al. Proton beam radiation as salvage therapy for bilateral colorectal liver metastases not amenable to second-stage hepatectomy. *Surgery*. 2017 Jun;161(6):1543-1548

187. Dionisi F, Brolese A, Siniscalchi B, et al. Clinical results of active scanning proton therapy for primary liver tumors. *Tumori Journal*. 2020.
188. Dionisi F, Ben-Josef E. The use of proton therapy in the treatment of gastrointestinal cancers: liver. *Cancer J*. 2014;20(6):371-7.
189. Dionisi F, Widesott L, Lorentini S, Amichetti M. Is there a role for proton therapy in the treatment of hepatocellular carcinoma? A systematic review. *Radiother Oncol*. 2014 April;111(1):1-10.
190. Dyer MA, McDonnell EI, Yeap BY, et al. Change in platelet count and normal liver dosimetry in patients receiving proton radiation therapy for unresectable hepatocellular carcinoma or intrahepatic cholangiocarcinoma. *Int J Radiat Oncol Biol Phys*. 2016 Oct 1;96(2S):E174-E175.
191. Fukumitsu N, Hashimoto T, Okumura T, et al. Investigation of the geometric accuracy of proton beam irradiation in the liver. *Int J Radiat Oncol Biol Phys*. 2012; 82(2): 826-833.
192. Fukumitsu N, Okumura T, Numajiri H, et al. Follow-up study of liver metastasis from breast cancer treated by proton beam therapy. *Mol Clin Oncol*. 2017;7(1): 56-60.
193. Fukumitsu N, Okumura T, Takizawa D, et al. Proton beam therapy for metastatic liver tumors. *Radiother Oncol*. 2015 November; 117(2):322-7.
194. Fukumitsu N, Sugahara S, Nakayama H, et al. A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys*. 2009;74(3):831-836.
195. Fukumitsu N, Okumura T, Takizawa D, et al. Proton beam therapy for liver metastases from gastric cancer. *J Radiat Res*. 2016;1-6.
196. Gandhi SJ, Liang X, Ding X, et al. Clinical decision tool for optimal delivery of liver stereotactic body radiation therapy: photons versus protons. *Pract Radiat Oncol*. 2015 July-August;5(4):209-18.
197. Hashimoto S, Ogino H, Iwata H, et al. Efficacy of Proton Beam Therapy for Hepatocellular Carcinoma With Portal Vein or Inferior Vena Cava Tumor Thrombosis. *Int J Radiat Oncol Biol Phys*. 2017 October 1; 99(2): E152-153.
198. Hashimoto T, Tokuyue K, Fukumitsu N, et al. Repeated proton beam therapy for hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys*. 2006;65(1):196-202.
199. Hata M, Tokuyue K, Sugahara S, et al. Proton beam therapy for aged patients with hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys*. 2007;69(3):805-812.
200. Hata M, Tokuyue K, Sugahara S, et al. Proton beam therapy for hepatocellular carcinoma patients with severe cirrhosis. *Strahlenther Onkol*. 2006b;182(12):713-720.
201. Hata M, Tokuyue K, Sugahara S, et al. Proton beam therapy for hepatocellular carcinoma with limited treatment options. *Cancer*. 2006a;107(3):591-598.
202. Hata M, Tokuyue K, Sugahara S, et al. Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus. *Cancer*. 2005;104(4):794-801.
203. Hata M, Tokuyue K, Sugahara S, et al. Proton irradiation in a single fraction for hepatocellular carcinoma patients with uncontrollable ascites. *Strahlenther Onkol*. 2007;183(8):411-416.
204. Hsieh CE, Venkatesulu BP, Lee CH, et al. Predictors of radiation-induced liver disease in eastern and western patients with hepatocellular carcinoma undergoing proton beam therapy. *Int J Radiat Oncol Biol Phys*. 2019 Sep 1;105(1):73-86..

205. Hong TS, Delaney TF, Mamon HJ et al. A prospective feasibility study of respiratory gated proton beam therapy. *Pract Radiat Oncol*. 2014;4(5):316-322.
206. Hong TS, Grassberger C, Yeap BY, et al. Hepatocyte growth factor is associated With liver dysfunction and survival: biomarker results of a phase 2 study of proton beam therapy in patients with hepatocellular carcinoma and intrahepatic cholangiocarcinoma. *Int J Radiat Oncol Biol Phys*. 2017 Oct 1;99(2):S89.
207. Hong TS, Wo JY, Borger DR, et al. Phase II study of proton-based stereotactic body radiation therapy for liver metastases: importance of tumor genotype. *J Natl Cancer Inst*. 2017;109(9):dix031.
208. Hong TS, Wo JY, Yeap BY, et al. Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. *J Clin Oncol*. 2016;34(5): 460-468.
209. Hsieh CE, Hong JH, Lin CC, et al. Complete response of unresectable icteric-type hepatocellular carcinoma to hypofractionated proton beam therapy with concurrent plus adjuvant sorafenib: a case report. *Ther Radiol Oncol*. 2018.
210. Hung SP, Huang BS, Hsieh CE, et al. Clinical outcomes of patients with unresectable cholangiocarcinoma treated with proton beam therapy. *American Journal of Clinical Oncology*. 2019.
211. Iwata H, Ogino H, Hattori Y, et al. Image-guided proton therapy for elderly patients with hepatocellular carcinoma: high local control and quality of life preservation. *Cancers*. 2021.
212. Kanemoto A, Mizumoto M, Okumura T, et al. Dose-volume histogram analysis for risk factors of radiation-induced rib fracture after hypofractionated proton beam therapy for hepatocellular carcinoma. *Acta Oncol*. 2013;52(3):538-544.
213. Kang JI, Sufficool DC, Hsueh CT, et al. A phase I trial of proton stereotactic body radiation therapy for liver metastases. *J Gastrointest Oncol*. 2018.
214. Kawashima M, Furuse J, Nishio T, et al. Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. *J Clin Oncol*. 2005;23(9):1839-1846.
215. Kawashima M, Kohno R, Nakachi K, et al. Dose-volume histogram analysis of the safety of proton beam therapy for unresectable hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys*. 2011;79(5):1479-1486.
216. Kim JY, et al. Normal liver sparing by proton beam therapy for hepatocellular carcinoma: Comparison with helical intensity modulated radiotherapy and volumetric modulated arc therapy. *Acta Oncologica*. 2015;54(10): 1827-1832.
217. Kim TH, Park JW, Kim BH, et al. Optimal time of tumour response evaluation and effectiveness of hypofractionated proton beam therapy for inoperable or recurrent hepatocellular carcinoma. *Oncotarget*. 2017;9(3):4034-4043.
218. Kim TH, Park JW, Kim YJ, et al. Phase I dose-escalation study of proton beam therapy for inoperable hepatocellular carcinoma. *Cancer Res Treat*. 2015 January; 47(1):34-45.
219. Kimura K, Nakamura T, Ono T, et al. Clinical results of proton beam therapy for hepatocellular carcinoma over 5 cm. *Hepatol Res*. 2017 February 14. doi: 10.1111/hepr.12874.
220. Klein J, Dawson LA. Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities. *Int J Radiat Oncol Biol Phys*. 2013 Sep 1;87(1):22-32.

221. Kobashi K, Prayongrat A, Kimoto T, et al. Assessing the uncertainty in a normal tissue complication probability difference (Δ NTCP): radiation-induced liver disease (RILD) in liver tumour patients treated with proton vs X-ray therapy. *J Radiat Res*. 2018. doi: 10.1093/jrr/rry018.
222. Komatsu S, Fukumoto T, Demizu Y, et al. Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma. *Cancer*. 2011;117(21):4890-4904.
223. Komatsu S, Fukumoto T, Demizu Y, et al. The effectiveness of particle radiotherapy for hepatocellular carcinoma associated with inferior vena cava tumor thrombus. *J Gastroenterol*. 2011;46(7):913-920.
224. Lee CH, Hung SP, Hong JH, et al. How small is too small? New liver constraint is needed – proton therapy of hepatocellular carcinoma patients with small normal liver. *PLoS One*. 2018;13(9).
225. Leung HWC, Chan ALF. Cost-utility of stereotactic radiation therapy versus proton beam therapy for inoperable advanced hepatocellular carcinoma. *Oncotarget*. 2017 Apr 21. doi: 10.18632/oncotarget.
226. Ling TC, Kang JI, Bush DA, et al. Proton therapy for hepatocellular carcinoma. *Chin J Cancer Res*. 2012;24(4):361-367.
227. Masato A, Okumura T, Fukuda K, et al. A phase I study on combined therapy with proton-beam radiotherapy and in situ tumor vaccination for locally advanced recurrent hepatocellular carcinoma. *Radiat Oncol*. 2013;8(239).
228. Matsuzaki Y, Osuga T, Chiba T, et al. New, effective treatment using proton irradiation for unresectable hepatocellular carcinoma. *Intern Med*. 1995;34(4):302-304.
229. Mizumoto M, Okumura T, Hashimoto T, et al. Evaluation of liver function after proton beam therapy for hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys*. 2012;82(3):e529-e535.
230. Mizumoto M, Okumura T, Hashimoto T, et al. Proton beam therapy for hepatocellular carcinoma: a comparison of three treatment protocols. *Int J Radiat Oncol Biol Phys*. 2011;81(4):1039-1045.
231. Mizumoto M, Oshiro Y, Okumura T, et al. Proton beam therapy for hepatocellular carcinoma: a review of the University of Tsukuba experience. *Int J Part Ther*. 2016:571-578.
232. Mizumoto M, Tokuyue K, Sugahara S, et al. Proton beam therapy for hepatocellular carcinoma adjacent to the porta hepatis. *Int J Radiat Oncol Biol Phys*. 2008;71(2):462-467.
233. Mizumoto M, Tokuyue K, Sugahara S, et al. Proton beam therapy for hepatocellular carcinoma with inferior vena cava tumor thrombus: report of three cases. *Jpn J Clin Oncol*. 2007;37(6):459-462.
234. Mondlane G, Gubanski M, Lind PA, et al. Comparative study of the calculated risk of radiation-induced cancer after photo- and proton-beam based radiosurgery of liver metastases. *Eur J Med Phys*. 2017 Oct;42:263-270.
235. Mondlane G, Ureba A, Michael G, et al. Evaluation of the risk for radiation-induced liver disease following photon- or proton-beam radiosurgery of liver metastases. *Radiat Oncol*. 2018, <http://urn.kb.se/resolve?urn=urn:nbn:se:su:diva-158223>.
236. Nakayama H, Sugahara S, Fukuda K, et al. Proton beam therapy for hepatocellular carcinoma located adjacent to the alimentary tract. *Int J Radiat Oncol Biol Phys*. 2011;80(4):992-995.
237. Nakayama H, Sugahara S, Tokita M, et al. Proton beam therapy for hepatocellular carcinoma. The University of Tsukuba experience. *Cancer*. 2009;115(23):5499-5506.

238. Niizawa G, Ikegami T, Matsuzaki Y, et al. Monitoring of hepatocellular carcinoma, following proton radiotherapy, with contrast-enhanced color Doppler ultrasonography. *J Gastroenterol*. 2005;40(3):283-290.
239. Ohara K, Okumura T, Tsuji H, et al. Clearance of parenchymal tumors following radiotherapy: analysis of hepatocellular carcinomas treated by proton beams. *Radiother Oncol*. 1996;41(3):233-236.
240. Ohara K, Okumura T, Tsuji H, et al. Radiation tolerance of cirrhotic livers in relation to the preserved functional capacity: analysis of patients with hepatocellular carcinoma treated by focused proton beam radiotherapy. *Int J Radiat Oncol Biol Phys*. 1997;38(2):367-372.
241. Ohkawa A, Mizumoto M, Ishikawa H, et al. Proton beam therapy for unresectable intrahepatic cholangiocarcinoma. *J Gastroenterol Hepatol*. 2015 May;30(5):957-63.
242. Oshiro Y, Mizumoto M, Okumura T, et al. Analysis of repeated proton beam therapy for patients with hepatocellular carcinoma. *Radiother Oncol*. 2017 May;123(2):240-245.
243. Otsuka M, Ohara K, Takada Y, et al. Radiation therapy for intrahepatic recurrence after hepatectomy for hepatocellular carcinoma. *Int J Clin Oncol*. 2003;8(3):151-155.
244. Parzen JS, Hartsell W, Chang J, et al. Hypofractionated proton beam radiotherapy in patients with unresectable liver tumors: multi-institutional prospective results from the Proton Collaborative Group. *Radiat Oncol*. 2020 Nov 4;15(1):255.
245. Petersen JB, Lassen Y, Hansen AT, et al. Normal liver tissue sparing by intensity-modulated proton stereotactic body radiotherapy for solitary liver tumours. *Acta Oncol*. 2011 Aug;50(6):823-828.
246. Qi WX, Shen F, Qing Z, Xiao-Mao G. Charged particle therapy versus photon therapy for patients with hepatocellular carcinoma: a systematic review and meta-analysis. *Radiat Oncol*. 2015;114:289-295.
247. Schlachterman A, Craft WW Jr, Hilgenfeldt E, et al. Current and future treatments for hepatocellular carcinoma. *World J Gastroenterol*. 2015 July;21(28):8478-8491.
248. Shibata S, Takamatsu S, Yamamoto K, et al. Proton beam therapy without fiducial markers using four-dimensional CT planning for large hepatocellular carcinomas. *Cancers*. 2018; 10(3), 71; doi:10.3390/cancers10030071.
249. Shimizu S, Okumura T, Oshiro Y, et al. Clinical outcomes of previously untreated patients with unresectable intrahepatic cholangiocarcinoma following proton beam therapy. *Radiation Oncology*. 2019.
250. Sugahara S, Nakayama H, Fukuda K, et al. Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis. *Strahlenther Onkol*. 2009;185(12):782-788.
251. Sugahara S, Oshiro Y, Nakayama H, et al. Proton beam therapy for large hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys*. 2010;76(2):460-466.
252. Taddei PJ, Howell RM, Krishnan S, et al. Risk of second malignant neoplasm following proton versus intensity-modulated photon radiotherapies for hepatocellular carcinoma. *Phys Med Biol*. 2010;55(23):7055-65.
253. Takahashi H, Mori K, Sekino Y, et al. Angiographic findings in patients with hepatocellular carcinoma previously treated using proton beam therapy. *Journal of Oncology*. 2019.
254. Tamura S, Okamura Y, Sugiura T, et al. A comparison of the outcomes between surgical resection and proton beam therapy for single primary hepatocellular carcinoma. *Surgery Today*. 2019

255. Wang X, Krishnan S, Zhang X, et al. Proton radiotherapy for liver tumors: dosimetric advantages over photon plans. *Med Dosim*. 2008 Winter;33(4):259-67.
256. Yamaguchi H, Honda M, Hamada K, et al. The effectiveness of proton beam therapy for liver metastatic recurrence in gastric cancer patients. *Japanese Journal of Clinical Oncology*. 2020.
257. Yeung R, Bowen SR, Mullen TD, et al. Chest Wall Toxicity in Hypofractionated proton beam therapy for liver malignancies. *Int J Radiat Oncol Biol Phys*. 2017;99(2):E202.
258. Yeung RH, Chapman TR, Bowen SR, Apisarnthanarax S. Proton beam therapy for hepatocellular carcinoma. *Expert Rev Anticancer Ther*. 2017 Oct;17(10):911-924.
259. Yoshida M, Ogino H, Iwata H, et al. Transient increases of serum AFP and PIVKA-II levels After proton therapy do not necessarily indicate progression of hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys*. 2017;99(2S):E203.
260. Kangpyo Kim, Jeong Il Yu, Hee Chul Park, et. al, A phase II trial of hypofractionated high-dose proton beam therapy for unresectable liver metastases, *Radiotherapy and Oncology*, 2022, ISSN 0167-8140, <https://doi.org/10.1016/j.radonc.2022.09>

Pancreas

261. Gorte J, Beyreuther E, Danen EH, et al. Comparative proton and photon irradiation combined with pharmacological inhibitors in 3D pancreatic cancer cultures. *Cancers*. 2020;12(11):3216.
262. Hitchcock K, Nichols R, Morris C, et al. Feasibility of pancreatectomy following high-dose proton therapy for unresectable pancreatic cancer. *World J Gastrointest Surg*. 2017 Apr 27;9(4):103–108.
263. Hong TS, Ryan DP, Blaszkowsky LS, et al. Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the head. *Int J Radiat Oncol Biol Phys*. 2011;79(1):151-157.
264. Lee D, Komatsu S, Terashima K, et al. Surgical spacer placement for proton radiotherapy in locally advanced pancreatic body and tail cancers: initial clinical results. *Radiation Oncology*. 2021;16(3).
265. Maemura K, Mataka Y, Kurahara H, et al. Comparison of proton beam radiotherapy and hyperfractionated accelerated chemoradiotherapy for locally advanced pancreatic cancer. *Pancreatology*. 2017 Sep – Oct;17(5):833-838.
266. Nichols RC Jr, George TJ, Zaiden RA Jr, et al. Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity. *Acta Oncol*. 2013;52(3):498-505.
267. Nichols RC Jr, Huh S, Li Z, Rutenberg M. Proton therapy for pancreatic cancer. *World J Gastrointest Oncol*. 2015 Sep;7(9):141-147.
268. Nichols RC Jr, Huh SN, Prado KL, et al. Protons offer reduced normal-tissue exposure for patients receiving postoperative radiotherapy for resected pancreatic head cancer. *Int J Radiat Oncol Biol Phys*. 2012 May 1;83(1):158-163.
269. Nichols RC Jr, Morris CG, Hoppe BS, Rutenberg MS. A phase II trial of escalated dose proton radiotherapy with elective nodal irradiation and concomitant chemotherapy for patients with unresectable, borderline resectable, or medically inoperable pancreatic adenocarcinoma. *J Clin Oncol*. 2017;35(4).

270. Nichols RC Jr, Morris CG, Prabhu K, et al. Postoperative proton therapy for pancreatic cancer patients enrolled on the Proton Collaborative Group (PCG) registry. *J Clin Oncol*. 2018;36(4):513.
271. Nichols RC Jr, Morris CG, Tottenham L, et al. Proton therapy for pancreatic and ampullary carcinoma. *Int J Radiat Oncol Biol Phys*. 2017;99(2): E176-177.
272. Rutenberg MS, Nichols RC. Proton beam radiotherapy for pancreas cancer. *J Gastrointest Oncol*. 2020;11(1):166-175.
273. Sio TT, Merrell KW, Beltran CJ, et al. Spot-scanned pancreatic stereotactic body proton therapy: a dosimetric feasibility and robustness study. *Phys Med*. 2016 Feb;32(2):331-42.
274. Takatori K, Terashima K, Yoshida R, et al. Upper gastrointestinal complications associated with gemcitabine-concurrent proton radiotherapy for inoperable pancreatic cancer. *J Gastroenterol*. 2014 Jun;49(6):1074-1080.
275. Terashima K, Demizu Y, Hashimoto N, et al. A phase I/II study of gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer without distant metastasis. *Radiother Oncol*. 2012;103(1):25-31.
276. Thompson RF, et al. A dosimetric comparison of proton and photon therapy in unresectable cancers of the head of pancreas. *Med Phys*. 2014 Aug;41(8):081711.
277. Yu Z, Hong Z, Shang Q, et al. Proton and carbon ion radiation therapy for locally advanced pancreatic cancer: a phase I dose escalation study. *Pancreatol*. 2020.

Rectus

278. Colaco RJ, Nichols RC, Huh S, et al. Protons offer reduced bone marrow, small bowel, and urinary bladder exposure for patients receiving neoadjuvant radiotherapy for resectable rectal cancer. *J Gastrointest Oncol*. 2014;5(1):3-8.
279. Pedersen J, Flampouri S, Bryant C, et al. Cross-modality applicability of rectal normal tissue complication probability models from photon- to proton-based radiotherapy. *Radiotherapy and Oncology*. 2019.
280. Radu C, Norrlid O, Braendengen M, et al. Integrated peripheral boost in preoperative radiotherapy for the locally most advanced non-resectable rectal cancer patients. *Acta Oncol*. 2013; 52(3):528-537.
281. Wolff HA, Wagner DM, Conradi L, et al. Irradiation with protons for the individualized treatment of patients with locally advanced rectal cancer: A planning study with clinical implications. *Radiother Oncol*. 2012; 102(1): 30-37.

Other Gastrointestinal

282. Barsky AR, Reddy VK, Plastaras JP, et al. Proton beam re-irradiation for gastrointestinal malignancies: a systematic review. *Journal of Gastrointestinal Oncology*. 2020.
283. Barsky AR, Reddy VK, Plastaras JP, et al. Proton beam re-irradiation for gastrointestinal malignancies: a systematic review. *Journal of Gastrointestinal Oncology*. 2019.
284. Hallemeier CL, Ashman JB, Maddock MG. A brief overview of the use of proton beam radiotherapy for gastrointestinal cancers. *J Gastrointest Oncol*. 2020 Feb;11(2):139-143.

285. Plastaras JP, Dionisi F, Wo JY. Gastrointestinal cancer: non-liver proton therapy for gastrointestinal cancers. *Cancer Journal*. 2014;20(6):387-86.

GENITOURINARY

286. Choo R, Kazemba B, Choo CS, Lester SC, Whitaker T. Proton therapy for stage IIA-B seminoma: a new standard of care for treating retroperitoneal nodes. *Int J Part Ther*. 2018. In-Press.
287. Hata M, Miyanaga N, Tokuyue K, et al. Proton beam therapy for invasive bladder cancer: a prospective study of bladder-preserving therapy with combined radiotherapy and intraarterial chemotherapy. *Int J Radiat Oncol Biol Phys*. 2006;64(5):1371-1379.

GYNECOLOGY

288. Arimoto T, Kitagawa T, Tsujii H, Ohhara K. High-energy proton beam radiation therapy for gynecologic malignancies. Potential of proton beam as an alternative to brachytherapy. *Cancer*. 1991;68(1):79-83.
289. Clivio A, Kluge A, Cozzi L, et al. Intensity modulated proton beam radiation for brachytherapy in patients with cervical carcinoma. *Int J Radiat Oncol Biol Phys*. 2013 December 1;87(5):897-903.
290. Kagei K, Tokuyue K, Okumura T, et al. Long-term results of proton beam therapy for carcinoma of the uterine cervix. *Int J Radiat Oncol Biol Phys*. 2003;55(5):1265-1271.
291. Marnitz S, Wlodarczyk W, Neumann O, et al. Which technique for radiation is most beneficial for patients with locally advanced cervical cancer? Intensity modulated proton therapy versus intensity modulated photon treatment, helical tomotherapy and volumetric arc therapy for primary radiation – an intraindividual comparison. *Radiat Oncol*. 2015;10:91.
292. Pollock AE, Risher H, Bentzen S, et al. Clinical outcomes of patients treated with intensity modulated proton therapy (IMPT) re-irradiation for gynecologic malignancies. *Int J Radiat Oncol Biol Phys*. 2021;111(3): e627-e628.
293. Verma V, Simone CB, Wahl AO, et al. Proton radiotherapy for gynecologic neoplasms. *Acta Oncol*. 2016 Nov;55(11):1257-1265.
294. Meixner, E., Wark, A., Forster, T. et al. Health-related quality of life and patient-reported symptoms after postoperative proton beam radiotherapy of cervical and endometrial cancer: 2-year results of the prospective phase II APROVE-trial. *Radiat Oncol* 18, 5 (2023). <https://doi.org/10.1186/s13014-023-02198-4>

HEAD AND NECK

295. Blanchard P, Frank SJ. Proton therapy for head and neck cancers. *Cancer Radiother*. 2017; 21:515-520.
296. Blanchard P, Frank SJ. SP-016: the value of proton therapy for head and neck malignancies: reducing side effects and improving outcomes. *Radiother Oncol*. 2017;122(2):12.
297. Blanchard P, Wong AJ, Gunn GB, et al. Toward a model-based patient selection strategy for proton therapy: External validation of photon-derived normal tissue complication probability models in a head and neck proton therapy cohort. *Radiother Oncol*. 2016 Dec;121(3):381-386.
298. Chan A, Liebsch N. Proton radiation therapy for head and neck cancer. *J Surg Oncol*. 2008;97(8):697-700.

299. Cheng Q, Roelofs E, Ramaekers BLT, et al. Development and evaluation of an online three-level proton vs photon decision support prototype for head and neck cancer – comparison of dose, toxicity, and cost-effectiveness. *Radiother Oncol*. 2016;118(2):281-285.
300. Gunn GB, Garden AS, Ausat N, et al. Clinical outcomes after proton therapy for head and neck cancer: a 12 year single institution experience. *Int J Radiat Oncol Biol Phys*. 2019;105(1s).
301. Lee A, Kitpanit S, Romesser PB, et al. Long-term update of proton beam re-irradiation for recurrent head and neck cancer. *Int J Radiat Oncol Biol Phys*. 2020;106(5):1181.
302. Lee A, Kitpanit S, Marqueen KE, et al. Proton therapy for non-skull base head and neck adenoid cystic carcinoma. *Int J Radiat Oncol Biol Phys*. 2020;106(5):1196.
303. Pelak MJ, Walser M, Bachtiary B, et al. Clinical outcomes of head and neck adenoid cystic carcinoma patients treated with pencil beam-scanning proton therapy. *Oral Oncology*. 2020;107.
304. Deshpande, T. S., Blanchard, P., Wang, L., Foote, R. L., Zhang, X., & Frank, S. J. (2018). Radiation-Related Alterations of Taste Function in Patients With Head and Neck Cancer: a Systematic Review. *Current Treatment Options in Oncology*, 19(12). <https://doi.org/10.1007/S11864-018-0580-7>

Nasopharynx

305. Brown AP, Urie MM, Chisin R, et al. Proton therapy for carcinoma of the nasopharynx: a study in comparative treatment planning. *Int J Radiat Oncol Biol Phys*. 1989;16:1607–1614.
306. Chan A, Adams JA, Weyman E, et al. A Phase II trial of proton radiation therapy with chemotherapy for nasopharyngeal carcinoma. *Int J Radiat Oncol Biol Phys*. 2012;84:S151–S152
307. Chan A, Liebsch L, Deschler D, et al. Proton radiotherapy for T4 nasopharyngeal carcinoma. *J Clin Oncol*. 2004;22:5574
308. Dagan R, Uezono H, Bryant CM, et al. Long-term follow-up of primary and adjuvant proton therapy for sinonasal cancer. *Int J Radiat Oncol Biol Phys*. 2020;108(3S).
309. Heimovaara JH, Blommaert J, Free J, et al. Proton therapy of a pregnant patient with nasopharyngeal carcinoma. *Clin Transl Radiat Oncol*. 2002. <https://doi.org/10.1016/j.ctro.2022.04.014>.
310. Hojo H, Zenda S, Akimoto T, et al. Impact of early radiological response evaluation on radiotherapeutic outcomes in the patients with nasal cavity and paranasal sinus malignancies. *J Radiat Res (Tokyo)*. 2012;53(5):704-709.
311. Holliday EB, Frank SJ. Proton therapy for nasopharyngeal carcinoma. *Chin Clin Oncol*. 2016 April;5(2):25.
312. Holliday EB, Garden AS, Rosenthal DI, et al. Proton therapy reduces treatment-related toxicities for patients with nasopharyngeal cancer: a case-match control study of intensity-modulated proton therapy and intensity-modulated photon therapy. *Int J Part Ther*. 2015;2(1):1-10.
313. Lewis GD, Holliday EB, Kocak-Uzel E, et al. Intensity-modulated proton therapy for nasopharyngeal carcinoma: decreased radiation dose to normal structures and encouraging clinical outcomes. *Head Neck*. 2016 Apr;38 Suppl 1:E1886-1895.
314. Li G, Qiu B, Huan YX, et al. Cost-effectiveness analysis of proton beam therapy for treatment decision making in paranasal sinus and nasal cavity cancers in China. *BMC Cancer*. 2020;20(599).
315. Li X, Kitpanit S, Lee A, et al. Toxicity profiles and survival outcomes among patients with nonmetastatic nasopharyngeal carcinoma treated with intensity-modulated proton therapy vs. intensity-modulated radiation therapy. *JAMA Netw Open*. 2021;4(6):e2113205.

316. Lin R, Slater JD, Yonemoto LT, et al. Nasopharyngeal carcinoma: repeat treatment with conformal proton therapy – dose-volume histogram analysis. *Radiology*. 1999;213(2):489-494.
317. Lin Y-H, Cheng J-Y, Huang B-S, Luo S-D, Lin W-C, Chou S-Y, Juang P-J, Li S-H, Huang E-Y, Wang Y-M. Significant reduction in vertebral artery dose by intensity modulated proton therapy: A pilot study for nasopharyngeal carcinoma. *J Pers Med*. 2021 Aug 22;11(8):822. doi: 10.3390/jpm11080822.
318. Liu S-W, Li J-M, Chang J-Y, et al. A treatment planning comparison between proton beam therapy and intensity-modulated x-ray therapy for recurrent nasopharyngeal carcinoma. *J X-Ray Sci Technol*. 2010;18:443–450.
319. Lomax AJ, Goitein M, Adams J. Intensity modulation in radiotherapy: Photons versus protons in the paranasal sinus. *Radiother Oncol*. 2003;66:11–18.
320. McDonald MW, Liu Y, Moore MG, Johnstone PA. Acute toxicity in comprehensive head and neck radiation for nasopharynx and paranasal sinus cancers: cohort comparison of 3D conformal proton therapy and intensity modulated radiation therapy. *Radiat Oncol*. 2016;11:32.
321. Minatogawa H, Yasuda K, Matsuura T, et al. The potential benefit of adaptive intensity modulated proton therapy in nasopharyngeal carcinoma: planning comparison study. *Int J Radiat Oncol Biol Phys*. 2019;E394.
322. Mock U, Georg D, Bogner J, et al. Treatment planning comparison of conventional, 3D conformal, and intensity-modulated photon (IMRT) and proton therapy for paranasal sinus carcinoma. *Int J Radiat Oncol Biol Phys*. 2004;58:147–154.
323. Nichols AC, Chan AW, Curry WT, et al. Esthesioneuroblastoma: the Massachusetts Eye and Ear Infirmary and Massachusetts General Hospital experience with craniofacial resection, proton beam radiation, and chemotherapy. *Skull Base*. 2008. 18;(5):327-336.
324. Nishimura H, Ogino T, Kawashima M, et al. Proton-beam therapy for olfactory neuroblastoma. *Int J Radiat Oncol Biol Phys*. 2007;68(3):758-762.
325. Okano S, Tahara M, Zenda S, et al. Induction chemotherapy with docetaxel, cisplatin and S-1 followed by proton beam therapy concurrent with cisplatin in patients with T4b nasal and inonasal malignancies. *Jpn J Clin Oncol*. 2012;42(8):691-696.
326. Patel SH, Wang Z, Wong WW, et al. Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: a systematic review and meta-analysis. *Lancet Oncol*. 2014 Aug;15(9):1028-1038.
327. Russo AL, Adams JA, Weyman EA, et al. Long-term outcomes after proton beam therapy for sinonasal squamous cell carcinoma. *Int J Radiat Oncol Biol Phys*. 2016;95(1):368-376.
328. Slater JD, Lored LN, Chung A, et al. Fractionated proton radiotherapy for benign cavernous sinus meningiomas. *Int J Radiat Oncol Biol Phys*. 2012;83(5):e633-e637.
329. Taheri-Kadkhoda Z, Björk-Eriksson T, Nill S, et al. Intensity-modulated radiotherapy of nasopharyngeal carcinoma: a comparative treatment planning study of photons and protons. *Radiat Oncol*. 2008;3:4.
330. Truong MT, Kamat UR, Liebsch NJ, et al. Proton radiation therapy for primary sphenoid sinus malignancies: treatment outcome and prognostic factors. *Head Neck*. 2009;31(10):1297-308.
331. Weber DC, Chan AW, Lessell S, et al. Visual outcome of accelerated fractionated radiation for advanced sinonasal malignancies employing photons/protons. *Radiother Oncol*. 2006;81(3):243-249.

332. Widesott L, Pierelli A, Fiorino C, et al. Intensity-modulated proton therapy versus helical tomotherapy in nasopharynx cancer: Planning comparison and NTCP evaluation. *Int J Radiat Oncol Biol Phys*. 2008 Oct 1;72(2):589-596.
333. Williams VM, Parvathaneni U, Laramore GE, et al. Intensity-modulated proton therapy for nasopharynx cancer: 2-year outcomes from a single institution. *Int J Part Ther*. 2021. doi: <https://doi.org/10.14338/IJPT-20-00057.1>
334. Zenda S, Kohno R, Kawashima M, et al. Proton beam therapy for unresectable malignancies of the nasal cavity and paranasal sinuses. *Int J Radiat Oncol Biol Phys*. 2011;81(5):1473-1478.

Oropharynx

335. Arts T, Breedveld S, de Jong MA, et al. The impact of treatment accuracy on proton therapy patient selection for oropharyngeal cancer patients. *Radiother Oncol*. 2017 October 23. <https://doi.org/10.1016/j.radonc.2017.09.028>.
336. Ausat N, Rosenthal DI, Gunn GB, et al. Outcomes following proton therapy for squamous cell carcinoma of the larynx. *Int J Radiat Oncol Biol Phys*. 2020;106(5):1213.
337. Bagley AF, Ye R, Hernandez M, Frank SJ. (P30) Prospective outcomes of xerostomia-related quality of life in oropharyngeal carcinoma patients treated with proton therapy. *Int J Radiat Oncol Biol Phys*. 2018;101(2):E32-E33.
338. Bagley AF, Ye R, Garden AS, et al. Xerostomia-related quality of life for patients with oropharyngeal carcinoma treated with proton therapy. *Radiotherapy and Oncology*. 2019.
339. Blanchard P, Garden AS, Gunn GB, et al. Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer - A case matched analysis. *Radiother Oncol*. 2016 Jul;120(1):48-55.
340. Brodin NP, Kabarriti R, Schechter CB, et al. Individualized quality of life benefit and cost-effectiveness estimates of proton therapy for patients with oropharyngeal cancer. *Radiation Oncology*. 2021;16.
341. Cao J, Zhang X, Jiang B, et al. Intensity-modulated proton therapy for oropharyngeal cancer reduces rates of late xerostomia. *Radiother Oncol*. 2021;160:32-39.
342. Deshpande TS, Gunn GB, Fuller CD, et al. Xerostomia impacts dysgeusia in oropharyngeal cancer patients treated with proton therapy. *Int J Radiat Oncol Biol Phys*. 2019;105(1):414-415.
343. Frank SJ, Blanchard P, Lee JJ, et al. Comparing intensity-modulated proton therapy with intensity-modulated photon therapy for oropharyngeal cancer: the journey from clinical trial concept to activation. *Semin Radiat Oncol*. 2018. doi: 10.1016/j.semradonc.2017.12.002.
344. Frank SJ, Rosenthal DI, Ang K, et al. Gastrostomy tubes decrease by over 50% with intensity modulated proton therapy (IMPT) during the treatment of oropharyngeal cancer patients: a case-control study. *Int J Radiat Oncol Biol Phys*. 2013 October 1;87(2):S144.
345. Gunn GB, Blanchard P, Garden AS, et al. Clinical outcomes and patterns of disease recurrence following intensity modulated proton therapy for oropharyngeal squamous carcinoma: results from single institution prospective registry studies. *Int J Radiat Oncol Biol Phys*. 2016 May 1;95(1):360-367.
346. Gunn GB, Frank SJ. Advances in radiation oncology for the management of oropharyngeal tumors. *Otolaryngol Clin North Am*. 2013 Aug;46(4):629-643.

347. Hayashi Y, Nakamura T, Mitsudo K, et al. Retrograde intra-arterial chemotherapy and daily concurrent proton beam therapy for recurrent oral cavity squamous cell carcinoma: analysis of therapeutic results in 46 cases. *Head Neck*. 2016 Aug;38(8):1145-1151.
348. Holliday EB, Frank SJ. Dosimetric advantages of intensity modulated proton therapy for oropharyngeal cancer compared with intensity-modulated radiation: A case-matched control analysis. *Med Dosim*. 2016;41(3):189-194.
349. Kutcheson K, Lewin JS, Garden AS, et al. Early experience with IMPT for the treatment of oropharyngeal tumors: acute toxicities and swallowing-related outcomes. *Int J Radiat Oncol Biol Phys*. 2013;87:S604.
350. Manzar GS, Lester SC, Routman DM, et al. Comparative analysis of acute toxicities and patient reported outcomes between intensity-modulated proton therapy (IMPT) and volumetric modulated arc therapy (VMAT) for the treatment of oropharyngeal cancer. *Radiotherapy and Oncology*. 2020;147(64-74).
351. McDonald MW, Bates JE, Patel MR, et al. Patient-reported Outcomes in Oropharyngeal Cancer Treated With Definitive Chemoradiation vs. Surgery With Postoperative Radiation With or Without Chemotherapy. *Int J Radiat Oncol Biol Phys*. 2022 May;113(1):e2.
352. Phan J, Bagley A, Adam G, et al. Reirradiation with SBRT, IMRT and proton therapy for recurrent oropharynx squamous cell carcinoma: efficacy and toxicity outcomes. *Int J Radiat Oncol Biol Phys*. 2020;106(5):1144.
353. Rwigema JC, Langendijk JA, van der Laan HP, et al. A model-based approach to predict short-term toxicity benefits with proton therapy for oropharyngeal cancer. *Int J Radiat Oncol Biol Phys*. 2019.
354. Rwigema JC, Langendijk JA, van der Laan HP, et al. Proton therapy improves toxicity for oropharyngeal cancer: an outcomes and predictive model-based approach. *Int J Radiat Oncol Biol Phys*. 2017;99(2S):S135.
355. Sanghvi SM, Slater JD, Kang JJ. Acute toxicity following ipsilateral head and neck radiation therapy: proton vs. intensity-modulated photon radiotherapy. *Int J Radiat Oncol Biol Phys*. 2021;111(3S):378.
356. Sharma S, Zhou O, Thompson R, et al. Quality of life of postoperative photon versus proton radiation therapy for oropharynx cancer. *Int J Part Ther*. 2018. In-press.
357. Sio TT, Lin HK, Shi Q, et al. Intensity modulated proton therapy versus intensity modulated photon radiation therapy for oropharyngeal cancer: first comparative results of patient-reported outcomes. *Int J Radiat Oncol Biol Phys*. 2016 Jul 15;95(4):1107-1114.
358. Slater JD, Yonemoto LT, Mantik DW, et al. Proton radiation for treatment of cancer of the oropharynx: early experience at Loma Linda University Medical Center using a concomitant boost technique. *Int J Radiat Oncol Biol Phys*. 2005;62(2):494-500.
359. Van de Water TA, Lomax AJ, Bijl HP, et al. Potential benefits of scanned intensity-modulated proton therapy versus advanced photon therapy with regard to sparing of the salivary glands in oropharyngeal cancer. *Int J Radiat Oncol Biol Phys*. 2011, 79(4):1216-1224.
360. Van de Water TA, Lomax AJ, Bijl HP, et al. Using a reduced spot size for intensity-modulated proton therapy potentially improves salivary gland-sparing in oropharyngeal cancer. *Int J Radiat Oncol Biol Phys*. 2012;82:e313-319.
361. Yasuda K, Minatogawa H, Dekura Y, et al. Analysis of acute-phase toxicities of intensity-modulated proton therapy using a model-based approach in pharyngeal cancer patients. *Journal of Radiation Research*. 2021.

Paranasal Sinuses

- 362. Chera BS, Malyapa R, Louis D, et al. Proton therapy for maxillary sinus carcinoma. *Am J Clin Oncol*. 2009;32:296–303.
- 363. Dagan R, Bryant C, Li Z, et al. Outcomes of sinonasal cancer treated with proton therapy. *Int J Radiat Oncol Biol Phys*. 2016;95(1):377-385.
- 364. Fitzek MM, Thornton AF, Varvares M, et al. Neuroendocrine tumors of the sinonasal tract. Results of a prospective study incorporating chemotherapy, surgery, and combined protonphoton radiotherapy. *Cancer*. 2002;94(10):2623-2634.
- 365. Fuji H, Yoshikawa S, Kasami M, et al. High-dose proton beam therapy for sinonasal mucosal malignant melanoma. *Radiat Oncol*. 2014 July 23;9:162.
- 366. Fukumitsu N, Okumura T, Mizumoto M, et al. Outcome of T4 (International Union Against Cancer Staging System, 7th edition) or recurrent nasal cavity and paranasal sinus carcinoma treated with proton beam. *Int J Radiat Oncol Biol Phys*. 2012;83(2):704-711.

Other Head and Neck

- 367. Bhattasali O, Holliday EB, Kies MS, et al. Definitive proton radiation therapy and concurrent cisplatin for unresectable head and neck adenoid cystic carcinoma: A series of 9 cases and a critical review of the literature. *Head and Neck*. 2016 April;38(Suppl 1):E1472-E1480.
- 368. Buszek SM, Ludmir EB, Grosshans DR, et al. Disease control and patterns of failure after proton beam therapy for rhabdomyosarcoma. *Int J Radiat Oncol Biol Phys*. 2021;109(3):718-725.
- 369. Cozzi L, Fogliata A, Lomax A, Bolsi A. A Treatment Planning Comparison of 3D Conformal Therapy, Photon Therapy, and Proton Therapy for Treatment of Advanced Head and Neck Tumors. *Radiother Oncol*. 2001 Dec;61(3):287-297.
- 370. Demizu Y, Fujii O, Terashima K, et al. Particle therapy for mucosal melanoma of the head and neck. A single-institution retrospective comparison of proton and carbon ion therapy. *Strahlenther Onkol*. 2014;190(2):186-191.
- 371. Demizu Y, Murakami M, Miyawaki D, et al. Analysis of vision loss caused by radiation-induced optic neuropathy after particle therapy for head-and-neck and skull-base tumors adjacent to optic nerves. *Int J Radiat Oncol Biol Phys*. 2009;75(5):1487-1492.
- 372. El-Sawy T, Frank SJ, Hanna E, et al. Multidisciplinary management of lacrimal sac/nasolacrimal duct carcinomas. *Ophthal Plast Reconstr Surg*. 2013 Nov-Dec; 29(6):454-7.
- 373. Endo H, Takayama K, Mitsudo K, et al. Proton beam therapy in combination with intra-arterial infusion chemotherapy for T4 squamous cell carcinoma of the maxillary gingiva. *Cancers*. 2018;10(9).
- 374. Frank SJ, Cox JD, Gillin M, et al. Multifield optimization intensity modulated proton therapy for head and neck tumors: a translation to practice. *Int J Radiat Oncol Biol Phys*. 2014 Jul 15;89(4):846-853.
- 375. Harrell LM, Paulino AC, Mahajan A, et al. Clinical outcomes and toxicity following proton radiation therapy for head and neck rhabdomyosarcoma. *Int J Radiat Oncol Biol Phys*. 2016 Oct 1;96(2S):E549-E550.
- 376. Holliday EB, Bhattasali O, Kies MS, et al. Effective use of Intensity-Modulated Proton Therapy for Robust Delivery of Post-operative Radiation for Head and Neck Adenoid Cystic Carcinoma. *Int J Part Ther*. 2016; 2(4): 533-543.

377. Holliday EB, Bhattasali O, Kies MS, et al. Postoperative intensity-modulated proton therapy for head and neck adenoid cystic carcinoma. *Int J Part Ther*. 2016. doi: 10.14338/IJPT-15-00032.1.
378. Holliday EB, Frank SJ. Current applications of proton beam radiation for the treatment of head and neck tumors. *Otorinolaringo*. 2014; 64(1):1-11.
379. Holliday EB, Frank SJ. Proton radiation therapy for head and neck cancer: a review of the clinical experience to date. *Int J Radiat Oncol Biol Phys*. 2014; 89(2):292-302.
380. Jakobi A, Stützer K, Bandurska-Luque A, et al. NTCP reduction for advanced head and neck cancer patients using proton therapy for complete or sequential boost treatment versus photon therapy. *Acta Oncologica*. 2015;54(9):1658-1664.
381. Kandula S, Zhu X, Garden AS, et al. Spot-scanning beam proton therapy vs intensity-modulated radiation therapy for ipsilateral head and neck malignancies. *Med Dosim*. 2013 Winter;38(4):390-394.
382. Kim K, Doucette A, Amaniera I, et al. Acute toxicity in patients treated with proton vs. photon chemoradiotherapy for locally advanced head and neck cancer. *Int J Radiat Oncol Biol Phys*. 2021;111(3):e371-372.
383. Leeman JE, Romesser PB, Zhou Y, et al. Proton therapy for head and neck cancer: expanding the therapeutic window. *Lancet Oncol*. 2017;18(5):e254-265.
384. Li X, Lee A, Cohen MA, et al. Past, present, and future of proton therapy for head and neck cancer. *Oral Oncology*. 2020;110.
385. Linton OR, Moore MG, Brigance JS, et al. Proton therapy for head and neck adenoid cystic carcinoma: initial clinical outcomes. *Head Neck*. 2015;37(1):117-124.
386. Liu W, Frank SJ, Li X, et al. Effectiveness of robust optimization in intensity-modulated proton therapy planning for head and neck cancers. *Medical Physics*. 2013;40(5):051711.
387. Ludmir EB, Paulino AC, Grosshans DR, et al. Patterns of failure with proton therapy for head and neck rhabdomyosarcoma. *Int J Radiat Oncol Biol Phys*. 2018 July 15;101(4):1007.
388. Lukens JN, Lin A, Hahn SM. Proton therapy for head and neck cancer. *Curr Opin Oncol*. 2015 May;27(3):165-171.
389. Malyapa RS, Weber DC, Schneider R, et al. Pencil beam scanning intensity modulated proton therapy for head and neck cancers involving skull base. *J Neurol Surg B*. 2016;77-A087.
390. McKeever MR, Sio TT, Gunn GB, et al. Reduced acute toxicity and improved efficacy from intensity-modulated proton therapy (IMPT) for the management of head and neck cancer. *Chin Clin Oncol*. 2016 Aug;5(4):54.
391. Miralbell R, Crowell C, Suit HD. Potential improvement of three-dimension treatment planning and proton therapy in the outcome of maxillary sinus cancer. *Int J Radiat Oncol Biol Phys*. 1992;22:305–310.
392. Phan J, Sio TT, Nguyen TP, et al. Reirradiation of head and neck cancers with proton therapy: outcomes and analyses. *Int J Radiat Oncol Biol Phys*. 2016 Sep 1;96(1):30-41.
393. Ramaekers BL, Grutters JPC, Pijls-Johannesma M, et al. Protons in head and neck cancer: bridging the gap of evidence. *Int J Radiat Oncol Biol Phys*. 2013;85(5):1282-1288.

394. Ramaekers BL, Pijls-Johannesma M, Joore MA, et al. Systematic review and meta-analysis of radiotherapy in various head and neck cancers: comparing photon, carbon ions and protons. *Cancer Treat Rev.* 2011;37(3):185-201.
395. Romesser PB, Cahlon O, Scher E, et al. Proton beam radiation therapy results in significantly reduced toxicity compared with intensity-modulated radiation therapy for head and neck tumors that require ipsilateral radiation. *Radiother Oncol.* 2016 Feb;118(2):286-292.
396. Romesser PB, Cahlon O, Scher E, et al. Proton beam re-irradiation for recurrent head and neck cancer: multi-institutional report on feasibility and early outcomes. *Int J Radiat Oncol Biol Phys.* 2016;95(1):386-395.
397. Scandurra D, Kierkels RGJ, Gelderman M, et al. EP-1542 Can proton therapy for head and neck cancer reduce side effects while maintaining target robustness? *Radiother Oncol.* 2017 May; 123(1):S1-S1077.
398. Sheu T, Garden AS, Fuller CD, et al. Reirradiation utilizing proton radiation therapy may improve toxicity free survival in patients with small-volume, recurrent head and neck cancer. *Int J Radiat Oncol Biol Phys.* 2016 Oct 1;96(2S):E331.
399. Simone CB, Ly D, Dan TD, et al. Comparison of intensity-modulated radiotherapy, adaptive radiotherapy, proton radiotherapy, and adaptive proton radiotherapy for treatment of locally advanced head and neck cancer. *Radiother Oncol.* 2011 Dec; 101(3):376-382.
400. Steneker M, Lomax A, Schneider U. Intensity modulated photon and proton therapy for the treatment of head and neck tumors. *Radiother Oncol.* 2006;80:263–267.
401. Thaker NG, Frank SJ, Feeley TW. Comparative costs of advanced proton and photon radiation therapies: lessons from time-driven activity-based costing in head and neck cancer. *J Comp Eff Res.* 2015;4(4):297-301.
402. Tokuyue K, Akine Y, Kagei K, et al. Proton therapy for head and neck malignancies at Tsukuba. *Strahlenther Onkol.* 2004;180(2):96-101.
403. Van de Water TA, Bijl HP, Schilstra C, et al. The potential benefit of radiotherapy with protons in head and neck cancer with respect to normal tissue sparing: a systematic review of literature. *Oncologist.* 2011;16(3):366-377.
404. Van der Laan HP, van de Water TA, van Herpt HE, et al. The potential of intensity-modulated proton radiotherapy to reduce swallowing dysfunction in the treatment of head and neck cancer. *Acta Oncol.* 2013 Apr;52(3):561-569.
405. Waddle MR, Heckman M, Diehl NN, et al. Survival after proton and photon radiation therapy in patients with head and neck cancers: a study of the National Cancer Database. *Int J Radiat Oncol Biol Phys.* 2018;100(5):1330.
406. Yeh B, Holliday EB, Frank SJ. Is adaptive planning necessary for intensity modulated proton therapy for head and neck cancer? Submitted to *Med Dosim*; Nov 2015.
407. Zenda S, Kawashima M, Nishio T, et al. Proton beam therapy as a nonsurgical approach to mucosal melanoma of the head and neck: a pilot study. *Int J Radiat Oncol Biol Phys.* 2011;81(1):135-139.

KIDNEY

408. Fukumitsu N, Ishikawa H, Arimura T, et al. Proton therapy for primary renal cell carcinoma: the first nationwide retrospective study in Japan. *In Vivo.* 2020;34:2883-9.

LYMPHOMA

409. Andolino DL, Hoene T, Xiao L, et al. Dosimetric comparison of involved-field three-dimensional conformal photon radiotherapy and breast-sparing proton therapy for the treatment of Hodgkin's lymphoma in female pediatric patients. *Int J Radiat Oncol Biol Phys*. 2011 Nov 15;81(4):e667-71.
410. Bellardini JA, Bajwa A, Seeram V, et al. Effects of proton therapy on pulmonary function in Hodgkin lymphoma patients. *Am J Respir Crit Care Med*. 2016;193:A6037.
411. Cella L, Conson M, Pressello MC, et al. Hodgkin's lymphoma emerging radiation treatment techniques: trade-offs between late radio-induced toxicities and secondary malignant neoplasms. *Radiat Oncol*. 2013;8:22.
412. Chera BS, Rodriguez C, Morris CG, et al. Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin's lymphoma patients: conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy. *Int J Radiat Oncol Biol Phys*. 2009;75:1173-1180.
413. Guzhva L, Mendenhall NP, Morris CG, et al. Evaluating cardiac biomarkers after chemotherapy and proton therapy for mediastinal hodgkin lymphoma. *Int J Part Ther*. 2017; DOI 10.14338/IJPT-D-17-00022.
414. Hoppe BS, Flampouri S, Lynch J, et al. Improving the therapeutic ratio in Hodgkin Lymphoma through the use of proton therapy. *Oncology* (Williston Park). 2012;26(5):456-459, 462-65.
415. Hoppe BS, Flampouri S, Su Z, et al. Consolidated involved-node proton therapy for stage IA-III B mediastinal hodgkin lymphoma: preliminary dosimetric outcomes from a phase II study. *Int J Radiat Oncol Biol Phys*. 2012;83(1):260-267.
416. Hoppe BS, Flampouri S, Su Z, et al. Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma. *Int J Radiat Oncol Biol Phys*. 2012 Oct 1;84(2):449-455
417. Hoppe BS, Flampouri S, Zaiden R, et al. Involved-node proton therapy in combined modality therapy for Hodgkin lymphoma: results of a phase 2 study. *Int J Radiat Oncol Biol Phys*. 2014 Aug 1;89(5):1053-1059.
418. Hoppe BS, Hill-Kayser CE, Tseng YD, et al. Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma. *Ann Oncol*. 2017 Sep 1;28(9):2179-2184.
419. Hoppe BS, Hill-Kayser CE, Tseng YD, et al. The use of consolidative proton therapy after first-line therapy among patients with Hodgkin lymphoma at academic and community proton centers. *Int J Radiat Oncol Biol Phys*. 2016;96:S39.
420. Hoppe BS, Mendenhall NP, Louis D, et al. Comparing breath hold and free breathing during intensity-modulated radiation therapy and proton therapy in patients with mediastinal Hodgkin lymphoma. *Int J Part Ther*. 2017 Spring;3(4):492-496.
421. Hoppe BS, Tsai H, Larson G, et al. Proton therapy patterns-of-care and early outcomes for Hodgkin lymphoma: results from the Proton Collaborative Group Registry. *Acta Oncol*. 2016;55:1378-1380.
422. Horn S, Fournier-Bidoz N, Pernin V, et al. Comparison of passive-beam proton therapy, helical tomotherapy and 3D conformal radiation therapy in Hodgkin's lymphoma female patients receiving involved-field or involved site radiation therapy. *Cancer Radiother*. 2016 Apr;20(2):98-103.

423. Jorgensen AY, Maraldo MV, Brodin NP, et al. The effect on esophagus after different radiotherapy techniques for early stage Hodgkin's lymphoma. *Acta Oncol.* 2013;52:1559-1565.
424. Knausl B, Lutgendorf-Caucig C, Hopfgartner J, et al. Can treatment of pediatric Hodgkin's lymphoma be improved by PET imaging and proton therapy? *Strahlenther Onkol.* 2013;189:54-61.
425. Li J, Dabaja B, Reed V, et al. Rationale for and preliminary results of proton beam therapy for mediastinal lymphoma. *Int J Radiat Oncol Biol Phys.* 2011;81(1):167-174.
426. Maraldo MV, Brodin NP, Aznar MC, et al. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma. *Ann Oncol.* 2013;24:2113-2118.
427. Mohindra P, Tseng YD, Badiyan SN, et al. Proton therapy for lymphoma: A multi-institutional patterns of care study. *Int J Radiat Oncol Biol Phys.* 2017 Oct 1; 99(2):E433.
428. Plastaras JP, Maity A, Flampouri S, et al. Bi-institutional report on consolidative proton therapy after initial chemotherapy for mediastinal diffuse large B-cell and primary mediastinal large B-cell lymphomas. *Int J Radiat Oncol Biol Phys.* 2018;102(3).
429. Plastaras JP, Vogel J, Elmongy H, et al. First clinical report of pencil beam scanned proton therapy for mediastinal lymphoma. *Int J Radiat Oncol Biol Phys.* 2016;96:E497.
430. Rechner LA, Maraldo MV, Vogelius IR, et al. Life years lost attributable to late effects after radiotherapy for early stage Hodgkin lymphoma: The impact of proton therapy and/or deep inspiration breath hold. *Radiother Oncol.* 2017;125(1):41-47.
431. Ricardi U, Maraldo MV, Levis M, et al. Proton therapy for lymphomas: current state of the art. *Onco Targets Ther.* 2019;12:8033-8046.
432. Ricardi U, Dabaja B, Hodgson DC. Proton therapy in mediastinal Hodgkin lymphoma: moving from dosimetric prediction to clinical evidence. *Ann Oncol.* 2017 Sep 1;28(9):2049-2050.
433. Rutenberg MS, Flampouri, Hoppe BS. Proton therapy for Hodgkin lymphoma. *Curr Hematol Malig Rep.* 2014 Sep;9(3):203-211
434. Sachsman S, Flampouri S, Li Z, et al. Proton therapy in the management of non-Hodgkin lymphoma. *Leuk Lymphoma.* 2015;56(9):2608-2612
435. Toltz A, Shin N, Mitrou E, et al. Late radiation toxicity in Hodgkin lymphoma patients: proton therapy's potential. *J Appl Clin Med Phys.* 2015 Sep 8;16(5):167-178.
436. Tseng YD, Hoppe BS, Miller D, et al. Rates of toxicity and outcomes after mediastinal proton therapy for relapsed/refractory lymphoma. *Int J Radiat Oncol Biol Phys.* 2017;99:S62-S63.
437. Vega RBM, Patel S, Bates JE, et al. Cost-effectiveness of proton therapy for young adults with mediastinal lymphoma: analysis of an institutional cohort. *Klin Padiatr.* 2020;232(02):103.
438. Vega RBM, Hoppe BS, Hodgson D, et al. Access to proton beam therapy (PBT) for patients with large mediastinal adenopathy (LMA). *Klin Padiatr.* 2020;232(02):108.
439. Winkfield KM, Gallotto S, Adams JA, et al. Proton therapy for mediastinal lymphomas: An 8-year single-institution report. *Int J Radiat Oncol Biol Phys.* 2015;93:E461.
440. Zeng C, Plastaras JP, James P, et al. Proton pencil beam scanning for mediastinal lymphoma: treatment planning and robustness assessment. *Acta Oncol.* 2016 Sep-Oct;55(9-10):1132-1138.

441. Chirayu G. Patel, Jennifer Peterson, Bradford Hoppe, et al. Systematic review for deep inspiration breath hold in proton therapy for mediastinal lymphoma: A PTCOG Lymphoma Subcommittee report and recommendations, Radiotherapy and Oncology, 2022, ISSN 0167-8140

OCULAR

442. Agarwal A, Thaker NG, Tawk B, et al. The evolution of radiation therapy for retinoblastoma: the MD Anderson Cancer Center experience. *Int J Part Ther*. 2016;2(4):490-498.
443. Arvola ND, Lessell S, Bussiere M, et al. Visual outcome and tumor control after conformal radiotherapy for patients with optic nerve sheath meningioma. *Int J Radiat Oncol Biol Phys*. 2009;75(4):1166-1172.
444. Aziz S, Taylor A, McConnachie A, et al. Proton beam radiotherapy in the management of uveal melanoma: clinical experience in Scotland. *Clin Ophthalmol*. 2009;3(1):49-55.
445. Bellmann C, Lumbroso-Le Rouic L, Levy C, et al. Uveal melanoma: management and outcome of patients with extraocular spread. *Br J Ophthalmol*. 2010;94(5):569-574.
446. Bellocq D, Pascal R, Laurent K, et al. 20-year assessment of metastatic latency and subsequent time to death after proton therapy for uveal melanomas. *Melanoma Research*. 2018.
447. Bui M, Frank SJ, Nasser QJ, et al. Multidisciplinary management of primary adenoid cystic carcinoma of the eyelid with perineural invasion. *Ophthalm Plast Reconstr Surg*. 2013 Nov-Dec;29(6):e143-6.
448. Busch C, Löwen J, Pilger D, et al. Quantification of radiation retinopathy after beam proton irradiation in centrally located choroidal melanoma. *Graefes Arch Clin Exp Ophthalmol*. 2018. <https://doi.org/10.1007/s00417-018-4036-3>.
449. Caujolle J-P, Mammar H, Chamorey E, et al. Proton beam radiotherapy for uveal melanomas at Nice teaching hospital: 16 years' experience. *Int J Radiat Oncol Biol Phys*. 2010;78(1):98-103.
450. Caujolle J-P, Paoli V, Chamorey E, et al. Local recurrence after uveal melanoma proton beam therapy: recurrence types and prognostic consequences. *Int J Radiat Oncol Biol Phys*. 2013;85(5):1218-1224.
451. Chang JW, Yu YS, Kim JY, et al. The clinical outcomes of proton beam radiation therapy for retinoblastomas that were resistant to chemotherapy and focal treatment. *Korean J Ophthalmol*. 2011;25(6):387-393.
452. Chappell MC, Char DH, Cole TB, et al. Uveal melanoma: molecular pattern, clinical features, and radiation response. *Am J Ophthalmol*. 2012;154(2):227-232.
453. Char DH, Bove R, Phillips TL. Laser and proton radiation to reduce uveal melanoma-associated exudative retinal detachments. *Trans Am Ophthalmol Soc*. 2003;101:53-56.
454. Conway RM, Poothullil AM, Daftari IK, et al. Estimates of ocular and visual retention following treatment of extra-large uveal melanomas by proton beam radiotherapy. *Arch Ophthalmol*. 2006;124(6):838-843.
455. Courdi A, Caujolle JP, Grange JD, et al. Results of proton therapy of uveal melanomas treated in Nice. *Int J Radiat Oncol Biol Phys*. 1999;45(1):5-11.
456. Damato B, Kacperek A, Chopra M, et al. Proton beam radiotherapy of choroidal melanoma: the Liverpool-Clatterbridge experience. *Int J Radiat Oncol Biol Phys*. 2005;62(5):1405-1411.

457. Damato B, Kacperek A, Chopra M, et al. Proton beam radiotherapy of iris melanoma. *Int J Radiat Oncol Biol Phys.* 2005;63(1):109-115.
458. Dendale R, Lumbroso-Le Rouic L, Noel G, et al. Proton beam radiotherapy for uveal melanoma: results of Curie Institut-Orsay proton therapy center (ICPO). *Int J Radiat Oncol Biol Phys.* 2006, 65(3):780-787. Epub 2006 May 2.
459. Desjardins L, Lumbroso-Le Rouic L, Levy-Gabriel C, et al. Combined proton beam radiotherapy and transpupillary thermotherapy for large uveal melanomas: a randomized study of 151 patients. *Ophthalmic Res.* 2006;38(5):255-260.
460. Egger E, Schalenbourg A, Zografos L, et al. Maximizing local tumor control and survival after proton beam radiotherapy of uveal melanoma. *Int J Radiat Oncol Biol Phys.* 2001, 51(1):138-147.
461. Egger E, Zografos L, Schalenbourg A, et al. Eye retention after proton beam radiotherapy for uveal melanoma. *Int J Radiat Oncol Biol Phys.* 2003; 55(4): 867-80.
462. Fuss M, Loredó LN, Blacharski PA, et al. Proton radiation therapy for medium and large choroidal melanoma: preservation of the eye and its functionality. *Int J Radiat Oncol Biol Phys.* 2001;49(4):1053-1059.
463. Gollrad J, Rabsahl C, Riechardt A. et al. Quality of life and treatment-related burden during ocular proton therapy: a prospective trial of 131 patients with uveal melanoma. *Radiat Oncol.* 2021;16(74).
464. Gragoudas E, Li W, Goitein M, et al. Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. *Arch Ophthalmol.* 2002b;120(12):1665-1671.
465. Gragoudas ES, Lane AM, Munzenrider J, et al. Long-term risk of local failure after proton therapy for choroidal/ciliary body melanoma. *Trans Am Ophthalmol Soc.* 2002a;100:43-50.
466. Gragoudas ES, Lane AM, Regan S, et al. A randomized controlled trial of varying radiation doses in the treatment of choroidal melanoma. *Arch Ophthalmol.* 2000;118(6):773-778.
467. Gragoudas ES, Li W, Lane AM, et al. Risk factors for radiation maculopathy and papillopathy after intraocular irradiation. *Ophthalmology.* 1999;106(8):1571-1578.
468. Hadden PW, Damato BE, McKay IC. Bilateral uveal melanoma: a series of four cases. *Eye.* 2003;17(5):613 616.
469. Hannouche D, Frau E, Desjardins L, et al. Efficacy of proton therapy in circumscribed choroidal hemangiomas associated with serious retinal detachment. *Ophthalmology.* 1997;104(11):1780 1784.
470. Höcht S, Bechrakis NE, Nausner M, et al. Proton therapy of uveal melanomas in Berlin. 5 years of experience at the Hahn-Meitner Institute. *Strahlenther Onkol.* 2004;180(7):419-424.
471. Höcht S, Wachtlin J, Bechrakis NE, et al. Proton or photon irradiation for hemangiomas of the choroid? A retrospective comparison. *Int J Radiat Oncol Biol Phys.* 2006;66(2):345-351.
472. Holliday EB, Esmaeli B, Picknard J, et al. A multidisciplinary orbit-sparing treatment approach that includes proton therapy for epithelial tumors of the orbit and ocular adnexa. *Int J Radiat Oncol Biol Phys.* 2016 May 1;95(1):344-352.
473. Hrbacek J, Mishra KK, Kacperek A, et al. Practice patterns analysis of ocular proton therapy centers: the International OPTIC Survey. *Int J Radiat Oncol Biol Phys.* 2016 May;95(1):336-343.
474. Hussain R, Hassan S, Kacperek A, et al. Proton beam radiotherapy (PBR) for the treatment of retinal capillary haemangioblastoma stabilises tumour progression but with poor visual outcomes. *Eye.* 2019.

475. Hussain R, Hassan S, Ho V, et al. Proton beam radiotherapy (PBR) for the treatment of retinal capillary haemangioblastoma. *Acta Ophthalmol.* 2016;94(S256).
476. Hussain RN, Kalirai H, Groenewald C, et al. Prognostic biopsy of choroidal melanoma after proton beam radiation therapy. *Ophthalmology.* 2016.
477. Jung SK, Park YH, Shin DH, et al. Visual outcomes of proton beam therapy for choroidal melanoma at a single institute in the Republic of Korea. *PLoS ONE.* 2021;15(12):e0242966.
478. Kamran SC, Collier J, Lane AM, et al. Outcomes of proton therapy for the treatment of uveal melanoma. *Int J Radiat Oncol Biol Phys.* 2014 December 1;90(5):1044-1050.
479. Kent D, Noonan CP, Damato BE. Management of Irish patients with intraocular melanoma referred to Liverpool, England. *Acta Ophthalmol Scand.* 1998;76(5):584-588.
480. Kim IK, Lane AM, Egan KM, et al. Natural history of radiation papillopathy after proton beam irradiation of parapapillary melanoma. *Ophthalmology.* 2010a;117(8):1617-1622.
481. Kim JY, Park Y. Treatment of retinoblastoma: the role of external beam radiotherapy. *Yonsei Med J.* 2015 November;56(6):1478-1491.
482. Kim TW, Choi E, Park J, et al. Clinical outcomes of proton beam therapy for choroidal melanoma at a single institute in Korea. *Cancer Res Treat.* 2017 Apr 19. doi: 10.4143/crt.2017.070.
483. Kodjikian L, Roy P, Rouberol F, et al. Survival after proton-beam irradiation of uveal melanomas. *Am J Ophthalmol.* 2004;137(6):1002-1010.
484. Konstantinidis L, Roberts D, Errington RD, et al. Whole anterior segment proton beam radiotherapy for diffuse iris melanoma. *Br J Ophthalmol.* 2013;97(4):471-474.
485. Lane AM, Kim IK, Gragoudas ES. Long-term risk of melanoma-related mortality for patients with uveal melanoma treated with proton beam therapy. *JAMA Ophthalmol.* 2015 Jul;133(7):792-796.
486. Lane AM, Kim IK, Gragoudas ES. Proton irradiation for peripapillary and parapapillary melanomas. *Arch Ophthalmol.* 2011;129(9):1127-1130.
487. Lee HJ, Stacey A, Klesert TR, et al. Corneal substructure dosimetry predicts corneal toxicity in patients with uveal melanoma treated with proton beam therapy. *Int J Radiat Oncol Biol Phys.* 2019.
488. Levy-Gabriel C, Lumbroso-Le Rouic L, Plancher C, et al. Long-term results of low-dose proton beam therapy for circumscribed choroidal hemangiomas. *Retina.* 2009;29(2):170-175.
489. Li W, Gragoudas ES, Egan KM. Metastatic melanoma death rates by anatomic site after proton beam irradiation for uveal melanoma. *Arch Ophthalmol.* 2000;118(8):1066-1070.
490. Li W, Gragoudas ES, Egan KM. Tumor basal area and metastatic death after proton beam irradiation for choroidal melanoma. *Arch Ophthalmol.* 2003;121(1):68-72.
491. Lumbroso L, Desjardins L, Levy C, et al. Intraocular inflammation after proton beam irradiation for uveal melanoma. *Br J Ophthalmol.* 2001;85(11):1305-1308.
492. Lumbroso-Le Rouic L, Delacroix S, Dendale R, et al. Proton beam therapy for iris melanomas. *Eye.* 2006;20(11):1300-1305.
493. Macdonald EC, Cauchi P, Kemp EG. Proton beam therapy for the treatment of uveal melanoma in Scotland. *Br J Ophthalmol.* 2011;95(12):1691-1695.

494. Marucci L, Ancukiewicz M, Lane AM, et al. Uveal melanoma recurrence after fractionated proton beam therapy: comparison of survival in patients treated with reirradiation or with enucleation. *Int J Radiat Oncol Biol Phys*. 2011;79(3):842-846.
495. Marucci L, Lane AM, Li W, et al. Conservation treatment of the eye: conformal proton reirradiation for recurrent uveal melanoma. *Int J Radiat Oncol Biol Phys*. 2006;64(4):1018-1022.
496. Mishra KK, Daftari IK, Weinberg V, et al. Risk factors for neovascular glaucoma after proton beam therapy of uveal melanoma: a detailed analysis of tumor and dose-volume parameters. *Int J Radiat Oncol Biol Phys*. 2013;87(2):330-336.
497. Mizumoto M, Nakayama H, Tokita M, et al. Technical considerations for noncoplanar proton beam therapy of patients with tumors proximal to the optic nerve. *Strahlenther Onkol*. 2010;186(1):36-39.
498. Mosci C, Lanza FB, Barla A, et al. Comparison of clinical outcomes for patients with large choroidal melanoma after primary treatment with enucleation or proton beam radiotherapy. *Ophthalmologica*. 2012;227(4):190-196.
499. Mouw KW, Sethi RV, Yeap BY, et al. Proton radiation therapy for the treatment of retinoblastoma. *Int J Radiat Oncol Biol Phys*. 2014 Nov 15;90(4):863-869.
500. Mukkamala LK, Mishra K, Daftari I, et al. Phase I/II randomized study of proton beam with anti-VEGF for exudative age-related macular degeneration: long term results. *Eye*. 2020.
501. Naeser P, Blomquist E, Montelius A, Thuomas K-A. Proton irradiation of malignant uveal melanoma. *Ups J Med Sci*. 1998;103(3):203-211.
502. Oxenreiter MM, Lane AM, Aronow MB, et al. Proton beam irradiation of uveal melanoma involving the iris, ciliary body and anterior choroid without surgical localization (light field). *British Journal of Ophthalmology*. 2020.
503. Papakostas TD, Lane AM, Morrison M. Long-term outcomes after proton beam irradiation in patients with large choroidal melanomas. *JAMA Ophthalmol*. 2017; 135(11): 1191-1196. doi:10.1001/jamaophthalmol.2017.3805.
504. Park SS, Walsh SM, Gragoudas ES. Visual-field deficits associated with proton beam irradiation for parapapillary choroidal melanoma. *Ophthalmology*. 1996;103(1):110-116.
505. Pica A, Weber DC, Vallat L, et al. Good long-term visual outcomes of parapapillary choroidal melanoma patients treated with proton therapy: a comparative study. *International Ophthalmology*. 2020.
506. Pica A, Hrbacek J, Zografos L, et al. Long-term visual acuity preservation after proton therapy for peri- and parapapillary melanoma patients treated at the Paul Scherrer Institute. *Acta Ophthalmol*. 2016;94(S256).
507. Qureshi S, Hussain R, Kalirai H, et al. Histomorphological changes of uveal melanoma (UM) following proton beam therapy (PBR). *Acta Ophthalmol*. 2016;94(S256).
508. Rahmi A, Mammar H, Thariat J, et al. Proton beam therapy for presumed and confirmed iris melanomas: a review of 36 cases. *Graefes Arch Clin Exp Ophthalmol*. 2014 Sep;252(9):1515-1521.
509. Riechardt AI, Pilger D, Cordini D2, et al. Neovascular glaucoma after proton beam therapy of choroidal melanoma: incidence and risk factors. *Graefes Arch Clin Exp Ophthalmol*. 2017 Nov;225(11):2263-2269.
510. Romanowska Dixon B, Jasinska K, Michalik M, et al. Uveal melanoma clonogenic response to proton beam irradiation. *Acta Ophthalmol*. 2016;94(S256)..

511. Rundle P, Singh AD, Rennie I. Proton beam therapy for iris melanoma: a review of 15 cases. *Eye*. 2007;21(1):79-82.
512. Schonfeld S, Cordini D, Riechardt AI, et al. Proton beam therapy leads to excellent local control rates in choroidal melanoma in the intermediate fundus zone. *Am J Ophthalmol*. 2014 Dec; 158(6):1184-1191.
513. Seibel I, Cordini D, Hager A, et al. Cataract development in patients treated with proton beam therapy for uveal melanoma. *Graefes Arch Clin Exp Ophthalmol*. 2016 Aug;254(8):1625-1630.
514. Seibel I, Cordini D, Rehak M, et al. Local recurrence after primary proton beam therapy in uveal melanoma: risk factors, retreatment approaches and outcome. *Am J Ophthalmol*. 2015 Oct;160(4):628-636.
515. Sethi RV, Shih HA, Yeap BY, et al. Second nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy. *Cancer*. 2014;120(1):126-133.
516. Sikuade MJ, Salvi S, Rundle PA, et al. Outcomes of treatment with stereotactic radiosurgery or proton beam therapy for choroidal melanoma. *Eye*. 2015 Sep;29(9):1194-1198.
517. Thariat J, Salleron J, Maschi C, et al. Oncologic and visual outcomes after postoperative proton therapy of localized conjunctival melanomas. *Radioation Oncology*. 2019.
518. Thariat J, Grange JD, Mosci C, et al. Visual outcomes of parapapillary uveal melanomas following proton beam therapy. *Int J Radiat Oncol Biol Phys*. 2016 May 1;95(1):328-335.
519. Thariat J, Jacob S, Caujolle JP, et al. Cataract avoidance with proton therapy in ocular melanomas. *Invest Ophthalmol Vis Sci*. 2017;58(12):5378-5386.
520. Tran E, Ma R, Paton K, et al. Outcomes of proton radiation therapy for peripapillary choroidal melanoma at the BC Cancer Agency. *Int J Radiat Oncol Biol Phys*. 2012;83(5):1425-1431.
521. Tsina EK, Lane AM, Zacks DN, et al. Treatment of metastatic tumors of the choroid with proton beam irradiation. *Ophthalmology*. 2005;112(2):337-343.
522. Vavvas D, Kim I, Lane AM, et al. Posterior uveal melanoma in young patients treated with proton beam therapy. *Retina*. 2010;30(8):1267-1271.
523. Wang Z, Nabhan M, Schild SE, et al. Charged Particle Radiation Therapy for Uveal Melanoma:A Systematic Review and Meta-Analysis. *Int J Radiat Oncol Biol Phys*. 2013;86(1):18-26.
524. Willerding GD, Cordini D, Moser L, et al. Neoadjuvant proton beam irradiation followed by transscleral resection of uveal melanoma in 106 cases. *Br J Ophthalmol*. 2016 Apr;100(4):463-467.
525. Wilson MW, Hungerford JL. Comparison of episcleral plaque and proton beam radiation therapy for the treatment of choroidal melanoma. *Ophthalmology*. 1999;106(8):1579-1587.
526. Wuestmeyer H, Sauerwein W, Meller D, et al. Proton radiotherapy as an alternative to extenteration in the management of extended conjunctival melanoma. *Graefes Arch Clin Exp Ophthalmol*. 2006;244(4):438-446.
527. Zografos L, Egger E, Bercher L, et al. Proton beam irradiation of choroidal hemangiomas. *Am J Ophthalmol*. 1998;126(2):261-268.
528. Zografos L, Schalenbourg A. Proton beam irradiation of choroidal hemangiomas after unsuccessful photodynamic therapy. *Acta Ophthalmol*. 2015;93(S255).

PEDIATRIC

529. Alapetite C, Puget S, Nauraye C, et al. Conservative surgery followed by proton therapy for craniopharyngioma in children: a phase II study to examine the feasibility of dose escalation. *Neuro-Oncology*. 2018;20(2):i42-i43.
530. Ares C, Albertini F, Frei-Welte M, et al. Pencil beam scanning proton therapy for pediatric intracranial ependymoma. *J Neuro Oncol*. 2016 May;128(1):137-145.
531. Armstrong FD, Holtz Children's Hospital. Proton-beam radiation therapy and health-related quality of life in children with CNS tumors. *J Clin Oncol*. 2012;30(17):2028-2029.
532. Baba K, Mizumoto M, Oshiro Y, et al. An analysis of vertebral body growth after proton beam therapy for pediatric cancer. *Cancers*. 2021.
533. Badiyan S, Ulmer S, Ahlhelm FA, et al. Clinical and radiologic outcomes in adults and children treated with pencil-beam scanning proton therapy for low-grade glioma. *Int J Part Ther*. 2017 Spring;3(4):450-460.
534. Baliga S, Yock T. Proton beam therapy in pediatric oncology. *Current Opinion in Pediatrics*. 2019;31(1):28-34.
535. Bavle A, Confer N, Simpson H, et al. NCOG-64. Incidence of early ocular complications after proton radiation for childhood brain tumors. *Neuro-Oncology*. 2020;22(2).
536. Bishop AJ, Greenfield B, Mahajan A, et al. Proton beam therapy versus conformal photon radiation therapy for childhood craniopharyngioma: multi-institutional analysis of outcomes, cyst dynamics, and toxicity. *Int J Radiat Oncol Biol Phys*. 2014 October 1;90(2):354-61.
537. Bojaxhiu B, Ahlhelm F, Walser M, et al. Radiation necrosis and white matter lesions in pediatric patients with brain tumors treated with pencil beam scanning proton therapy. *Int J Radiat Oncol Biol Phys*. 2017. 10.1016/j.ijrobp.2017.11.037.
538. Buszek SM, Ludmir EB, Grosshans DR, et al. Patterns of failure and toxicity following proton beam therapy for pediatric bladder and prostate rhabdomyosarcoma. *Int J Radiat Oncol Biol Phys*. 2019.
539. Carbonara R, Di Rito A, Monti A, et al. Proton versus photon radiotherapy for pediatric central nervous system malignancies: a systematic review and meta-analysis of dosimetric comparison studies. 2019.
540. Chhabra A, Mahajan A. Treatment of common pediatric CNS malignancies with proton therapy. *Chin Clin Oncol*. 2016 Aug;5(4):49.
541. Childs SK, Kozak KR, Friedmann AM, et al. Proton radiotherapy for parameningeal rhabdomyosarcoma: clinical outcomes and late effects. *Int J Radiat Oncol Biol Phys*. 2012;82(2):635-642.
542. Cotter SE, Herrup DA, Friedmann A, et al. Proton radiotherapy for pediatric bladder/prostate rhabdomyosarcoma: clinical outcomes and dosimetry compared to intensity-modulated radiation therapy. *Int J Radiat Oncol Biol Phys*. 2011;81(5):1367-1373.
543. Cotter SE, McBride SM, Yock TI. Proton radiotherapy for solid tumors of childhood. *Technol Cancer Res Treat*. 2012;11(3):267-278.
544. De B, Cahlon O, Hug EB, et al. Growth outcomes of pediatric patients receiving proton craniospinal irradiation. *Int J Radiat Oncol Biol Phys*. 2017 October 1; 99(2): E566-567.
545. De B, Cahlon O, Sine K, et al. Early axial growth outcomes of pediatric patients receiving proton craniospinal irradiation. *J Pediatr Hematol Oncol*. 2018 June. doi: 10.1097/MPH.0000000000001242.

546. Dell'Oro M, Short M, Wilson P, et al. Lifetime attributable risk of radiation induced second primary cancer from scattering and scanning proton therapy - A model for out-of-field organs of paediatric patients with cranial cancer. *Radiother Oncol*. 2022 April. doi.org/10.1016/j.radonc.2022.04.027.
547. Doyen J, Jazmati D, Geismar D, et al. Outcome and patterns of relapse in childhood parameningeal rhabdomyosarcoma treated with proton beam therapy. *Int J Radiat Oncol Biol Phys*. 2019.
548. Eaton BR, Goldberg S, Tarbell NJ, et al. Long-term health related quality of life in pediatric brain tumor survivors treated with proton radiotherapy at <4 years of age. *Neuro-Oncology*. 2020.
549. Eaton BR, Chowdry V, Weaver K, et al. Use of proton therapy for re-irradiation in pediatric intracranial ependymoma. *Radiother Oncol*. 2015 Aug;116(2):301-8.
550. Eaton BR, Esiashvili N, Kim S, et al. Clinical outcomes among children with standard risk medulloblastoma treated with proton and photon radiotherapy: a comparison of disease control and overall survival. *Int J Radiat Oncol Biol Phys*. 2016 Jan 1;94(1):133-138.
551. Fournier-Goodnight, A.S., Ashford, J.M., Merchant, T.E. et al. Neurocognitive functioning in pediatric craniopharyngioma: performance before treatment with proton therapy. *J Neurooncol*. 2017. doi:10.1007/s11060-017-2492-y.
552. Fuss M, Hug EB, Schaefer RA, et al. Proton radiation therapy (PRT) for pediatric optic pathway gliomas: comparison with 3D planned conventional photons and a standard photon technique. *Int J Radiat Oncol Biol Phys*. 1999;45(5):1117-1126.
553. Gallagher K. In silico clinical trial comparing predicted subsequent malignant neoplasms in photon versus proton therapy of a pediatric cohort with intracranial tumors. Oregon State Libraries. 2017.
554. Geng C, Moteabbed M, Xie Y, et al. Assessing the radiation-induced second cancer risk in proton therapy for pediatric brain tumors: the impact of employing a patient-specific aperture in pencil beam scanning. *Phys Med Biol*. 2015;61(1):12-22.
555. Gentile MS, Yeap BY, Paganetti H, al. Brainstem injury in pediatric patients with posterior fossa tumors treated with proton beam therapy and associated dosimetric factors. *Int J Radiation Oncol Biol Phys*. 2017 Nov. <https://doi.org/10.1016/j.ijrobp.2017.11.026>.
556. Grant SR, Grosshans DR, Bilton SD, et al. Proton versus conventional radiotherapy for pediatric salivary gland tumors: acute toxicity and dosimetric characteristics. *Radiother Oncol*. 2015 August;116(2):309-315.
557. Greenberger BA, Yock TI. The role of proton therapy in pediatric malignancies: recent advances and future directions. *Seminars in Oncology*. 2020.
558. Greenberger BA, Pulsifer MB, Ebb DH, et al. Clinical outcomes and late endocrine, neurocognitive, and visual profiles of proton radiation for pediatric low-grade gliomas. *Int J Radiat Oncol Biol Phys*. 2014 August 1; 89(5):1060-1068.
559. Greenfield BJ, Jaramillo S, Abboud M, et al. Outcomes for pediatric patients with central nervous system germ cell tumors treated with proton therapy. *Clin Translat Radiat Oncol*. 2016;1:9-14.
560. Grewal AS, Li Y, Fisher MJ, et al. Primary site irradiation using proton therapy in young children with medulloblastoma. *Int J Radiat Oncol Biol Phys*. 2018;102(3).

561. Haas-Kogan D, Indelicato D, Paganetti H, et al. National Cancer Institute workshop on proton therapy for children: considerations regarding brainstem injury. *Int J Radiat Oncol Biol Phys.* 2018;101(1):152-168.
562. Habrand J-L, Mammar H, Ferrand R, et al. Proton beam therapy (PT) in the management of CNS tumors in childhood. *Strahlenther Onkol.* 1999;175(Suppl 2):91-94.
563. Habrand J-L, Schneider R, Alapetite C, et al. Proton therapy in pediatric skull base and cervical canal low-grade bone malignancies. *Int J Radiat Oncol Biol Phys.* 2008;71(3):672-675.
564. Hall MD, Bradley JA, Rotondo RL, et al. Incidence and multimodality predictors of vasculopathy after proton therapy for pediatric tumors of the central nervous system and skull base. *Int J Radiat Oncol Biol Phys.* 2018 July 15;101(4):1008.
565. Hashimoto T, Shimizu S, Takao S, et al. Clinical experience of craniospinal intensity-modulated spot-scanning proton therapy using large fields for central nervous system medulloblastomas and germ cell tumors in children, adolescents, and young adults. *J Radiat Res.* 2019; pii: rrz022.
566. Hattangadi J, Esty B, Winey B, et al. Radiation recall myositis in pediatric Ewing sarcoma. *Pediatr Blood Cancer.* 2012;59(3):570-572.
567. Hattangadi JA, Rombi B, Yock TI, et al. Proton radiotherapy for high-risk pediatric neuroblastoma: early outcomes and dose comparison. *Int J Radiat Oncol Biol Phys.* 2012;83(3):1015-1022.
568. Hess CB, Indelicato DJ, Paulino AC, et al. An Update from the Pediatric Proton Consortium Registry. *Front Oncol.* 2018. doi: 10.3389/fonc.2018.00165.
569. Hill-Kayser C, Tochner Z, Li Yimei, et al. Outcomes after proton therapy for treatment of pediatric high-risk neuroblastoma. *Int J Radiat Oncol Biol Phys.* 2019.
570. Hill-Kayser C, Kirk M. Brainstem-sparing craniospinal irradiation delivered with pencil beam scanning proton therapy. *Pediatr Blood Cancer.* 2015 Apr;62(4):718-720.
571. Hill-Kayser C, Tochner Z, Both S, et al. Proton versus photon radiation therapy for patients with high-risk neuroblastoma: the need for a customized approach. *Pediatr Blood Cancer.* 2013;60(10):1606-1611.
572. Hoch BL, Nielsen GP, Liebsch NJ, Rosenberg AE. Base of skull chordomas in children and adolescents. A clinicopathologic study of 73 cases. *Am J Surg Pathol.* 2006;30(7):811-818.
573. Holtzman A, Flampouri S, Li Z, et al. Proton therapy in a pediatric patient with stage III Hodgkin lymphoma. *Acta Oncol.* 2013 Apr;52(3):592-594.
574. Hug EB, Adams J, Fitzek M, et al. Fractionated, three dimensional, planning assisted proton radiation therapy for orbital rhabdomyosarcoma: a novel technique. *Int J Radiat Oncol Biol Phys.* 2000;47(4):979-984.
575. Hug EB, Muenster MW, Adams JA, et al. 3 D conformal radiation therapy for pediatric giant cell tumors of the skull base. *Strahlenther Onkol.* 2002;178(5):239-244.
576. Hug EB, Muenster MW, Archambeau JO, et al. Conformal proton radiation therapy for pediatric low-grade astrocytomas. *Strahlenther Onkol.* 2002;178(1):10-17.
577. Hug EB, Sweeney RA, Nurre PM, et al. Proton radiotherapy in management of pediatric base of skull tumors. *Int J Radiat Oncol Biol Phys.* 2002;52(4):1017-1024.
578. Jaramillo S, Grosshans DR, Philip N, et al. Radiation for ETMR: literature review and case series of patients treated with proton therapy. *Clinical and Translational Radiation Oncology.* 2018.

579. Jimenez RB, Sethi R, Depauw N, et al. Proton radiation therapy for pediatric medulloblastoma and supratentorial primitive neuroectodermal tumors: outcomes for very young children treated with upfront chemotherapy. *Int J Radiat Oncol Biol Phys*. 2013;87(1):120-126.
580. Journy N, Indelicato DJ, Withrow DR, et al. Patterns of proton therapy use in pediatric cancer management in 2016: an international survey. *Radiotherapy and Oncology*. 2018.
581. Kahalley LS, Peterson R, Ris MD, et al. Superior intellectual outcomes after proton radiotherapy compared with photon radiotherapy for pediatric medulloblastoma. *Journal of Clinical Oncology*. 2019.
582. Kahalley LS, Mahajan A, Okcu MF, et al. Prospective, longitudinal study of neurocognitive change in pediatric brain tumor patients treated with proton beam radiotherapy versus surgery only. *Neuro-Oncology*. 2018;20(2):i175.
583. Kahalley LS, Ris MD, Grosshans DR, et al. Comparing intelligence quotient change after treatment with proton versus photon radiation therapy for pediatric brain tumors. *J Clin Oncol*. 2016 Apr 1;34(10):1043-1049.
584. Kopecky A, Khan A, Pan W, et al. Outcomes and patterns of care in a nationwide cohort of pediatric medulloblastoma: factors affecting proton therapy utilization. *Adv in Radiat Oncol*. 2017 Jul 19;2(4):588-596.
585. Kralik SF, Mereniuk TR, Grignon L, et al. Radiation induced cerebral microbleeds in pediatric patients with brain tumors treated with proton radiotherapy. *Int J Radiat Oncol Biol Phys*. 2018.
586. Kuhlthau KA, Pulsifer MB, Yeap BY, et al. Prospective study of health-related quality of life for children with brain tumors treated with proton radiotherapy. *J Clin Oncol*. 2012;30(17):2079-2086.
587. Kumar RJ, Shai H, Both S, Tochner Z, et al. Breast cancer screening for childhood cancer survivors after craniospinal irradiation with protons versus x rays: a dosimetric analysis and review of the literature. *J Pediatr Hematol Oncol*. 2013 Aug;35(6):462-467.
588. Laack NN, Harmsen WS, Paulino AC, et al. Factors associated with acute toxicity in pediatric patients treated with proton radiation therapy: a report of the Pediatric Proton Consortium Registry. *Int J Radiat Oncol*. 2018.
589. Ladra MM, Szymonifka JD, Mahajan A, et al. Preliminary results of a phase II trial of proton radiotherapy for pediatric rhabdomyosarcoma. *J Clin Oncol*. 2014 Oct 20; epub ahead of print.
590. Ladra MM, Yock TI. Proton radiotherapy for pediatric sarcoma. *Cancers*. 2014 Mar;6(1):112-127.
591. Laffond C, Dellatolas G, Alapetite C, et al. Quality-of-life, mood and executive functioning after childhood craniopharyngioma treated with surgery and proton beam therapy. *Brain Inj*. 2012;26(3):270-281.
592. Lane SA, Moncion M, Wakefield DV, et al. Microbeam proton radiotherapy allows for greater sparing of periorbital growth plate and vision related structures in pediatric cancer patients with orbital primary tumors. *Int J Radiat Oncol Biol Phys*. 2019;105(1s).
593. Lautenschlaeger S, Iancu G, Flatten V, et al. Advantage of proton-radiotherapy for pediatric patients and adolescents with Hodgkin's disease. *Radiation Oncology*. 2019;14.
594. Lee CT, Bilton SD, Famiglietti RM, et al. Treatment planning with protons for pediatric retinoblastoma, medulloblastoma, and pelvic sarcoma: how do protons compare with other conformal techniques? *Int J Radiat Oncol Biol Phys*. 2005, 63(2):362-372.

595. Leiser D, Calaminus G, Malyapa R, et al. Tumour control and Quality of Life in children with rhabdomyosarcoma treated with pencil beam scanning proton therapy. *Radiother Oncol*. 2016 Jul; 120(1):163-168.
596. Lim PS, Hrbacek J, Bachtary B, et al. Pencil beam scanning proton therapy for paediatric neuroblastoma with motion mitigation strategy for moving target volumes. *Clinical Oncology*. 2020.
597. Liu KX, Ioakeim-Ioannidou M, Susko MS, et al. A Multi-institutional Comparative Analysis of Proton and Photon Therapy-Induced Hematologic Toxicity in Patients With Medulloblastoma. *Int J Radiat Oncol Biol Phys*. 2021;109(3):726-735.
598. Logan JK, Mahajan A, Grosshans DR, et al. Associations between Neurocognitive Outcomes and Hippocampal and Subventricular Doses in Children Receiving Proton Radiation. *Int J Radiat Oncol Biol Phys*. 2017;99(2):E570.
599. Lucas JT, Ladra MM, MacDonald SM, et al. Proton therapy for pediatric and adolescent esthesioneuroblastoma. *Pediatr Blood Cancer*. 2015 Sep;62(9):1523-1528.
600. Lundkvist J, Ekman M, Ericsson SR, et al. Cost-effectiveness of proton radiation in the treatment of childhood medulloblastoma. *Cancer*. 2005b;103(4):793-801.
601. Luu QT, Lored LN, Archambeau JO, et al. Fractionated proton radiation treatment for pediatric craniopharyngioma: preliminary report. *Cancer J*. 2006;12(2):155-159.
602. Kim H, Kim T, Jung J, et al. The regression patterns of pediatric optic pathway glioma after proton beam therapy. *Int J Radiat Oncol Biol Phys*. 2019;105(4):912.
603. MacDonald SM, Safai S, Trofimov A, et al. Proton radiotherapy for childhood ependymoma: initial clinical outcomes and dose comparisons. *Int J Radiat Oncol Biol Phys*. 2008;71(4):979-986.
604. MacDonald SM, Sethi R, Lavally B, et al. Proton radiotherapy for pediatric central nervous system ependymoma: clinical outcomes for 70 patients. *Neuro Oncol*. 2013; 15(11): 1552-9.
605. MacDonald SM, Trofimov A, Safai S, et al. Proton radiotherapy for pediatric central nervous system germ cell tumors: early clinical outcomes. *Int J Radiat Oncol Biol Phys*. 2011;79(1):121-129.
606. Mahajan A, Strother D, Pollack I, et al. ATRT -10: Early post radiation changes and efficacy in children with ATRT treated on COG ACNS 0333: A comparison of proton vs. photon therapy. *Neuro Oncol*. 2017;19 (suppl_4): iv3.
607. Mailhot VR, Kim J, Bussière M, et al. Cost effectiveness of proton therapy compared with photon therapy in the management of pediatric medulloblastoma. *Cancer*. 2013;119(24):4299-4307.
608. Mailhot VR, Kim J, Hollander A, et al. Cost effectiveness of proton versus photon radiation therapy with respect to the risk of growth hormone deficiency in children. *Cancer*. 2015 May 15;121(10):1694-1702.
609. Main C, Dandapani M, Pritchard M, et al. The effectiveness and safety of proton beam radiation therapy in children with malignant central nervous system (CMS) tumours: protocol for a systematic review. *Syst Rev*. 2016;5(1):124.
610. McAllister B, Archambeau JO, Nguyen MC, et al. Proton therapy for pediatric cranial tumors: preliminary report on treatment and disease-related morbidities. *Int J Radiat Oncol Biol Phys*. 1997;39(2):455-460.

611. McGovern SL, Okcu MF, Munsell MF, et al. Outcomes and acute toxicities of proton therapy for pediatric atypical teratoid/rhabdoid tumor of the central nervous system. *Int J Radiat Oncol Biol Phys.* 2014 December 1;90(5):1143-1152.
612. Merchant TE, Hua CH, Sabin ND, et al. Progression-free survival after proton therapy for childhood craniopharyngioma: early results from a prospective trial. *Int J Radiat Oncol Biol Phys.* 2017 Oct 1;99(2):S59.
613. Miralbell R, Lomax A, Bortfeld T, et al. Potential role of proton therapy in the treatment of pediatric ependymoma/primitive neuroectodermal tumors: reduction of the supratentorial target volume. *Int J Radiat Oncol Biol Phys.* 1997;38(3):477-484.
614. Miralbell R, Lomax A, Cella L, Schneider U. Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. *Int J Radiat Oncol Biol Phys.* 2002;54(3):824-829.
615. Mizumoto M, Akutsu H, Yamamoto T, et al. Preliminary result of hypofractionated high-dose proton beam radiotherapy for pediatric skull base chordomas. *J Cancer Ther.* 2017;(8):327-332.
616. Mizumoto M, Fuji H, Miyachi M, et al. Proton beam therapy for children and adolescents and young adults (AYAs): JASTRO and JSPHO Guidelines. *Cancer Treat Rev.* 2021. doi: <https://doi.org/10.1016/j.ctrv.2021.102209>.
617. Mizumoto M, Murayama S, Akimoto T, et al. Preliminary results of proton radiotherapy for pediatric rhabdomyosarcoma: a multi-institutional study in Japan. *Cancer Med.* 2018; doi:10.1002/cam4.1464.
618. Mizumoto M, Oshiro Y, Takizawa D, et al. Proton beam therapy for pediatric ependymoma. *Pediatr Int.* 2015 Aug;57(4):567-571.
619. Moeller BJ, Chintagumpala M, Philip JJ, et al. Low early ototoxicity rates for pediatric medulloblastoma patients treated with proton radiotherapy. *Radiat Oncol.* 2011;6:58.
620. Moteabbed M, Yock TI, Paganetti H, et al. The risk of radiation-induced second cancers in the high to medium dose region: a comparison between passive and scanned proton therapy, IMRT and VMAT for pediatric patients with brain tumors. *Phys Med Bio.* 2014 Jun 21;59(12):2883-2899.
621. Mu X, Bjork-Eriksson T, Nill S, et al. Does electron and proton therapy reduce the risk of radiation induced cancer after spinal irradiation for childhood medulloblastoma? A comparative treatment planning study. *Acta Oncol.* 2005;44(6):554-562.
622. Noël G, Habrand JL, Helfre S, et al. Proton beam therapy in the management of central nervous system tumors in childhood: the preliminary experience of the Centre de Protonthérapie d'Orsay. *Med Pediatr Oncol.* 2003;40(5):309-315.
623. Oshiro Y, Sugahara S, Fukushima T, et al. Pediatric nasopharyngeal carcinoma treated with proton beam therapy. Two case reports. *Acta Oncol.* 2011;50(3):470-473.
624. Perez-Andujar A, Newhauser WD, Taddei PJ, et al. The predicted relative risk of premature ovarian failure for three radiotherapy modalities in a girl receiving craniospinal irradiation. *Phys Med Biol.* 2013 May 21;58(10):3107-3123.
625. Perkins, Stephanie M. and et al. An update from the Pediatric Proton Consortium Registry. *Frontiers in Oncology.* 2018;8(165). https://digitalcommons.wustl.edu/open_access_pubs/6893

626. Peters S, Frisch S, Stickan-Verfuerth M, Plaude S, Blasé C, Tippelt S, Timmerman B. Proton beam therapy for ependymomas of childhood; early data from the prospective KiProReg Registry. *Int J Radiat Oncol Biol Phys*. 2018 July 15;101(4):1009.
627. Petrovic A, Bergin C, Schalenbourg A, et al. Proton therapy for uveal melanoma in 43 juvenile patients: long-term results. *Ophthalmology*. 2014 Apr; 121(4):898-904.
628. Pham A, Wong K, Chang EL. Quality of life in pediatric brain tumor patients treated with proton therapy: a review of the literature. *Expert Rev Qual Life Cancer Care*. 2016;1(4):329-338.
629. Pulsifer MB, Duncanson H, Grieco J, et al. Cognitive and adaptive outcomes following proton radiation for pediatric patients with brain tumors. *Int J Radiat Oncol Biol Phys*. 2018;102(2):391-398. <https://doi.org/10.1016/j.ijrobp.2018.05.069>.
630. Ray GL, Buchsbaum JC, McMullen KP, et al. Definitive treatment of leptomeningeal spinal metastases in children. *Pediatr Blood Cancer*. 2013;60(11):1839-1841.
631. Rombi B, Ares C, Hug EB, et al. Spot-scanning proton radiation therapy for pediatric chordoma and chondrosarcoma: clinical outcome of 26 patients treated at Paul Scherrer Institute. *Int J Radiat Oncol Biol Phys*. 2013;86(3):578-584.
632. Rombi B, DeLaney TF, MacDonald SM, et al. Proton radiotherapy for pediatric Ewing's sarcoma: initial clinical outcomes. *Int J Radiat Oncol Biol Phys*. 2012;82(3):1142-1148.
633. Rombi B, Vennarini S, Vinante L, et al. Proton radiotherapy for pediatric tumors: review of first clinical results. *Ital J Pediatr*. 2014 Sep 26;40:74.
634. Roth AK, Ris MD, Orobio J, et al. Cognitive mediators of adaptive functioning outcomes in survivors of pediatric brain tumors treated with proton radiotherapy. *Pediatric Blood & Cancer*. 2019.
635. Rutz HP, Weber DC, Goitein G, et al. Postoperative spot-scanning proton radiation therapy for chordoma and chondrosarcoma in children and adolescents: initial experience at Paul Scherrer Institute. *Int J Radiat Oncol Biol Phys*. 2008;71(1):220-225.
636. Sabin ND, Merchant TE, Harreld JH, et al. Imaging changes in very young children with brain tumors treated with proton therapy and chemotherapy. *AJNR Am J Neuroradiol*. 2013;34(2):446-450.
637. Sands SA. Proton beam radiation therapy: the future may prove brighter for pediatric patients with brain tumors. *J Clin Oncol*. 2016 Apr 1;34(10):1024-1026.
638. Secco DE, Cacchione A, Del Bufalo F, et al. Late neuropsychological outcomes with proton radiation in children with brain tumor. *Neuro-Oncology*. 2018;20(2):i178.
639. Song S, Park HJ, Yoon JH, et al. Proton beam therapy reduces the incidence of acute haematological and gastrointestinal toxicities associated with craniospinal irradiation in pediatric brain tumors. *Acta Oncol*. 2014 Sep;53(9):1158-1164.
640. St Clair WH, Adams JA, Bues M, et al. Advantage of protons compared to conventional X-ray or IMRT in the treatment of a pediatric patient with medulloblastoma. *Int J Radiat Oncol Biol Phys*. 2004;58(3):727-734.
641. Suneja G, Poorvu PD, Hill-Kayser C, Lustig RA. Acute toxicity of proton beam radiation for pediatric central nervous system malignancies. *Pediatr Blood Cancer*. 2013;60(9):1431-1436.

642. Suzuki S, Kato T, Murakami M. Impact of lifetime attributable risk of radiation-induced secondary cancer in proton craniospinal irradiation with vertebral-body-sparing for young pediatric patients with medulloblastoma. *Journal of Radiation Research*. 2020.
643. Tann AW, McAleer MF, McGovern SL, et al. Clinical outcomes of pediatric patients with pelvic tumors treated with proton therapy. *Int J Radiat Oncol Biol Phys*. 2016 Oct 1;96(2S):E555.
644. Thorp N. Proton therapy for children. *RAD Magazine*. 2010;36(418):17-18.
645. Timmermann B, Schuck A, Niggli F, et al. Spot-scanning proton therapy for malignant soft tissue tumors in childhood: first experiences at the Paul Scherrer Institute. *Int J Radiat Oncol Biol Phys*. 2007;67(2):497-504.
646. Tran S, Lim PS, Bojaxhiu B, et al. Clinical outcomes and quality of life in children and adolescents with primary brain tumors treated with pencil beam scanning proton therapy. *Pediatric Blood & Cancer*. 2020.
647. Tringale KR, Casey DL, Niyazov G, Wolden SL. Second Cancer Risk in Childhood Cancer Survivors Treated with Intensity-Modulated Radiation Therapy (IMRT): An Updated Analysis of More Than 10 Years of Follow-Up. *Int J Radiat Oncol Biol Phys*. 2021;111(3):e170-e171.
648. Vega RM, Kim J, Hollander A, et al. Cost effectiveness of proton versus photon radiation therapy with respect to the risk of growth hormone deficiency in children. *Cancer*. 2015 May 15;121(1):1694-1702.
649. Ventura LM, Grieco JA, Evans CL, et al. Executive functioning, academic skills, and quality of life in pediatric patients with brain tumors post-proton radiation therapy. *J Neurooncol*. 2017.doi.org/10.1007/s11060-017-2703-6.
650. Vidal G, Amtzen J, Henson C. A dosimetric comparison of proton versus photon irradiation for pediatric glomus tumor. *Int J Radiat Oncol Biol Phys*. 2020;106(5):1217-1218.
651. Vogel J, Both S, Kirk M, et al. Proton therapy for pediatric head and neck malignancies. *Pediatr Blood Cancer*. 2017 Oct 23. DOI: 10.1002/pbc.26858.
652. Warren E, Child A, Cirino P, et al. Better social, cognitive, and academic outcomes among pediatric brain tumor survivors treated with proton versus photon radiation therapy. *Neuro-Oncology*. 2018;20(2):i166.
653. Weber DC, Ares C, Albertini F, et al. Pencil beam scanning proton therapy for pediatric parameningeal rhabdomyosarcomas: clinical outcome of patients treated at the Paul Scherrer Institute. *Pediatr Blood Cancer*. 2016 Oct;63(170):1731-1736.
654. Weber DC, Ares C, Malya R, et al. Tumor control and QoL outcomes of very young children with atypical teratoid/rhabdoid tumor treated with focal only chemoradiation therapy using pencil beam scanning proton therapy. *J Neurooncol*. 2015 Jan;121(2):389-397.
655. Weber DC, Habrand JL, Hoppe BS. Proton therapy for pediatric malignancies: fact, figures, and costs. A joint consensus statement from the pediatric subcommittee of PTCOG, PROS, and EPTN. *Radiother Oncol*. 2018.
656. Welch GD, Lin KY, Fisher MJ, Hill-Kayser C. Cardiac toxicity after craniospinal irradiation: a late effect that may be eliminated with proton therapy. *J Pediatr Hematol Oncol*. 2017 Dec 1. doi: 10.1097/MPH.0000000000001029.

657. Winkfield KM, Linsenmeier C, Yock TI, et al. Surveillance of craniopharyngioma cyst growth in children treated with proton radiotherapy. *Int J Radiat Oncol Biol Phys*. 2009;73(3):716-721.
658. Wray J, Flampouri S, Slayton W, et al. Proton therapy for pediatric Hodgkin lymphoma. *Pediatr Blood Cancer*. 2016 Sep;63(9):1522-1526.
659. Yahya N, Manan HA. Neurocognitive impairment following proton therapy for paediatric brain tumour: a systematic review of post-therapy assessments. *Supportive Care in Cancer*. 2020.
660. Yock T, Schneider R, Friedmann A, et al. Proton radiotherapy for orbital rhabdomyosarcoma: clinical outcome and a dosimetric comparison with photons. *Int J Radiat Oncol Biol Phys*. 2005, 63(4):1161-1168.
661. Yock TI, Bhat S, Szymonifka J, et al. Quality of life outcomes in proton and photon treated pediatric brain tumor survivors. *Radiother Oncol*. 2014 Oct;113(1):89-94.
662. Yock TI, Tarbell NJ. Technology insight: proton beam radiotherapy for treatment in pediatric brain tumors. *Nat Clin Pract Oncol*. 2004;1(2):97-103.
663. Yock TI, Yeap BY, Ebb DH, et al. Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single-arm study. *Lancet Oncol*. 2016 Mar;17(3):287-298.
664. Yuh GE, Loredó LN, Yonemoto LT, et al. Reducing toxicity from craniospinal irradiation: using proton beams to treat medulloblastoma in young children. *Cancer J*. 2004;10(6):386-390.
665. Zhang R, Howell RM, Giebler A, et al. Comparison of risk of radiogenic second cancer following photon and proton craniospinal irradiation for a pediatric medulloblastoma patient. *Phys Med Biol*. 2013;58(4):807-823.
666. Zhang R, Howell RM, Homann K, et al. Predicted risks of radiogenic cardiac toxicity in two pediatric patients undergoing photon or proton radiotherapy. *Radiat Oncol*. 2013 Jul 23;8(1):184.

PROSTATE

667. Arimura T, Kondo N, Matsukawa K, et al. The role of proton beam therapy for patients with intermediate- and high-risk prostate cancer. *J Clin Oncol*. 2018;36(6):97.
668. Arimura T, Yoshiura T, Matsukawa K, et al. Proton Beam Therapy Alone for Intermediate- or High-Risk Prostate Cancer: An Institutional Prospective Cohort Study. *Cancers*. 2018;10(4):116. <https://doi.org/10.3390/cancers10040116>.
669. Benk VA, Adams JA, Shipley WU, et al. Late rectal bleeding following combined x-ray and proton high dose irradiation for patients with stages T3-T4 prostate cancer. *Int J Radiat Oncol Biol Phys*. 1993;26(3):551-557.
670. Bowyer J, Natha S, Marsh I, Foy P. Visual complications of proton beam therapy for clival chordoma. *Eye*. 2003;17(3):318-323.
671. Bryant C, Henderson RH, Nichols RC, et al. Consensus statement on proton therapy for prostate cancer. *Int J Part Ther*. 2021. doi: 10.14338/IJPT-20-00031.1.
672. Bryant C, Smith TL, Henderson RH, et al. Five-year biochemical results, toxicity, and patient-reported quality of life following delivery of dose-escalated image-guided proton therapy for prostate cancer. *Int J Radiat Oncol Biol Phys*. 2016;95(1):422-434.

673. Choi S, Blanchard P, Ye R, et al. Outcomes following proton therapy for the treatment of prostate cancer: efficacy and toxicity results from 2 prospective single institution cohorts. *Int J Radiat Oncol Biol Phys.* 2017;99(2S):E221.
674. Chuong MD, Hartsell WH, Larson GL, et al. Minimal toxicity after proton beam therapy for prostate and pelvic nodal irradiation: results From the Proton Collaborative Group REG001-09 trial. *Int J Radiat Oncol Biol Phys.* 2017;99(2S): E223.
675. Coen JJ, Bae K, Zietman AL, et al. Acute and late toxicity after dose escalation to 82 GyE using conformal proton radiation for localized prostate cancer: initial report of American College of Radiology phase II study 03-12. *Int J Radiat Oncol Biol Phys.* 2011;81(4):1005-1009.
676. Coen JJ, Paly JJ, Niemierko A, et al. Long-term quality of life outcome after proton beam monotherapy for localized prostate cancer. *Int J Radiat Oncol Biol Phys.* 2012;82(2):e201-e209.
677. Coen JJ, Zietman AL, Rossi CJ, et al. Comparison of high-dose proton radiotherapy and brachytherapy in localized prostate cancer: a case-matched analysis. *Int J Radiat Oncol Biol Phys.* 2012;82(1):e25-e31.
678. Deville C, Hwang WT, Barskey AR, et al. Initial clinical outcomes for prostate cancer patients undergoing adjuvant or salvage proton therapy after radical prostatectomy. *Acta Oncologica.* 2020.
679. Efsthathiou JA, Gray PJ, Zietman AL. Proton beam therapy and localized prostate cancer: current status and controversies. *Br J Cancer.* 2013;108(6):1225-1230.
680. Forsthoefel M, Hankins R, Ballew E, et al. Prostate Cancer Treatment with Pencil Beam Proton Therapy Using Rectal Spacers sans Endorectal Balloons. *Int J Part Ther.* 2022 Apr. doi.org/10.14338/IJPT-21-00039.
681. Galbraith ME, Ramirez JM, Pedro LW. Quality of life, health outcomes, and identity for patients with prostate cancer in five different treatment groups. *Oncol Nurs Forum.* 2001;28(3):551-560.
682. Gardner BG, Zietman AL, Shipley WU, et al. Late normal tissue sequelae in the second decade after high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer. *J Urol.* 2002;167(1):123-126.
683. Goenka A, Newman NB, Fontanilla H, et al. Patient reported quality of life following proton beam therapy for prostate cancer: the impact of prostate size. *Clin Genitourin Cancer.* 2017 Dec;15(6):704-710.
684. Gray PJ, Paly JJ, Yeap BY, et al. Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. *Cancer.* 2013;119(9):1729-1735.
685. Han JE, Chang J, Rosen L, et al. Treatment interruptions affect biochemical failure rates in prostate cancer patients treated with proton beam therapy: report from the multi-institutional proton collaborative group registry. *Clinical and Translational Radiation Oncology.* 2020;25:94-101.
686. Hattori Y, Iwata H, Nakajima K, et al. Changes in sexual function and serum testosterone levels in patients with prostate cancer after image-guided proton therapy. *J Radiat Res.* 2021. <https://doi.org/10.1093/jrr/rrab002>.
687. Henderson RH, Hoppe BS, Marcus RB Jr, et al. Urinary functional outcomes and toxicity five years after proton therapy for low- and intermediate-risk prostate cancer: results of two prospective trials. *Acta Oncol.* 2013;52(3):463-469.

688. Ho CK, Bryant CM, Mendenhall NP, et al. Long-term outcomes following proton therapy for prostate cancer in young men with a focus on sexual health. *Acta Oncol.* 2018. <https://doi.org/10.1080/0284186X.2018.1427886>.
689. Hoppe BS, Harris S, Rhoton-Vlasak A, et al. Sperm preservation and neutron contamination following proton therapy for prostate cancer study. *Acta Oncol.* 2016.
690. Hoppe BS, Michalski JM, Mendenhall NP, et al. Comparative effectiveness study of patient reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer. *Cancer.* 2014 Apr 1;120(7):1076-1082.
691. Hoppe BS, Nichols RC, Henderson RH, et al. Erectile function, incontinence, and other quality of life outcomes following proton therapy for prostate cancer in men 60 years old and younger. *Cancer.* 2012.118(18):4619-4626.
692. Jabbari S, Weinberg VK, Shinohara K, et al. Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost. *Int J Radiat Oncol Biol Phys.* 2010;76(1):36-42.
693. Jain et al. Acute and late toxicity report of post-prostatectomy proton therapy for prostate cancer patients undergoing adjuvant or salvage radiotherapy. *Int J Radiat Oncol Biol Phys.* 2017;98(2):e25.
694. Johansson S, Åström L, Sandin F, et al. Hypofractionated proton boost combined with external beam radiotherapy for treatment of localized prostate cancer. *Prostate Cancer.* 2012;654861.
695. Kharod SM, Mercado CE, Morris CG, et al. Postoperative or Salvage Proton Radiotherapy for Prostate Cancer After Radical Prostatectomy. *Int J Part Ther.* 2021 Spring. <https://doi.org/10.14338/IJPT-20-00021.1>.
696. Kil WJ, Nichols RC Jr., Hoppe BS, et al. Hypofractionated passively scattered proton radiotherapy for low- and intermediate-risk prostate cancer is not associated with posttreatment testosterone suppression. *Acta Oncol.* 2013;52(3):492-497.
697. Kim S, Shen S, Moore DF, et al. Late gastrointestinal toxicities following radiation therapy for prostate cancer. *Eur Urol.* 2011;60(5):908-916.
698. Kim YJ, Cho KH, Pyo HR, et al. A phase II study of hypofractionated proton therapy for prostate cancer. *Acta Oncol.* 2013;52(3):477-485.
699. Konski A, Speier W, Hanlon A, et al. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? *J Clin Oncol.* 2007;25(24):3603-3608.
700. Lee DT, Mendenhall NP, Smith TL, et al. Patient-reported quality of life in men with transurethral resection of the prostate undergoing proton therapy for management of prostate cancer. *Int J Part Ther.* 2016 Spring;2(4):518-524.
701. Lee HJ, Macomber MW, Spraker MB, et al. Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes. *Radiat Oncol.* 2018;13:179.
702. Maeda Y, Sato Y, Shibata S, et al. Effects of organ motion on proton prostate treatments, as determined from analysis of daily CT imaging for patient positioning. *Med Phys.* 2018; doi: 10.1002/mp.12869.

703. Mahal BA, Chen YW, Efstathiou JA, et al. National trends and determinants of proton therapy use for prostate cancer: a National Cancer Data Base study. *Cancer*. 2016 May 15;122(10):1505-1512.
704. Mayahara H, Murakami M, Kagawa K, et al. Acute morbidity of proton therapy for prostate cancer: the Hyogo Ion Beam Medical Center experience. *Int J Radiat Oncol Biol Phys*. 2007;69(2):434-443.
705. McGee L, Mendenhall NP, Henderson RH, et al. Outcomes in men with large prostates (≥ 60 cm³) treated with definitive proton therapy for prostate cancer. *Acta Oncol*. 2013;52(3):470-476.
706. Mendenhall NP, Hoppe BS, Nichols RC et al. Five-year outcomes from 3 prospective trials of image-guided proton therapy for prostate cancer. *Int J Radiat Oncol Biol Phys*. 2013;88(3): 596-602.
707. Mendenhall NP, Li Z, Hoppe BS, et al. Early outcomes from three prospective trials of image guided proton therapy for prostate cancer. *Int J Radiat Oncol Biol Phys*. 2012;82(1):213-221.
708. Mendenhall NP, Wong W, Bryant C et al. Comparison of clinical outcomes with IMRT and proton therapy for prostate cancer. *J Clin Oncol*. 2017; e16555-e16555.
709. Mendenhall NP, Wong W, Bryant C, et al. Potential Improved Outcomes with Proton Therapy in Prostate Cancer: a Comparison of IMRT and Proton Cohorts. *Int J Radiat Oncol Biol Phys*. 2017 Oct 1;99(2):E254.
710. Mishra MV, Khairnar R, Bentzen SM, et al. Patient reported outcomes following proton pencil beam scanning vs. passive scatter/uniform scanning for localized prostate cancer: secondary analysis of PCG 001-09. *Clinical and Translational Radiation Oncology*. 2020;22:50-54.
711. Murakami M, Ishikawa H, Shimizu S, et al. Optimal androgen deprivation therapy combined with proton beam therapy for prostate cancer: results from a multi-institutional study of the Japanese Radiation Oncology Study Group. *Cancers*. 2020;12:1690.
712. Nakajima K, Iwata H, Ogino H, et al. Acute toxicity of image-guided hypofractionated proton therapy for localized prostate cancer. *Int J Radiat Oncol Biol Phys*. 2017. <https://doi.org/10.1007/s10147-017-1209-8>.
713. Nguyen PL, Zietman AL. High-dose external beam radiation for localized prostate cancer: current status and future challenges. *Cancer J*. 2007;13(5):295-301.
714. Nichols RC Jr, Morris CG, Hoppe BS, et al. Proton radiotherapy for prostate cancer is not associated with post-treatment testosterone suppression. *Int J Radiat Oncol Biol Phys*. 2012;82(3):1222-1226.
715. Nihei K, Ogino T, Ishikura S, et al. Phase II feasibility study of high-dose radiotherapy for prostate cancer using proton boost therapy: first clinical trial of proton beam therapy for prostate cancer in Japan. *Jpn J Clin Oncol*. 2005;35(12):745-752.
716. Nihei K, Ogino T, Onozawa M, et al. Multi-institutional phase II study of proton beam therapy for organ-confined prostate cancer focusing on the incidence of late rectal toxicities. *Int J Radiat Oncol Biol Phys*. 2011;81(2):390-396.
717. Pan HY, Jiang J, Hoffman KE, et al. Comparative toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men with Prostate Cancer. *J Clin Oncol*. 2018; JCO.2017755371.
718. Philip N, Pugh TJ, Ye R, et al. A Phase II trial of hypofractionated proton therapy in prostate cancer: 3-year physician and patient reported outcomes. *Int J Radiat Oncol Biol Phys*. 2019;E302.

719. Polf JC, Chuong M, Zhang B, Mehta M. Anteriorly oriented beam arrangements with daily in vivo range verification for proton therapy of prostate cancer: rectal toxicity rates. *Int J Part Ther*. 2016;510-517.
720. Quinn TJ, Hamstra D. Hypofractionation in prostate cancer using proton beam. *Int J Radiat Oncol Biol Phys*. 2019;105(4):723-726.
721. Ricks LJ, Sambyal A, McDonald J, et al. Utilization of machine learning and Proton Collaborative Group data to develop a model for predictive prostate cancer proton radiation therapy outcomes. *Int J Radiat Oncol Biol Phys*. 2017 Oct 1; 99(2): E262.
722. Rossi CJ Jr, Slater JD, Yonemoto LT, et al. Influence of patient age on biochemical freedom from disease in patients undergoing conformal proton radiotherapy of organ-confined prostate cancer. *Urology*. 2004;64(4):729-732.
723. Royce TJ, Efsthathiou JA. Proton therapy for prostate cancer: a review of the rationale, evidence, and current state. *Urologic Oncology: Seminars and Original Investigations*. 2018.
724. Sato H, Kato T, Motoyanagi T, et al. Preliminary analysis of prostate positional displacement using hydrogel spacer during the course of proton therapy for prostate cancer. *Journal of Radiation Research*. 2020.
725. Schmidt MQ, Vargas CE, Hartsell WF, et al. Toxicity, quality of life outcomes, and dosimetric impact in phase III trial of hypofractionated or standard fractionated proton therapy for low-risk prostate cancer patients: PCG GU 002. *J Clin Oncol*. 2017 Feb;35(6):S48.
726. Schroeck FR, Jacobs BL, Bhayani SB, et al. Cost of new technologies in prostate cancer treatment: systematic review of costs and cost effectiveness of robotic-assisted laparoscopic prostatectomy, intensity-modulated radiotherapy, and proton beam therapy. *Eur Urol*. 2017 Nov;72(5):712-735
727. Schulte RW, Slater JD, Rossi CJ Jr, Slater JM. Value and perspectives of proton radiation therapy for limited stage prostate cancer. *Strahlenther Onkol*. 2000;176(1):3-8.
728. Scobioala S, Kittel C, Wissman N, et al. A treatment planning study comparing tomotherapy, volumetric modulated arc therapy, Sliding Window and proton therapy for low-risk prostate carcinoma. *Radiat Oncol*. 2016;11(1):128.
729. Shah SK, Lui PD, Baldwin DD, Ruckle HC. Urothelial carcinoma after external beam radiation therapy for prostate cancer. *J Urol*. 2006;175(6):2063-2066.
730. Sheets NC, Goldin GH, Meyer A-M, et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. *JAMA*. 2012;307(15):1611-1620.
731. Shipley WU, Verhey LJ, Munzenrider JE, et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. *Int J Radiat Oncol Biol Phys*. 1995;32(1):3-12.
732. Slater JD, Rossi CJ Jr, Yonemoto LT, et al. Conformal proton therapy for early-stage prostate cancer. *Urology*. 1999;53(5):978-984.
733. Slater JD, Rossi CJ Jr, Yonemoto LT, et al. Proton therapy for prostate cancer: the initial Loma Linda University experience. *Int J Radiat Oncol Biol Phys*. 2004;59(2):348-352.
734. Slater JD, Yonemoto LT, Rossi CJ Jr, et al. Conformal proton therapy for prostate carcinoma. *Int J Radiat Oncol Biol Phys*. 1998;42(2):299-304.

735. Talcott JA, Rossi C, Shipley WU, et al. Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer. *JAMA*. 2010;303(11):1046-1053.
736. Thaker NG, Ali TN, Porter ME, et al. Communicating value in health care using radar charts: a case study of prostate cancer. *J Oncol Pract*. 2016 Sep;12(9):813-820.
737. Underwood T, Giantsoudi D, Moteabbed M, et al. Can we advance proton therapy for prostate? Considering alternative beam angles and RBE variations when comparing against IMRT. *Int J Radiat Oncol Biol Phys*. 2016 May;95(1):454-464.
738. Valery R, Mendenhall NP, Nichols RC Jr, et al. Hip fractures and pain following proton therapy for management of prostate cancer. *Acta Oncol*. 2013;52(3):486-491.
739. Vargas C, Fryer A, Mahajan C, et al. Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer. *Int J Radiat Oncol Biol Phys*. 2008 Mar 1;70(3):744-751.
740. Vargas CE, Hartsell WF, Dunn M, et al. Image-guided hypofractionated proton beam therapy for low-risk prostate cancer: analysis of quality of life and toxicity, PCG GU 002. *Rep Pract Oncol Radiother*. 2016;21(3):207-212.
741. Waki T, Tominaga Y, Niwa Y, et al. Proton therapy for prostate ca: Comparison of toxicity between mod-hypo and conventional fraction. *Radiother Oncol*. EP-1527, 2019.
742. Walsh S, Roelofs E, Kuss P, et al. Towards a clinical decision support System for external beam radiation oncology prostate cancer patients: proton vs. photon radiotherapy? A radiobiological study of Robustness and Stability. *Cancers*. 2018;10(55):1-16.
743. Wessels BW, Brindle JM, Cheng CW, et al. Retrospective prostate treatment plan comparison for proton, tomotherapy, and cyberknife therapy. *Int J Part Ther*. 2015;2(2).
744. Wisenbaugh ES, Andrews PE, Ferrigni RG, et al. Proton beam therapy for localized prostate cancer 101: basics, controversies, and facts. *Rev Urol*. 2014;16(2):67-75.
745. Wong JK, Vapiwala V, Handorf E, et al. A multi-institutional, propensity score-weighted comparison of moderately hypofractionated photon and proton therapy for 1850 patients with low or intermediate risk prostate cancer. *Int J Radiat Oncol Biol Phys*. 2020;108(3).
746. Yonemoto LT, Slater JD, Rossi CJ Jr, et al. Combined proton and photon conformal radiation therapy for locally advanced carcinoma of the prostate: preliminary results of a phase I/II study. *Int J Radiat Oncol Biol Phys*. 1997;37(1):21-29.
747. Yu JB, Soulos PR, Herrin J, et al. Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. *J Natl Cancer Inst*. 2013;105(1):25-32.
748. Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional-dose with high dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. *J Clin Oncol*. 2010;28(7):1106-1111.
749. Zietman AL. The Titanic and Iceberg: prostate proton therapy and health care economics. *J Clin Oncol*. 2007;25(24):3565-3566.

750. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. *JAMA*. 2005;294(10):1233-1239.

SARCOMA

Retroperitoneal Sarcoma

751. Brennenman RJ, Sharifai N, Fischer-Valuck B, et al. Abscopal effect following proton beam radiotherapy in a patient with inoperable metastatic retroperitoneal sarcoma. *Front Oncol*. 2019.
752. Chung CS, Adams J, Trofimov A, Delaney T. A comparison of 3D conformal proton therapy, intensity modulated proton therapy, and intensity modulated photon therapy for retroperitoneal sarcoma. *Int J Radiat Oncol Biol Phys*. 2006;66(3S):116.
753. DeLaney TF, Chen YL, Adams JA, et al. Phase 1 Trial of Preoperative Image Guided Intensity Modulated Proton Radiation Therapy (IMPT) With Simultaneously Integrated Boost to the High Risk Margin for Retroperitoneal Sarcomas. *Int J Radiat Oncol Biol Phys*. 2016 Oct 1;96(2S):S23. doi:10.1016/j.ijrobp.2016.06.068. PubMed PMID: 27675854.
754. Swanson EL, Indelicato DJ, Loius D, et al. Comparison of three-dimensional (3D) conformal proton radiotherapy (RT), 3D conformal photon RT, and intensity-modulated RT for retroperitoneal and intra-abdominal sarcomas. *Int J Radiat Oncol Biol Phys*. 2012;83(5):1549-1557.
755. Yoon SS, Chen Y-L, Kirsch DG, et al. Proton-beam, intensity-modulated, and/or intraoperative electron radiation therapy combined with aggressive anterior surgical resection for retroperitoneal sarcomas. *Ann Surg Oncol*. 2010;17(6):1515-1529.
756. Schmid MP, Harrabi S, Herfarth K, et al. Particle Therapy in Adult Patients with Pelvic Ewing Sarcoma—Tumor and Treatment Characteristics and Early Clinical Outcomes. *Cancers*. 2022; 14(24):6045. <https://doi.org/10.3390/cancers14246045>

Soft Tissue Sarcoma

757. Guttmann DM, Frick MA, Carmona R, et al. A prospective study of proton reirradiation for recurrent and secondary soft tissue sarcoma. *Radiother Oncol*. 2017 Jul 8. pii: S0167-8140(17)32444-1.

Other Sarcoma

758. Ciernik IF, Niemierko A, Harmon DC, et al. Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma. *Cancer*. 2011;117(19):4522-4530.
759. DeLaney TF, Haas RL. Innovative radiotherapy of sarcoma: proton beam radiation. *Eur J Cancer*. 2016 July;62:112-123.
760. DeLaney TF, Liebsch NJ, Pedlow FX, et al. Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. *Int J Radiat Oncol Biol Phys*. 2009;74(3):732-739.
761. Frisch S, Timmerman B. The Evolving Role of Proton Beam Therapy for Sarcomas. *Clin Oncol (R Coll Radiol)*. 2017 May 12. pii: S0936-6555(17)30221-2.
762. Fukumoto T, Komatsu S, Hori Y, et al. Particle beam radiotherapy with a surgical spacer placement for advanced abdominal leiomyosarcoma results in a significant clinical benefit. *J Surg Oncol*. 2010;101(1):97-99.

763. Gray ST, Chen Y-L, Lin DT. Efficacy of proton beam therapy in the treatment of Ewing's sarcoma of the paranasal sinuses and anterior skull base. *Skull Base*. 2009;19(6):409-416.
764. Uwa N, Terada T, Mohri T, et al. An unexpected skin ulcer and soft tissue necrosis after the nonconcurrent combination of proton beam therapy and pazopanib: a case of myxofibrosarcoma. *Auris Nasus Larynx*. 2017 Aug;44(4):484-488.
765. Weber DC, Rutz HP, Bolsi A, et al. Spot scanning proton therapy in the curative treatment of adult patients with sarcoma: the Paul Scherrer Institute experience. *Int J Radiat Oncol Biol Phys*. 2007;69(3):865-871.

SKULL BASE AND AXIAL SKELETON

766. Acharaya S, Robinson CG, Michalski JM, et al. Association of 1p/19q codeletion and Radiation Necrosis in Adult Cranial Gliomas after Proton or Photon Therapy. *Int J Radiat Oncol Biol Phys*. 2018. <https://doi.org/10.1016/j.ijrobp.2018.01.099>.
767. Ahmed KA, Demetriou SK, McDonald M, Johnstone PA. Clinical benefits of proton beam therapy for tumors of the skull base. *Cancer Control*. 2016 Jul;23(3):213-9.
768. Aibe N, Demizu Y, Sulaiman NS, et al. Outcomes of Patients with Primary Sacral Chordoma Treated with Definitive Proton Beam Therapy. *Int J Radiat Oncol Biol Phys*. 2018;100(4):972-979. <http://dx.doi.org/10.1016/j.ijrobp.2017.12.263>.
769. Amichetti M, Amelio D, Cianchetti M, et al. A systematic review of proton therapy in the treatment of chondrosarcoma of the skull base. *Neurosurg Rev*. 2010;33(2):155-165.
770. Amichetti M, Amelio D, Cianchetti M, et al. Proton therapy in chordoma of the base of the skull: a systematic review. *Neurosurg Rev*. 2009;32(4):403-416.
771. Amichetti M, Amelio D, Cianchetti M, et al. The treatment of chordoma and chondrosarcoma of the skull base with particular attention to radiotherapy. *Clinics in Oncology*. 2017;2(1195):1-7.
772. Ares C, Hug EB, Lomax AJ, et al. Effectiveness and safety of spot scanning proton radiation therapy for chordomas and chondrosarcomas of the skull base: first long-term report. *Int J Radiat Oncol Biol Phys*. 2009;75(4):1111-1118.
773. Beddok A, Saint-Martin C, Mammar H, et al. High-dose proton therapy and tomotherapy for the treatment of sacral chordoma: a retrospective monocentric study. *Acta Oncologica*. 2021;60(2).
774. Benk V, Liebsch NJ, Munzenrider JE, et al. Base of skull and cervical spine chordomas in children treated by high-dose irradiation. *Int J Radiat Oncol Biol Phys*. 1995;31(3):577-581.
775. Chakravarti A, Spiro IJ, Hug EB, et al. Megavoltage radiation therapy for axial and inoperable giant-cell tumor of bone. *J Bone Joint Surg Am*. 1999;81(11):1566-1573.
776. Chen Y-L, Liebsch N, Kobayashi W, et al. Definitive high-dose photon/proton radiotherapy for unresected mobile spine and sacral chordomas. *Spine*. 2013;38(15):E930-E936.
777. Combs SE, Kessel K, Habermehl, et al. Proton and carbon ion radiotherapy for primary brain tumors and tumors of the skull base. *Acta Oncol*. 2013;52(7):1504-1509.
778. Combs SE, Laperriere N, Brada M. Clinical controversies: proton radiation therapy for brain and skull base tumors. *Semin Radiat Oncol*. 2013;23(2):120-126.

779. Debus J, Hug EB, Liebsch NJ, et al. Brainstem tolerance to conformal radiotherapy of skull base tumors. *Int J Radiat Oncol Biol Phys*. 1997;39(5):967-975.
780. DeLaney TF, Liebsch NJ, Pedlow FX, et al. Long-term results of Phase II study of high dose photon/proton radiotherapy in the management of psine chordomas, chondrosarcomas, and other sarcomas. *J Surg Oncol*. 2014;110:115-122.
781. Demizu Y, Mizumoto M, Onoe T, et al. Proton beam therapy for bone sarcomas of the skull base and spine: a retrospective nationwide multicenter study in Japan. *Cancer Sci*. 2017 May;108(5):972-977
782. Deraniyagala RL, Yeung D, Mendenhall WM, et al. Proton therapy for skull base chordomas: an outcome study from the University of Florida Proton Therapy Institute. *J Neurol Surg B Skull Base*. 2014 February;75(1):53-7.
783. Dutz A, Agolli L, Butof R, et al. Neurocognitive function and quality of life after proton beam therapy for brain tumour patients. *Radiotherapy and Oncology*. 2020.
784. Dutz A, Luhr A, Agolli L, et al. Development and validation of NTCP models for acute side-effects resulting from proton beam therapy of brain tumours. *Radiother Oncol*. 2018.
785. Engeseth GM, Stieb S, Mohamed ASR, et al. Outcomes and patterns of radiation associated brain image change after proton therapy for head and neck skull base cancers. *Journal of the European Society for Therapeutic Radiology and Oncology*. 2020.
786. Feuvret L, Bracci S, Calugaru V, et al. Efficacy and safety of adjuvant proton therapy in combination with surgery for chondrosarcoma of the skull base: a retrospective, population-based study. *Int J Radiat Oncol Biol Phys*. 2016 May 1;95(1):312-21.
787. Fung V, Calugaru V, Bolle S, et al. Proton beam therapy for skull base chordomas in 106 patients: A dose adaptive radiation protocol. *Radiother Oncol*. 2017. <http://dx.doi.org/10.1016/j.radonc.2017.12.017>.
788. Gentile MS, Miao R, Liebsch NJ, et al. Combined surgical resection and adjuvant high dose photon/proton radiation therapy strategy results in high local control in cervical spine chordomas. *Int J Radiat Oncol Biol Phys*. 2017; 99(2): E752.
789. Glazer TA, Marentette LJ, Sullivan SE, McKean EL. Retrospective review of surgical and adjuvant treatment modalities that affect skull base chordoma recurrence rates. *J Neurol Surg B*. 2016;77-A012.
790. Grosshans DR, Zhu XR, Melancon A, et al. Spot scanning proton therapy for malignancies of the base of skull: treatment planning, acute toxicities, and preliminary clinical outcomes. *Int J Radiat Oncol Biol Phys*. 2014 Nov 1;90(3):540-546.
791. Gudjonsson O, Blomquist E, Nyberg G, et al. Stereotactic irradiation of skull base meningiomas with high energy protons. *Acta Neurochir (Wien)*. 1999;141(9):933-940.
792. Guillaume V, Valentin C, Bolle S, et al. Investigation of ectopic recurrent skull base and cervical chordomas: The Institut Curie's proton therapy center experience. *Head Neck*. 2016 Apr;38 Suppl 1:E1238-1246.
793. Hall DC, Trofimov AV, Winey BA, et al. Predicting patient-specific dosimetric benefits of proton therapy for skull-base tumors using a geometric knowledge-based method. *Int J Radiat Oncol Biol Phys*. 2017 Apr 1;97(5):1087-1094.

794. Hall MD, Bradley JA, Rotondo RL, et al. Risk of Radiation vasculopathy and stroke in pediatric patients treated with proton therapy for brain and skull base tumors. *Int J Radiat Oncol Biol Phys*. 2018; <https://doi.org/10.1016/j.ijrobp.2018.03.027>.
795. Hayashi Y, Mizumoto M, Akutsu H, et al. Hyperfractionated high dose proton beam radiotherapy for clival chordomas after surgical removal. *Br J Radiol*. 2016 Jul;89(1063):20151051.
796. Holliday EB, Mitra HS, Somerson JS, et al. Post operative proton therapy for chordomas and chondrosarcomas of the spine: adjuvant vs. salvage radiation therapy. *Spine*. 2015 Apr 15;40(8):544-549.
797. Hug EB, Fitzek MM, Liebsch NJ, Munzenrider JE. Locally challenging osteo- and chondrogenic tumors of the axial skeleton: results of combined proton and photon radiation therapy using three-dimensional treatment planning. *Int J Radiat Oncol Biol Phys*. 1995;31(3):467-476.
798. Hug EB, Loredó LN, Slater JD, et al. Proton radiation therapy for chordomas and chondrosarcomas of the skull base. *J Neurosurg*. 1999;91(3):432-439.
799. Hug EB, Slater JD. Proton radiation therapy for chordomas and chondrosarcomas of the skull base. *Neurosurg Clin N Am*. 2000;11(4):627-638.
800. Iannalfi A, E'ippolito E, Vitolo V, et al. P05.39 Skull-base chordoma treated with proton and carbon ion radiotherapy: C.N.A.O. clinical experience. *Neuro-Oncology*. 2018;20(3).
801. Igaki H, Tokuyue K, Okumura T, et al. Clinical results of proton beam therapy for skull base chordoma. *Int J Radiat Oncol Biol Phys*. 2004; 60(4): 1120-6.
802. Indelicato DJ, Rotondo RL, Begosh-Mayne D, et al. A prospective outcomes study of proton therapy for chordomas and chondrosarcomas of the spine. *Int J Radiat Oncol Biol Phys*. 2016;95(1):297-303.
803. Kabolizadeh P, Chen YL, Liebsch N, et al. Updated outcome and analysis of tumor response in mobile spine and sacral chordoma treated with definitive high-dose photon/proton radiation therapy. *Int J Radiat Oncol Biol Phys*. 2017;97(2):254-262.
804. Kralik JC, Xi L, Solberg TD, et al. Comparing proton treatment plans of pediatric brain tumors in two pencil beam scanning nozzles with different spot sizes. *J Appl Clin Med Phys*. 2015;16(6):41-50.
805. Leeman JE, Lee NY, Zhou Y, et al. Endoscopic resection followed by proton therapy with pencil beam scanning for skull base tumors. *The Laryngoscope*. 2018.
806. Lim PS, Tran S, Kroeze SGC, et al. Outcomes of adolescents and young adults treated for brain and skull base tumors with pencil beam scanning proton therapy. *Pediatric Blood & Cancer*. 2020.
807. McDonald MW, Linton OR, Shah MV. Proton therapy for reirradiation of progressive or recurrent chordoma. *Int J Radiat Oncol Biol Phys*. 2013;87(5):1107-1114.
808. Mima M, Demizu Y, Jin D, et al. Particle therapy using carbon ions or protons as a definitive therapy for patients with primary sacral chordoma. *Br J Radiol*. 2014 Jan;87(1033):20130512.
809. Miyawaki D, Murakami M, Demizu Y, et al. Brain injury after proton therapy or carbon ion therapy for head-and-neck cancer and skull base tumors. *Int J Radiat Oncol Biol Phys*. 2009;75(2):378-384.
810. Munzenrider JE, Liebsch NJ. Proton therapy for tumors of the skull base. *Strahlenther Onkol*. 1990;175(Suppl 2):57-63.

811. Noël G, Feuvret L, Calugaru V, et al. Chordomas of the base of the skull and upper cervical spine. One hundred patients irradiated by a 3D conformal technique combining photon and proton beams. *Acta Oncol.* 2005;44(7):700-708.
812. Noël G, Feuvret L, Ferrand R, et al. Radiotherapeutic factors in the management of cervical-basal chordomas and chondrosarcomas. *Neurosurgery.* 2004;55(6):1252-1260.
813. Noël G, Habrand JL, Jauffret E, et al. Radiation therapy for chordoma and chondrosarcoma of the skull base and the cervical spine. Prognostic factors and patterns of failure. *Strahlenther Onkol.* 2003;179(4):241-248.
814. Noël G, Habrand JL, Mammar H, et al. Combination of photon and proton radiation therapy for chordomas and chondrosarcomas of the skull base: the Centre de Protonthérapie d'Orsay experience. *Int J Radiat Oncol Biol Phys.* 2001;51(2):392-398.
815. Pai HH, Thornton A, Katznelson L, et al. Hypothalamic/pituitary function following high-dose conformal radiotherapy to the base of skull: demonstration of a dose-effect relationship using dose-volume histogram analysis. *Int J Radiat Oncol Biol Phys.* 2001;49(4):1079-1092.
816. Park L, DeLaney TF, Liebsch NJ, et al. Sacral chordomas: impact of high-dose proton/photonbeam radiation therapy combined with or without surgery for primary versus recurrent tumor. *Int J Radiat Oncol Biol Phys.* 2006;65(5):1514-1521.
817. Parsons M, Hoebel K, Chang K, et al. Effects of proton radiation on brain structure and function in low grade glioma. *Neuro-Oncology.* 2018;20(6).
818. Pehlivan B, Ares C, Lomax AJ, et al. Temporal lobe toxicity analysis after proton radiation therapy for skull base tumors. *Int J Radiat Oncol Biol Phys.* 2012;83(5):1432-1440.
819. Phan J, Frank SJ, Chun S, et al. Evaluation of intensity modulated proton therapy for stereotactic ablative radiation therapy of recurrent skull base tumors: a comparative treatment planning study with volumetric modulated arc therapy. *Int J Radiat Oncol Biol Phys.* 2016 Oct 1;96(2S):E677.
820. Pommier P, Liebsch NJ, Deschler DG, et al. Proton beam radiation therapy for skull base adenoid cystic carcinoma. *Arch Otolaryngol Head Neck Surg.* 2006;132(11):1242-1249.
821. Rief H, Chaudhri N, Tonndorf-Martini E, et al. Intensity-modulated radiotherapy versus proton radiotherapy versus carbon ion radiotherapy for spinal bone metastases: a treatment planning study. *J Appl Clin Med Phys.* 2015 Nov;16(6):186-194.
822. Roda RH, Gallia GL, Eberhart CG, et al. Epilepsy and temporal lobe injury after skull base proton beam therapy. *J Clin Neurosci.* 2009;16(9):1220-1221.
823. Rongthong W, Laack N, Beltran C, et al. Radiation induced signal changes on magnetic resonance imaging in adult patients with brain tumors treated with pencil beam scanning proton therapy. *Neuro-Oncology.* 2018;20(6).
824. Rotondo R, Flokert W, Liebsch NJ, et al. High-dose proton-based radiation therapy in the management of spine chordomas: outcomes and clinicopathological prognostic factors. *J Neurosurg Spine.* 2015;23(6):788-797.
825. Rutz HP, Weber DC, Sugahara S, et al. Extracranial chordoma: outcome in patients treated with function-preserving surgery followed by spot-scanning proton beam irradiation. *Int J Radiat Oncol Biol Phys.* 2007;67(2):512-520.

826. Santoni R, Liebsch N, Finkelstein DM, et al. Temporal lobe (TL) damage following surgery and high-dose photon and proton irradiation in 96 patients affected by chordomas and chondrosarcomas of the base of the skull. *Int J Radiat Oncol Biol Phys*. 1998;41(1):59-68.
827. Scala M, Vennarini S, Garre ML, et al. Radiation-induced moyamoya syndrome after proton therapy in a child with clival craniopharyngioma: natural history and surgical treatment. *World Neurosurgery*. 2018.
828. Sciubba DM, Chi JH, Rhines LD, et al. Chordoma of the spinal column. *Neurosurg Clin N Am*. 2008; 19(1): 5-15.
829. Staab A, Rutz HP, Area C, et al. Spot-scanning-based proton therapy for extracranial chordoma. *Int J Radiat Oncol Biol Phys*. 2011;81(4):e489-e496.
830. Stadel F, Dittmar JO, Jäkel O, et al. Influence of 68Ga-DOTATOC on sparing of normal tissue for radiation therapy of skull base meningioma: differential impact of photon and proton radiotherapy. *Radiat Oncol*. 2018; <https://doi.org/10.1186/s13014-018-1008-z>.
831. Stieb S, Snider III JW, Placidi L, et al. Long-term clinical safety of high-dose proton radiotherapy delivered with pencil beam scanning technique for extracranial chordomas and chondrosarcomas in adult patients: Clinical evidence of spinal cord tolerance. 2017. *Int J Radiat Oncol Biol Phys*. <https://doi.org/10.1016/j.ijrobp.2017.08.037>
832. Stoker J, Keole SR, Grosshans DR, et al. An investigation of hippocampal-sparing capabilities of intensity modulated proton therapy during whole-brain irradiation. *Int J Radiat Oncol Biol Phys*. 2016 Oct1;96(2S):E129.
833. Terahara A, Niemierko A, Goitein M, et al. Analysis of the relationship between tumor dose inhomogeneity and local control in patients with skull base chordoma. *Int J Radiat Oncol Biol Phys*. 1999;45(2):351-358.
834. Vernimmen FJ, Harris JK, Wilson JA, et al. Stereotactic proton beam therapy of skull base meningiomas. *Int J Radiat Oncol Biol Phys*. 2011;49(1):99-105.
835. Weber DC, Murray F, Combescure C, et al. Long term outcome of skull-base chondrosarcoma patients treated with high-dose proton therapy with or without conventional radiation therapy. *Radiother Oncol*. 2018.
836. Weber DC, Rutz HP, Pedroni ES, et al. Results of spot-scanning proton radiation therapy for chordoma and chondrosarcoma of the skull base: the Paul Scherrer Institut experience. *Int J Radiat Oncol Biol Phys*. 2005;63(2):401-409.
837. Yasuda M, Bresson D, Chibbaro S, et al. Chordomas and the skull base and cervical spine: clinical outcomes associated with a multimodal surgical resection combined with proton-beam radiation in 40 patients. *Neurosurg Rev*. 2012;35(2):171-182.
838. Bachtiary B, Veraguth D, Roos N, et al. Hearing Loss in Cancer Patients with Skull Base Tumors Undergoing Pencil Beam Scanning Proton Therapy: A Retrospective Cohort Study. *Cancers (Basel)*. 2022 Aug 9;14(16):3853. doi: 10.3390/cancers14163853. PMID: 36010847; PMCID: PMC9405884.

TESTICULAR

839. Pasalic D, Prajapati S, Ludmir EB, et al. Outcomes and toxicities of proton and photon radiation therapy for testicular seminoma. *Int J Part Ther*. 2020.

THORACIC

Chest Wall and Lymphatic

840. MacDonald SM, Jimenez R, Paetzold P, et al. Proton radiotherapy for chest wall and regional lymphatic radiation; dose comparisons and treatment delivery. *Radiat Oncol*. 2013 Mar 24;8(71).

Lung

841. Akita K, Iwata H, Ogino H, et al. A phase II trial of S-1 plus cisplatin with concurrent proton-beam therapy for locally advanced non-small cell lung cancer. *J Clin Oncol*. 2017;35(15):e20070
842. Badiyan S, Rutenberg MS, Hoppe BS, et al. Clinical outcomes of patients with recurrent lung cancer reirradiated with proton therapy on the Proton Collaborative Group and University of Florida Proton Therapy Institute Prospective Registry Studies. *Practical Radiation Oncology*. 2019.
843. Badiyan S, Mohindra P, Larson GL, et al. Clinical outcomes of patients with recurrent lung cancer reirradiated with proton therapy on the Proton Collaborative Group prospective registry trial. *Int J Radiat Oncol Biol Phys*. 2017;99(2):S209.
844. Berman AT, James SS, Rengan R. Proton beam therapy for non-small cell lung cancer: current clinical evidence and future directions. *Cancers*. 2015 July 2;7(3):1178-90.
845. Bonnet RB, Bush D, Cheek GA, et al. Effects of proton and combined proton/photon beam radiation on pulmonary function in patients with resectable but medically inoperable nonsmall cell lung cancer. *Chest*. 2001;120(6):1803-1810.
846. Boyce-Fappiano D, Nguyen QN, Chapman BV, et al. Single institution experience of proton and photon-based postoperative radiation therapy for non-small-cell lung cancer. *Clin Lung Cancer*. 2021;22(5):e745-e755.
847. Bush DA, Cheek G, Zaheer S, et al. High-dose hypofractionated proton beam radiation therapy is safe and effective for central and peripheral early-stage non-small cell lung cancer: results of a 12-year experience at Loma Linda University Medical Center. *Int J Radiat Oncol Biol Phys*. 2013;86(5):964-968.
848. Bush DA, Slater JD, Bonnet R, et al. Proton-beam radiotherapy for early-stage lung cancer. *Chest*. 1999;116(5):1313-1319.
849. Bush DA, Slater JD, Shin BB, et al. Hypofractionated proton beam radiotherapy for stage I lung cancer. *Chest*. 2004;126(4):1198-1203.
850. Chang JY, Jabbour SK, De Ruysscher D, et al. Consensus statement on proton therapy in early-stage and locally advanced non-small cell lung cancer. *Int J Radiat Oncol Biol Phys*. 2016 May; 95(1):505-16.
851. Chang JY, Komaki R, Lu C, et al. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. *Cancer*. 2011;117(20):4707-4713.
852. Chang JY, Komaki R, Wen HY, et al. Toxicity and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer. *Int J Radiat Oncol Biol Phys*. 2011;80(5):1350-1357.
853. Chang JY, Nantavithya C, Gomez DR, et al. (OA03) A phase II study of stereotactic body radiotherapy and stereotactic body proton therapy for high-risk medically inoperable early-stage non-small cell lung cancer. *Int J Radiat Oncol Biol Phys*. 2018;101(2):E2.

854. Chang JY, Verma V, Li M, et al. Proton beam radiotherapy and concurrent chemotherapy for unresectable stage III non–small-cell lung cancer: final results of a phase 2 study. *JAMA Oncol.* July 2017. doi:10.1001/jamaoncol.2017.2032.
855. Chang JY, Zhang W, Komaki R, et al. Long-term outcome of phase I/II prospective study of dose-escalated proton therapy for early-stage non-small cell lung cancer. *Radiother Oncol.* 2017;122(2):274-80.
856. Chang JY, Zhang X, Wang X, et al. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys.* 2006;65(4):1087-1096.
857. Chao HH, Berman AT, Simone CB 2nd, et al. Multi-institutional prospective study of reirradiation with proton beam radiotherapy for locoregionally recurrent non-small cell lung cancer. *J Thorac Oncol.* 2017 February;12(2):281-292.
858. Colaco RJ, Huh S, Nichols RC, et al. Dosimetric rationale and early experience at UFPTI of thoracic proton therapy and chemotherapy in limited-stage small cell lung cancer. *Acta Oncol.* 2013;52(3):506-513.
859. Cooper BT, Mah D, Chen CC, et al. Hypofractionated proton therapy for early stage non–small cell lung cancer: clinical outcomes and comparative dosimetric analysis. *Int J Radiat Oncol Biol Phys.* 2017; 99(2): E449.
860. Cox J, et al. MDACC - Presentation of findings in lung cancer and proton therapy; Chicago Multimodality Lung; November 2008.
861. Cushman TR, Verma V, Rwigema JM. Comparison of proton therapy and intensity modulated photon radiotherapy for locally advanced non-small cell lung cancer: considerations for optimal trial design. *J Thorac Dis.* 2018;3(2).
862. Dagan R, Bryant CM, Bradley JA, et al. A prospective evaluation of acute toxicity from proton therapy for targets of the parotid region. *Int J Part Ther.* 2016 Fall;3(2):285-290.
863. Das M. Concurrent chemotherapy and proton beam therapy in NSCLC. *Lancet Oncol.* 2017 Sep;18(9):e515. [http://dx.doi.org/10.1016/S1470-2045\(17\)30570-3](http://dx.doi.org/10.1016/S1470-2045(17)30570-3).
864. Deist TM, Yang P, Oberjje C, et al. Dosimetric analysis of randomized proton and photon plans with respect to radiation toxicity: the importance of high dose regions in lung and esophagus. *Int J Radiat Oncol Biol Phys.* 2017 May 1;98(1):246.
865. Fujii O, Demizu Y, Hashimoto N, et al. A retrospective comparison of proton therapy and carbon ion therapy for stage I non-small cell lung cancer. *Radiother Oncol.* 2013;109(1):32-37.
866. Gomez DR, Chang JY. Accelerated dose escalation with proton beam therapy for non-small cell lung cancer. *J Thorac Dis.* 2014 April;6(4):348-55.
867. Gomez DR, Gillin M, Liao Z, et al. Phase 1 study of dose escalation in hypofractionated proton beam therapy for non-small cell lung cancer. *Int J Radiat Oncol Biol Phys.* 2013;86(4):665-670.
868. Gomez DR, Li H, Chang JY. Proton therapy for early-stage non-small cell lung cancer (NSCLC). *Transl Lung Cancer Res.* 2018;7(2):199-204.
869. Gomez DR, Tucker SL, Martel MK, et al. Predictors of high-grade esophagitis after definitive three-dimensional conformal therapy, intensity-modulated radiation therapy, or proton beam therapy for non-small cell lung cancer. *Int J Radiat Oncol Biol Phys.* 2012;84(4):1010-1016.

870. Gridley DS, Bonnet RB, Bush DA, et al. Time course of serum cytokines in patients receiving proton or combined photon/proton beam radiation for resectable but medically inoperable non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys*. 2004;60(3):759-766.
871. Grutters JPC, Pijls-Johannesma M, De Ruyscher, et al. The cost-effectiveness of particle therapy in non-small cell lung cancer: exploring decision uncertainty and areas for future research. *Cancer Treat Rev*. 2010;36(6):468-476.
872. Hanania AN, Gunn GB, Rosenthal DI, et al. Intensity modulated proton therapy (IMPT) to the parotid gland: a seven-year experience. *Int J Radiat Oncol Biol Phys*. 2020;106(5):1195-1196.
873. Harada H, Fuji H, Ono A, et al. Dose escalation study of proton beam therapy with concurrent chemotherapy for stage III non-small cell lung cancer. *Cancer Sci*. 2016 July;107(7):1018-1021.
874. Harris WB, Zou W, Cheng C, et al. Higher dose volumes may be better for evaluating radiation pneumonitis in lung proton therapy patients compared to traditional photon-based dose constraints. *Advances in Radiation Oncology*. 2020.
875. Hata M, Tokuyue K, Kagei K, et al. Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: preliminary results of a phase I/II clinical study. *Int J Radiat Oncol Biol Phys*. 2007;68(3):786-793.
876. Hoppe BS, Flampouri S, Henderson RH, et al. Proton therapy with concurrent chemotherapy for non-small-cell lung cancer: technique and early results. *Clin Lung Cancer*. 2012;13(5):352-358.
877. Hoppe BS, Henderson R, Pham D, et al. A phase 2 trial of concurrent chemotherapy and proton therapy for stage III non-small cell lung cancer: results and reflections following early closure of a single-institution study. *Int J Radiat Oncol Biol Phys*. 2016;95(1):517-522.
878. Hoppe BS. Phase II trial of concurrent chemotherapy and proton therapy for stage 3 NSCLC. *Int J Part Ther*. 2014;2:58.
879. Iwata H, Demizu Y, Fujii O, et al. Long-term outcome of proton therapy and carbon-therapy for large (T2a-T2bN0M0) non-small-cell lung cancer. *J Thorac Oncol*. 2013; 8(6):726-735.
880. Iwata H, Murakami M, Demizu Y, et al. High-dose proton therapy and carbon-ion therapy for stage I nonsmall cell lung cancer. *Cancer*. 2010;116(10):2476-2485.
881. Jeter MD, Gomez D, Nguyen Q, et al. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume with Intensity-Modulated (Photon) Radiation Therapy or Intensity-Modulated Proton Therapy and Concurrent Chemotherapy for Stage II-III Non-Small Cell Lung Cancer: A Phase I Study. *Int J Radiat Oncol Biol Phys*. 2017; <https://doi.org/10.1016/j.ijrobp.2017.10.042>.
882. Kesarwala AH, Ko CJ, Ning H, et al. Intensity modulated proton therapy for elective nodal irradiation and involved field radiation in the definitive treatment of locally advanced non small cell lung cancer: a dosimetric study. *Clin Lung Cancer*. 2015 May;16(3):237-244.
883. Kharod SM, Nichols RC, Henderson RH, et al. Image-guided hypofractionated double-scattering proton therapy in the management of centrally-located early-stage non-small cell lung cancer. *Acta Oncologica*. 2020.
884. Koay EJ, Lege D, Mohan R, et al. Adaptive/nonadaptive proton radiation planning and outcomes in a phase II trial for locally advanced non small cell lung cancer. *Int J Radiat Oncol Biol Phys*. 2012;84(5):1093-1100.

885. Krayenbuehl J, Hartmann M, Lomax AJ, et al. Proton therapy for malignant pleural mesothelioma after extrapleural pleuropneumectomy. *Int J Radiat Oncol Biol Phys*. 2010;78(2):628-634.
886. Lee H, Zeng J, Bowen S, Rengan R. Proton therapy for malignant pleural mesothelioma: A three case series describing the clinical and dosimetric advantages of proton-based therapy. *Cureus*. 2017; 9(9): e1705.
887. Lee SU, Moon SH, Cho KH, et al. Ablative dose proton beam therapy for stage I and recurrent non-small cell lung carcinomas: ablative dose PBT for NSCLC. *Strahlen Onkolo*. 2016 Sep;192(9):649-657.
888. Li H, Zhu XR, Zhang X. Reducing dose uncertainty for spot-scanning proton beam therapy of moving tumors by optimizing the spot delivery sequence. *Int J Radiat Oncol Biol Phys*. 2015;93(3):547-556.
889. Liao Z, Lee JJ, Komaki R, et al. Bayesian adaptive randomization trial of passive scattering proton therapy and intensity-modulated photon radiotherapy for locally advanced non-small-cell lung cancer. *J Clin Oncol*. 2018. doi: 10.1200/JCO.2017.74.0720.
890. Lopez Guerra JL, Gomez DR, Zhuang Y, et al. Changes in pulmonary function after three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, or proton beam therapy for non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys*. 2012;83(4):e537-e543.
891. Makita C, Nakamura T, Takada A, et al. Clinical outcomes and toxicity of proton beam therapy for advanced cholangiocarcinoma. *Radiat Oncol*. 2014;9(26).
892. Makita B, Nakamura T, Takada A, et al. High dose proton beam therapy for stage I non small cell lung cancer: clinical outcomes and prognostic factors. *Acta Oncol*. 2015 Mar; 54(3):307-314.
893. McAvoy SA, Ciura K, Wei C, et al. Definitive reirradiation for locoregionally recurrent non-small cell lung cancer with proton beam therapy or intensity modulated radiation therapy: predictors of high-grade toxicity and survival outcomes. *Int J Radiat Oncol Phys*. 2014 Nov 15;90(4):819-827.
894. McAvoy SA, Ciura KT, Rineer JM, et al. Feasibility of proton beam therapy for reirradiation of locoregionally recurrent non-small cell lung cancer. *Radiother Oncol*. 2013;109(1):38-44.
895. McNamara AL, Hall DC, Shusharina N, et al. Perspectives on the model-based approach to proton therapy trials: a retrospective study of a lung cancer randomized trial. *Radiotherapy and Oncology*. 2020;147:8-14.
896. Moreno AC, Zhang N, Giordano SH, et al. Trends and Outcomes of Proton Radiation Therapy Use for Non-Small Cell Lung Cancer. *Int J Part Ther*. 2018;5(2):18-27.
897. Murai T, Muramatsu R, Omachi C, et al. Lung density changes after proton therapy for lung tumors: can dose constraints for photon therapy be applied to proton therapy? *Int J Radiat Oncol Biol Phys*. 2017;99(2S):E483.
898. Nagata I, Ogino T, Arimura T, et al. Clinical outcomes of proton beam therapy for ground-glass opacity-type lung cancer. *Lung Cancer: Targets and Therapy*. 2020;11:105-111.
899. Nakajima K, Iwata H, Ogino H, et al. Clinical outcomes of image-guided proton therapy for histologically confirmed stage I non-small cell lung cancer. *Radiat Oncol*. 2018;13:199.
900. Nakajima K, Iwata H, Ogino H, et al. Clinical outcomes of image-guided proton therapy for stage I non-small cell lung cancer. *Int J Radiat Oncol Biol Phys*. 2017;99(2S):E483.
901. Nakamura M, Ohnishi K, Ishikawa H, et al. Salvage photon or proton radiotherapy for oligo-recurrence in regional lymph nodes after surgery for non-small cell lung cancer. *In Vivo*. 2020;34:1883-1892.

902. Nakamura N, Hojo H, Inouye K, et al. Late radiological changes after passive scattering proton beam therapy for Stage I lung cancer. *J Radiat Res.* 2018. doi: 10.1093/jrr/rry028.
903. Nakayama H, Satoh H, Sugahara S, et al. Proton beam therapy of stage II and III non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys.* 2011;81(4):979-984.
904. Nakayama H, Sugahara S, Tokita M, et al. Proton beam therapy for patients with medically inoperable stage I non-small-cell lung cancer at the University of Tsukuba. *Int J Radiat Oncol Biol Phys.* 2010;78(2):467-471.
905. Nguyen QN, Blanchard P, Komaki RU, et al. Reported outcomes and toxicities for inoperable, stage II-III non-small cell lung cancer patients treated with concurrent chemotherapy and intensity modulated proton therapy. *Int J Radiat Oncol Biol Phys.* 2017;99(2S):E484.
906. Nguyen QN, Ly NB, Komaki R, et al. Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer. *Radiother Oncol.* 2015; 115:367-372.
907. Nihei K, Ogino T, Ishikura S, Nishimura H. High-dose proton beam therapy for stage I nonsmall- cell lung cancer. *Int J Radiat Oncol Biol Phys.* 2006;65(1):107-111.
908. Ohnishi K, Harada H, Nakamura N, et al. P2.05-005 Proton beam therapy for early stage lung cancer: a multi-institutional retrospective study in Japan. *J Thorac Oncol.* 2017;12(11):S2405.
909. Ohnishi K, Ishikawa H, Nakazawa, et al. Long-term outcomes of high-dose (74 GyE) proton beam therapy with concurrent chemotherapy for stage III nonsmall-cell lung cancer. *Thorac Cancer.* 2021 Mar 6. doi: 10.1111/1759-7714.13896.
910. Ohno T, Oshiro Y, Mizumoto M, et al. Comparison of dose-volume histograms between proton beam and X-ray conformal radiotherapy for locally advanced non small-cell lung cancer. *J Radiat Res.* 2015 Jan;56(1):128-133.
911. Ono T, Hareyama M, Nakamura T, et al. The clinical results of proton beam therapy in patients with idiopathic pulmonary fibrosis: a single center experience. *Radiat Oncol.* 2016;11(1):56.
912. Oshiro Y, Mizumoto M, Okumura T, et al. Results of proton beam therapy without concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer. *J Thor Oncol.* 2012 February;7(2):370-375.
913. Oshiro Y, Okumura T, Kurishima K, et al. High-dose concurrent chemo-proton therapy for stage III NSCLC: preliminary results of a phase II study. *J Radiat Res.* 2014;55:959-965.
914. Pan HY, Jiang S, Sutton J, et al. Early experience with intensity modulated proton therapy for lung-intact mesothelioma: a case series. *Pract Radiat Oncol.* 2015 Jul-Aug;5(4):e345-353.
915. Rice SR, Saboury B, Houshmand S, et al. Quantification of global lung inflammation using volumetric F-FDG PET/CT parameters in locally advanced non-small-cell lung cancer patients treated with concurrent chemoradiotherapy: a comparison of photon and proton radiation therapy. *Nuclear Medicine Communications.* 2019.
916. Schild SE, Rule WG, Ashman JB, et al. Proton beam therapy for locally advanced lung cancer: a review. *World J Clin Oncol.* 2014 Oct 10;5(4):568-575.
917. Sejpal S, Komaki R, Tsao A, et al. Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer. *Cancer.* 2011;117(13):3004-3013.

918. Shioyama Y, Tokuyasu K, Okumura T, et al. Clinical evaluation of proton radiotherapy for non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys*. 2003;56(1):7-13.
919. Verma V, Rwigyema JCM, Adeberg S, Simone CB. Enrollment of elderly patients with locally advanced non-small cell lung cancer onto multi-institutional trials of proton beam radiation therapy. *J Thorac Oncol*. 2016.
920. Wang X, Shi Q, Liao Z, et al. OA 01.07 Tracking major symptom burden from chemotherapy concurrent with 3D vs. IMRT vs. proton beam radiotherapy for NSCLC. *J Thorac Oncol*. 2017;12(11):S1745-S1746.
921. Wang X, Shi Q, Williams LA, et al. Prospective study of patient-reported symptom burden in patients with non-small-cell lung cancer undergoing proton or photon chemoradiation therapy. *J Pain Symptom Manage*. 2016 May;51(5):832-838.
922. Wang Z, Chen M, Sun J, et al. Lyman-Kutcher-Burman normal tissue complication probability modeling for radiation-induced esophagitis in non-small cell lung cancer patients receiving proton radiotherapy. *Radiotherapy & Oncology*. 2020;146:200-204.
923. Westover KD, Seco J, Adams JA, et al. Proton SBRT for medically inoperable stage I NSCLC. *J Thorac Oncol*. 2012;7(6):1021-1025.
924. Xiang Z-L, Erasmus J, Komaki R, et al. FDG uptake correlates with recurrence and survival after treatment of unresectable stage III non-small cell lung cancer with high-dose proton therapy and chemotherapy. *Radiat Oncol*. 2012;7:144.
925. Yang P, Xu T, Gomez DR, Deng W, et al. Patterns of local-regional failure after intensity-modulated radiation therapy or passive scattering proton therapy with concurrent chemotherapy for non-small cell lung cancer. *Int J Radiat Oncol Biol Phys*. 2018.
926. Yegya-Raman N, Zou W, Malhotra J, et al. Advanced radiation techniques for locally advanced non-small cell lung cancer: intensity-modulated radiation therapy and proton therapy. *J Thor Dis*. 2018.
927. Yu NY, DeWees TA, Breen W, et al. Intensity-modulated proton therapy (IMPT) versus intensity-modulated radiotherapy (IMRT) for patients with stage III non-small cell lung cancer: first comparative results of patient-reported outcomes (PRO). *Int J Radiat Oncol Biol Phys*. 2019.
928. Yue J, Jeter MD, Xu T, et al. Lung dosimetry, radiation pneumonitis, and FDG uptake in patients with stage II-III non-small cell lung cancer treated with passively scattered proton therapy or intensity modulated photon therapy. *Int J Radiat Oncol Biol Phys*. 2016 Oct 1;96(2S):E455-E456.
929. Masatoshi Nakamura, Hitoshi Ishikawa, et al. Effects of lymphopenia on survival in proton therapy with chemotherapy for non-small cell lung cancer, *Journal of Radiation Research*, 2023;, rrac084, <https://doi.org/10.1093/jrr/rrac084>

Thymoma

930. Vogel J, Lin L, Litzky LA, et al. Predicted rate of secondary malignancies following adjuvant proton versus photon radiation therapy for thymoma. *Int J Radiat Oncol Biol Phys*. 2017 Oct 1;99(2):427-433.

Thoracic Malignancies

931. Chang JY, Li H, Zhu XR, et al. Clinical implementation of intensity modulated proton therapy for thoracic malignancies. *Int J Radiat Oncol Biol Phys*. 2014 November 15;90(4):809-18.
932. Contreras J, Chundury A, Reynoso F, et al. Proton Therapy Reirradiation for Thoracic Recurrences: Toxicity and Outcomes. *Int J Radiat Oncol Biol Phys*. 2017; 99(2): E448.

933. Ho JC, et al. Reirradiation of thoracic cancers with intensity modulated proton therapy. *Int J Radiat Oncol Biol Phys*. 2017;98(1):222.
934. Kojima H, Isaka M, Nagata M, et al. Preoperative proton beam therapy for thymoma: a case report. *Ann Thorac Cardiovasc Surg*. 2016 June;22(3):186-188.
935. Liao Z, Gandhi SJ, Lin SH, Bradley J. Does Proton Therapy Offer Demonstrable Clinical Advantages for Treating Thoracic Tumors? *Semin Radiat Oncol*. 2018;28(2):114-124.
936. Lidestahl A, Mondlane G, Gubanski M, et al. Normal tissue toxicity following radiotherapy with photon- or scanned proton-beams in patients with thymic tumors. *Acta Oncologica*. 2018.
937. Mercado CE, Hartsell WF, Simone CB, et al. Proton therapy for thymic malignancies: multi-institutional patterns-of-care and early clinical outcomes from the Proton Collaboration Group and the University of Florida prospective registries. 2019.
938. Nanda R, et al. Pulmonary toxicity following proton therapy for thoracic lymphoma. *Int J Radiat Oncol Biol Phys*. 2017 Oct 1;99(2):494-497.
939. Patel NV, Yu NY, Koroulakis A, et al. Proton therapy for thoracic malignancies: a review of oncologic outcomes. *Expert Review of Anticancer Therapy*. 2021.

GENERAL

940. Ahmadi T, Itai Y, Onaya H, et al. CT evaluation of hepatic injury following proton beam irradiation: appearance, enhancement, and 3D size reduction pattern. *J Comput Assist Tomogr*. 1999;23(5):655-663.
941. Amichetti, M. The actual interest in radiotherapy for the utilization of proton beam, highlighting physics basis, technology and common clinical indications. *J Tumor*. 2016;4(2):378-385.
942. Archambeau JO, Bennett GW, Levine GS, et al. Proton radiation therapy. *Radiology*. 1974;110:445-457.
943. Baumann B, Hallahan DE, Michalski JM, et al. Concurrent chemo-radiation therapy with proton therapy: reduced toxicity with comparable oncological outcomes vs photon chemo-radiotherapy. *Br J Cancer*. 2020.
944. Baumann B, Mitra N, Harton J, et al. Comparative effectiveness of proton versus photon chemoradiotherapy for patients with private insurance. *J Clin Oncol*. 2020;38(15).
945. Baumann B, Mitra N, Harton JG, et al. Comparative effectiveness of proton vs photon therapy as part of concurrent chemoradiotherapy for locally advanced cancer. *JAMA Oncology*. 2019.
946. Bettega D, Calzolari P, Ciocca M, et al. Combining proton or photon irradiation with Etoposide B. An in vitro study of cytotoxicity in human cancer cells. *Biomed Phys Eng*. 24 July 2017;3(055009).
947. Bush DA, Dunbar RD, Bonnet R, et al. Pulmonary injury from proton and conventional radiotherapy as revealed by CT. *AJR Am J Roentgenol*. 1999;172(3):735-739.
948. Chaikh A, Calugaru V, Bondiau PY, et al. Impact of the NTCP modeling on medical decision to select eligible patient for proton therapy: the usefulness of EUD as an indicator to rank modern photon vs proton treatment plans. *Int J Radiat Biol*. 2018;7:1-26. doi: 10.1080/09553002.2018.1486516.
949. Chung CS, Keating N, Yock T, Tarbell N. "Comparative analysis of second malignancy risk in patients treated with Proton Therapy versus conventional Photon Therapy", *Red Journal* S0360-3016(08)01001-8. *Int J Radiat Oncol Biol Phys*. 2008, 72(1):S8.

950. Chung CS, Yock TI, Nelson K, et al. Incidence of second malignancies among patients treated with proton versus photon radiation. *Int J Radiat Oncol Biol Phys*. 2013;87(1):46-52.
951. Corkum MT, Liu W, Palma DA, et al. Online advertising and marketing claims by providers of proton beam therapy: are they guideline based? *Int J Radiat Oncol Biol Phys*. 2017;99(2S): E651.
952. DeLaney TF, Kooy HM. Proton and charged particle radiotherapy. Lippincott Williams and Wilkins, 2007.
953. Do SY, Bush DA, Slater JD. Comorbidity-adjusted survival in early stage lung cancer patients treated with hypofractionated proton therapy. *J Oncol*. 2010;251208.
954. Doyen J, Falk AT, Floquet V, et al. Proton beams in cancer treatments: clinical outcomes and dosimetric comparisons with photon therapy. *Cancer Treat Rev*. 2016 Feb;43:104-112.
955. Dvorak T, Wazer DE. Evaluation of potential proton therapy utilization in a market-based environment. *J Am Coll Radiol*. 2010;7(7):522-528.
956. Eaton BR, MacDonald SM, Yock TI, Tarbell NJ. Secondary malignancy risk following proton radiation therapy. *Front Oncol*. 2015 Nov;5:261.
957. Elnahal SM, Kerstiens J, Helsper RS, et al. Proton beam therapy and accountable care: the challenges ahead. *Int J Radiat Oncol Biol Phys*. 2013;85(4):e165 e172.
958. Foote RL, Stafford SL, Petersen IA, et al. The clinical case for proton beam therapy. *Radiat Oncol*. 2012 Oct 22;7:174.
959. Fukumitsu N, Takahashi S, Okumura T, et al. Normal liver tissue change after proton beam therapy. *Jpn J Radiol*. 2018. <https://doi.org/10.1007/s11604-018-0757-9>.
960. Goitein M, Jermann M. The relative costs of proton and x-ray radiation therapy. *Clin Oncol (R Coll Radiol)*. 2003;15(1):S37-S50.
961. Goitein M. Magical protons? *Int J Radiat Oncol Biol Phys*. 2008;70(3):654-656.
962. Grutters JPC, Abrams KR, de Ruyscher D, et al. When to wait for more evidence? Real options analysis in proton therapy. *Oncologist*. 2011;16(12):1752-1761.
963. Gupta A, Khan AJ, Goyal S, et al. Insurance approval for proton beam therapy and its impact on delays in treatment. *Int J Radiat Oncol Biol Phys*. 2018.
964. Gupta A, Millevoi R, El Sebai N, et al. Impact of insurance preauthorization requirements on delays in administering proton beam therapy. *Int J Radiat Oncol Biol Phys*. 2018;102(3).
965. Hashimoto T, Isobe T, Hashii H, et al. Influence of secondary neutrons induced by proton radiotherapy for cancer patients with implantable cardioverter defibrillators. *Radiat Oncol*. 2012;7:10.
966. Hofmann B. Fallacies in the arguments for new technology: the case of proton therapy. *J Med Ethics*. 2009;35(11):684-687.
967. Jarlskog CZ, Paganetti H. Sensitivity of different dose scoring methods on organ-specific neutron dose calculations in proton therapy. *Phys Med Biol*. 2008;53(17):4523-4532.
968. Jarosek S, Elliott S, Virnig BA. Proton beam radiotherapy in the U.S. Medicare population: growth in use between 2006 and 2009 (2012). AHRQ publication No. 12-EHC005. http://www.effectivehealthcare.ahrq.gov/ehc/products/439/1062/Data-Points-10_20120529.pdf. Accessed December, 2013.

969. Jin J. Prospect of radiotherapy technology development in the era of immunotherapy. *JNCC*. 2022 Apr. doi.org/10.1016/j.jncc.2022.04.001.
970. Johnstone PAS, Kerstiens J, Helsper R. Proton facilities economics: the importance of “simple” treatments. *J Am Coll Radiol*. 2012;9(8):560-563.
971. Jones DA, Smith J, Mei X, et al. A systematic review of health economic evaluations of proton beam therapy for adult cancer: appraising methodology and quality. *Clinical and Translational Radiation Oncology*. 2020;20:20-26.
972. Kerstiens J, Johnstone GP, Johnstone PAS. Proton facility economics: single-room centers. *J Am Coll Radiol*. 2018.
973. Khoo A, Sahoo N, Krishnan S, Diagaradjane P. Enhancing the Relative Biological Effectiveness of Proton Therapy Using EGFR-Targeted Gold Nanorods. *Int J Radiat Oncol Biol Phys*. 2016 Oct 1;96(2S):S236-S237. doi: 10.1016/j.ijrobp.2016.06.587. PubMed PMID: 27675870.
974. Kristensen I, Nilsson K, Nilsson P. Comparative proton and photon treatment planning in pediatric patients with various diagnoses. *Int J Part Ther*. 2015 Fall;2(2):367-375.
975. Laack NN, Whitaker TJ, Harmsen WS, et al. Patient-reported quality of life during photon and proton radiation therapy: results of a prospective registry of patient reported outcomes in a large-volume, multi-site practice. *Int J Radiat Oncol Biol Phys*. 2018.
976. Langendijk JA, Lambin P, De Ruyscher D et al. Selection of patients for radiotherapy with protons aiming at reduction of side effects: The model based approach. *Radiother Oncol*. 2013 Jun;107(3):267–273.
977. Langendijk JA, Orecchia R, Haustermans K, et al. Prospective data registration and clinical trials for particle therapy in Europe. *Radiother Oncol*. 2018;128(1):9-13.
978. Larsson B, Leksell L, Rexed B, et al. The high-energy proton beam as a neurosurgical tool. *Nature*. 1958 Nov 1;182(4644):1222-1223.
979. Lawell MP, Bajaj BVM, Galloto SL, et al. Increased distance from a treating proton center is associated with diminished ability to follow patients enrolled on a multicenter radiation oncology registry. *Radiat Oncol*. 2019;134:25-29.
980. Lin R, Hug EB, Schaefer RA, et al. Conformal proton radiation therapy in the posterior fossa: a study comparing protons with three dimensional planned photons in limiting dose to auditory structures. *Int J Radiat Oncol Biol Phys*. 2000;48(4):1219-1226.
981. Lowe M, Gosling A, Nicholas O, et al. Comparing proton to photon radiotherapy plan: UK consensus guidance for reporting under uncertainty for clinical trials. *Clin Oncol*. 2020;32(7):459-466.
982. Lundkvist J, Ekman M, Ericsson SR, et al. Proton therapy of cancer: potential clinical advantages and cost effectiveness. *Acta Oncol*. 2005c;44(8):850 861.
983. Macbeth FR, Williams MV. Proton therapy should be tested in randomized trials. *J Clin Oncol*. 2008;26(15):2590-2591.
984. Marucci L, Niemierko A, Liebsch NJ, et al. Spinal cord tolerance to high dose fractionated 3D conformal proton photon irradiation as evaluated by equivalent uniform dose and dose volume histogram analysis. *Int J Radiat Oncol Biol Phys*. 2004;59(2):551 555.

985. Mishra MV, Aggarwal S, Bentzen SM, et al. Establishing evidence-based indications for proton therapy: an overview of current clinical trials. *Int J Radiat Oncol Biol Phys*. 2017 Feb;97(2):228-235.
986. Mohan R. A review of proton therapy - Current status and future directions. *Prec Radiat Oncol*. 2022;1-13. <https://doi.org/10.1002/pro6.1149>.
987. Moteabbed M, Yock TI, Depauw N, et al. Impact of spot size and beam-shaping devices on the treatment plan quality for pencil beam scanning proton therapy. *Int J Radiat Oncol Biol Phys*. 2016 May 1;95(1):190-198.
988. Munck AR, Rosenschold P, Engelholm SA, et al. A retrospective evaluation of the benefit of referring pediatric cancer patients to an external proton therapy center. *Pediatr Blood Cancer*. 2016 Feb;63(2):262-269.
989. Ning MS, Gomez DR, Shah AK, et al. The insurance approval process for proton radiation therapy: a significant barrier to patient care. *Int J Radiat Oncol Biol Phys*. 2018.
990. Oborn B, Dowdell S, Metcalfe P, et al. A Feasible Small Footprint Bunker Concept for Real-Time Magnetic Resonance Imaging-Guided Proton Beam Therapy. *Int J Radiat Oncol Biol Phys*. 2016 Oct 1;96(2S):E602.
991. Odei BCL, Booth D, Keole S, et al. A 20-year analysis of clinical trials involving proton beam therapy. *Int J Part Ther*. 2016 Winter;3(3):398-406.
992. Paganetti H, et al. Assessment of radiation-induced second risks in proton therapy and IMRT for organs inside the primary radiation field. *Phys Med Bio*. 2012;57(19):6047-6061.
993. Paganetti H, Niemierko A, Ancukiewicz M, et al. Relative biological effectiveness (RBE) values for proton beam therapy. *Int J Radiat Oncol Biol Phys*. 2002;53(2):407-421.
994. Parikh-Patel A, Morris CR, Maguire FB, et al. A population-based assessment of proton beam therapy utilization in California. *Am J Manag Care*. 2020;26(2):e28-e35.
995. Park HS, James BY. Proton-based chemoradiotherapy – what level of evidence is necessary to justify its widespread use? *JAMA Oncology*. 2019.
996. Patel SH, Kostaras X, Parliament M, et al. Recommendations for the referral of patients for proton-beam therapy, an Alberta Health Services report: a model for Canada? *Curr Oncol*. 2014;21(5):251-262.
997. Peeters A, Grutters JPC, Pijls-Johannesma M, et al. How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon ions, proton and photons. *Radiother Oncol*. 2010;95(1):45-53.
998. Pieters RS, Niemierko A, Fullerton BC, Munzenrider JE. Cauda equine tolerance to high-dose fractionated irradiation. *Int J Radiat Oncol Biol Phys*. 2006;64(1):251-257.
999. Quantitative Analysis of Normal Tissue Effects in the Clinical (QUANTEC). *Int J Radiat Oncol Biol Phys*. 2010;76(3):S1-S160.
1000. Rana S, Zeidan O, Ramirez E, et al. Measurements of lateral penumbra for uniform scanning proton beams under various beam delivery conditions and comparison to the XiO treatment planning system. *Med Phys*. 2013;40(9):091708.
1001. Schneider U, Lomax A, Pemler P, et al. The impact of IMRT and proton radiotherapy on secondary cancer incidence. *Strahlenther Onkol*. 2006, 182(11):647-652.
1002. Shah A, Ricci KI, Efstathiou JA. Beyond a moonshot: insurance coverage for proton therapy. *Lancet Oncol*. 2016 May;17(5):559-561.

1003. Shusharina N, Liao Z, Mohan R, et al. Radiation pneumonitis dose response after photon or proton radiation therapy assessed by (18)F-FDG uptake. *Int J Radiat Oncol Biol Phys*. 2016 Oct 1;96(2S):E615.
1004. Simone CB 2nd, Plastaras JP, Jabbour SK, et al. Proton reirradiation: Expert recommendations for reducing toxicities and offering new chances of cure in patients with challenging recurrence malignancies. *Semin Radiat Oncol*. 2020;30(3):253-261.
1005. Slater J D. Clinical applications of proton radiation treatment at Loma Linda University: review of a 15-year experience. *Technol Cancer Res Treat*. 2006;5(2):81-89.
1006. Smith AR. Vision 20/20: proton therapy. *Med Phys*. 2009;36(2):556-568.
1007. Suzuki K, Palmer MB, Sahoo N, et al. Quantitative analysis of treatment process time and throughput capacity for spot scanning proton therapy. *Med Phys*. 2016 Jul;43(7):3975.
1008. Taylor PA. Clinical trials evaluating proton therapy. *Proton Therapy*. 2021.
1009. Thaker NG, Guzman AB, Feeley TW, et al. Defining the value of proton therapy using time-driven activity based costing. *Oncol Payers*. 2014;1(1):22-28.
1010. Thorwarth D, Soukup M, Alber M. Dose painting with IMPT, helical tomotherapy and IMXT: a dosimetric comparison. *Radiother Oncol*. 2008;86:30–34.
1011. Thuomas K-A, Naeser P. Long-term follow-up of proton irradiated malignant melanoma by glucose-fructose enhanced magnetic resonance imaging. *Acta Ophthalmol Scand*. 1997;75(1):17-21
1012. Tsujii H, Tsuji H, Inada T, et al. Clinical results of fractionated proton therapy. *Int J Radiation Oncology Biol Phys*. 1992;25(1):49-60.
1013. Umebayashi Y, Uyeno K, Tsujii H, Otsuka F. Proton radiotherapy of skin carcinomas. *Br J Dermatol*. 1994;130(1):88-91.
1014. Unkelbach J, Chan TC, Bortfeld T. Accounting for range uncertainties in the optimization of intensity modulated proton therapy. *Phys Med Biol*. 2007 May;52(10):2755-2773.
1015. Vemimmen FJ, Fredericks S, Wallace F. Long term follow up of patients treated at a single institution using a passively scattered proton beam; observations around the occurrence of second malignancies. *Int J Radiat Oncol Biol Phys*. 2018.
1016. Verma V, Mishra MV, Mehta MP. A systematic review of the cost and cost-effectiveness studies of proton radiotherapy. *Cancer*. 2016.
1017. Waddle MR, Sio TS, Van Houten HK, et al. Photon and proton radiotherapy utilization in a population of over 100 million commercially insured patients. *Int J Radiat Oncol Biol Phys*. 2017, doi: 10.1016/j.ijrobp.2017.07.042.
1018. Wang X, Poenisch F, Sahoo N, et al. Spot scanning proton therapy minimizes neutron dose in the setting of radiation therapy administered during pregnancy. *J Appl Clin Med Phys*. 2016 Sep 8;17(5):6327.
1019. Xiang M, Chang DT, Pollom EL, et al. Second cancer risk after primary cancer treatment with three-dimensional conformal, intensity-modulated, or proton beam radiation therapy. *Cancer*. 2020;126(15):3560-3568.
1020. Yoon M, Ahn SH, Kim J, et al. Radiation-induced cancers from modern radiotherapy techniques: intensity-modulated radiotherapy versus proton therapy. *Int J Radiat Oncol Biol Phys*. 2010;77(5):1477-85.